<!DOCTYPE html>
<html><head><meta charset="UTF-8">
<title>Earnings Call ë²ˆì—­</title>
<style>
    body { font-family: Arial; margin: 40px; background-color: #fdfdfd; }
    h1 { text-align: center; }
    h2 { margin-top: 50px; color: #003366; }
    h3 { color: #333; }
    table { border: 1px solid #ddd; width: 100%; border-collapse: collapse; }
    th { background: #f0f0f0; padding: 10px; border-bottom: 2px solid #ccc; }
    td { padding: 10px; border-bottom: 1px dotted #ccc; vertical-align: top; }
    p { line-height: 1.6; }
    hr { margin: 50px 0; border: none; border-top: 1px solid #ccc; }
    .back-button {
        display: inline-block;
        background-color: #5f5f5f;
        color: white;
        padding: 10px 16px;
        border-radius: 6px;
        text-decoration: none;
        font-weight: 500;
        box-shadow: 0 2px 6px rgba(0,0,0,0.1);
        margin-bottom: 30px;
    }
</style>
</head><body>
<a href="../../index.html" class="back-button">â†</a>
<h1>ğŸ“„ Earnings Call Transcript ë²ˆì—­ ê²°ê³¼</h1>

    <h2>ğŸ“Š Presentation</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>Thermo Fisher Scientific Inc. (NYSE:TMO) Q3 2025 Earnings Call October 22, 2025 8:30 AM EDT<br><br>Company Participants<br><br>Rafael Tejada - Vice President of Investor Relations<br>Marc Casper - Chairman, President & CEO<br>Stephen Williamson - Senior VP & CFO<br><br>Conference Call Participants<br><br>Michael Ryskin - BofA Securities, Research Division<br>Tycho Peterson - Jefferies LLC, Research Division<br>Jack Meehan - Nephron Research LLC<br>Daniel Arias - Stifel, Nicolaus & Company, Incorporated, Research Division<br>Daniel Brennan - TD Cowen, Research Division<br>Andrew Cooper - Raymond James & Associates, Inc., Research Division<br>Patrick Donnelly - Citigroup Inc.</td><td>ì¨ëª¨ í”¼ì…” ì‚¬ì´ì–¸í‹°í”½(NYSE:TMO) 2025ë…„ 3ë¶„ê¸° ì‹¤ì ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œ 2025ë…„ 10ì›” 22ì¼ ì˜¤ì „ 8ì‹œ 30ë¶„ EDT<br><br>íšŒì‚¬ ì°¸ì„ì<br><br>ë¼íŒŒì—˜ í…Œí•˜ë‹¤ - íˆ¬ìì ê´€ê³„ ë‹´ë‹¹ ë¶€ì‚¬ì¥<br>ë§ˆí¬ ìºìŠ¤í¼ - íšŒì¥, ì‚¬ì¥ ê²¸ CEO<br>ìŠ¤í‹°ë¸ ìœŒë¦¬ì—„ìŠ¨ - ìˆ˜ì„ ë¶€ì‚¬ì¥ ê²¸ CFO<br><br>ì»¨í¼ëŸ°ìŠ¤ ì½œ ì°¸ì„ì<br><br>ë§ˆì´í´ ë¦¬ìŠ¤í‚¨ - BofA ì¦ê¶Œ, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>íƒ€ì´ì½” í”¼í„°ìŠ¨ - ì œí¼ë¦¬ìŠ¤ LLC, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ì­ ë¯¸í•œ - ë„¤í”„ë¡  ë¦¬ì„œì¹˜ LLC<br>ë‹¤ë‹ˆì—˜ ì•„ë¦¬ì•„ìŠ¤ - ìŠ¤í‹°í , ë‹ˆì½œë¼ìš°ìŠ¤ ì•¤ ì»´í¼ë‹ˆ, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ë‹¤ë‹ˆì—˜ ë¸Œë ˆë„Œ - TD ì½”ì›¬, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ì•¤ë“œë¥˜ ì¿ í¼ - ë ˆì´ëª¬ë“œ ì œì„ìŠ¤ ì•¤ ì–´ì†Œì‹œì—ì´ì¸ , ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>íŒ¨íŠ¸ë¦­ ë„ë„¬ë¦¬ - ì‹œí‹°ê·¸ë£¹</td></tr>
<tr><td>Exchange Research<br><br>Presentation<br><br>Operator<br><br>Good morning, ladies and gentlemen, and welcome to the Thermo Fisher Scientific 2025 Third Quarter Conference Call. My name is Claire and I will be coordinating your call today. [Operator Instructions]<br><br>I would like to introduce our moderator for the call, Mr. Rafael Tejada, Vice President Investor Relations. Mr. Tejada, you may begin the call. Rafael Tejada<br>Vice President of Investor Relations<br><br>Good morning, and thank you for joining us. On the call with me today is Marc Casper, our Chairman, President and Chief Executive Officer; and Stephen Williamson, Senior Vice President and Chief Financial Officer.</td><td>ê±°ë˜ì†Œ ë¦¬ì„œì¹˜<br><br>í”„ë ˆì  í…Œì´ì…˜<br><br>ìš´ì˜ì<br><br>ì•ˆë…•í•˜ì‹­ë‹ˆê¹Œ, ì‹ ì‚¬ ìˆ™ë…€ ì—¬ëŸ¬ë¶„. Thermo Fisher Scientific 2025ë…„ 3ë¶„ê¸° ì»¨í¼ëŸ°ìŠ¤ ì½œì— ì˜¤ì‹  ê²ƒì„ í™˜ì˜í•©ë‹ˆë‹¤. ì œ ì´ë¦„ì€ Claireì´ë©°, ì˜¤ëŠ˜ ì—¬ëŸ¬ë¶„ì˜ í†µí™”ë¥¼ ì§„í–‰í•˜ê² ìŠµë‹ˆë‹¤. [ìš´ì˜ì ì•ˆë‚´ì‚¬í•­]<br><br>ì´ë²ˆ í†µí™”ì˜ ì‚¬íšŒìì¸ íˆ¬ìì ê´€ê³„ ë‹´ë‹¹ ë¶€ì‚¬ì¥ Rafael Tejada ì”¨ë¥¼ ì†Œê°œí•´ë“œë¦¬ê² ìŠµë‹ˆë‹¤. Tejada ì”¨, í†µí™”ë¥¼ ì‹œì‘í•´ ì£¼ì‹­ì‹œì˜¤.<br><br>Rafael Tejada<br>íˆ¬ìì ê´€ê³„ ë‹´ë‹¹ ë¶€ì‚¬ì¥<br><br>ì•ˆë…•í•˜ì‹­ë‹ˆê¹Œ, ì°¸ì—¬í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. ì˜¤ëŠ˜ ì €ì™€ í•¨ê»˜ í†µí™”ì— ì°¸ì„í•œ ë¶„ë“¤ì€ Marc Casper íšŒì¥ ê²¸ ì‚¬ì¥ ê²¸ ìµœê³ ê²½ì˜ìì™€ Stephen Williamson ìˆ˜ì„ ë¶€ì‚¬ì¥ ê²¸ ìµœê³ ì¬ë¬´ì±…ì„ìì…ë‹ˆë‹¤.</td></tr>
<tr><td>Please note this call is being webcast live and will be archived on the Investors section of our website, thermofisher.com under the heading News, Events and Presentations until February 1, 2026. A copy of the press release of our third quarter earnings is available in the Investors section of our website under the heading Financials. So before we begin, let me briefly cover our safe harbor statement. Various remarks that we may make about the company's future expectations, plans and prospects constitute forward-looking statements within the meaning of applicable securities laws.</td><td>ì´ í†µí™”ëŠ” ì‹¤ì‹œê°„ ì›¹ìºìŠ¤íŠ¸ë¡œ ì§„í–‰ë˜ê³  ìˆìœ¼ë©°, 2026ë…„ 2ì›” 1ì¼ê¹Œì§€ ì €í¬ ì›¹ì‚¬ì´íŠ¸ thermofisher.comì˜ íˆ¬ìì ì„¹ì…˜ì—ì„œ 'ë‰´ìŠ¤, ì´ë²¤íŠ¸ ë° í”„ë ˆì  í…Œì´ì…˜' í•­ëª© í•˜ì— ì•„ì¹´ì´ë¸Œë  ì˜ˆì •ì…ë‹ˆë‹¤. 3ë¶„ê¸° ì‹¤ì  ë³´ë„ìë£Œ ì‚¬ë³¸ì€ ì €í¬ ì›¹ì‚¬ì´íŠ¸ íˆ¬ìì ì„¹ì…˜ì˜ 'ì¬ë¬´ì •ë³´' í•­ëª©ì—ì„œ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì‹œì‘í•˜ê¸°ì— ì•ì„œ ì•ˆì „í•­ ì¡°í•­ì— ëŒ€í•´ ê°„ëµíˆ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. íšŒì‚¬ì˜ ë¯¸ë˜ ì „ë§, ê³„íš ë° ì˜ˆìƒì— ê´€í•œ ì €í¬ì˜ ë‹¤ì–‘í•œ ë°œì–¸ë“¤ì€ í•´ë‹¹ ì¦ê¶Œë²•ì˜ ì˜ë¯¸ ë‚´ì—ì„œ ë¯¸ë˜ì˜ˆì¸¡ì§„ìˆ ì— í•´ë‹¹í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the company's most recent reports on Form 10-K and Form 10-Q under the heading Risk Factors. These forward-looking statements are based on our current expectations and speak only as of the date they are made. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so even in the event of new information, future developments or otherwise.</td><td>ì‹¤ì œ ê²°ê³¼ëŠ” ìœ„í—˜ ìš”ì¸ì´ë¼ëŠ” ì œëª© í•˜ì— íšŒì‚¬ì˜ ê°€ì¥ ìµœê·¼ Form 10-K ë° Form 10-Q ë³´ê³ ì„œì—ì„œ ë…¼ì˜ëœ ì‚¬í•­ë“¤ì„ í¬í•¨í•˜ì—¬ ë‹¤ì–‘í•œ ì¤‘ìš” ìš”ì¸ë“¤ë¡œ ì¸í•´ ì´ëŸ¬í•œ ë¯¸ë˜ì „ë§ì§„ìˆ ì´ ë‚˜íƒ€ë‚´ëŠ” ë°”ì™€ ì‹¤ì§ˆì ìœ¼ë¡œ ë‹¤ë¥¼ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ë¯¸ë˜ì „ë§ì§„ìˆ ì€ í˜„ì¬ì˜ ê¸°ëŒ€ì— ê¸°ë°˜í•˜ë©° í•´ë‹¹ ì§„ìˆ ì´ ì´ë£¨ì–´ì§„ ë‚ ì§œë¥¼ ê¸°ì¤€ìœ¼ë¡œë§Œ ìœ íš¨í•©ë‹ˆë‹¤. ë‹¹ì‚¬ëŠ” í–¥í›„ ì–´ëŠ ì‹œì ì—ì„œ ë¯¸ë˜ì „ë§ì§„ìˆ ì„ ì—…ë°ì´íŠ¸í•  ìˆ˜ë„ ìˆì§€ë§Œ, ìƒˆë¡œìš´ ì •ë³´ë‚˜ í–¥í›„ ì „ê°œì‚¬í•­ ë˜ëŠ” ê¸°íƒ€ ì‚¬ìœ ê°€ ìˆë”ë¼ë„ ê·¸ë ‡ê²Œ í•  ì˜ë¬´ëŠ” ëª…ì‹œì ìœ¼ë¡œ ë¶€ì¸í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Also, during this call, we will be referring to certain financial measures not prepared in accordance with Generally Accepted Accounting Principles or GAAP. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP measures is available in the press release of our third quarter 2025 earnings and also in the Investors section of our website under the heading, Financials. So with that, I'll now turn the call over to Marc. Marc Casper<br>Chairman, President & CEO<br><br>Thank you, Raf. Good morning, everyone, and thanks for joining us today for our third quarter call.</td><td>ë˜í•œ ì´ë²ˆ ì»¨í¼ëŸ°ìŠ¤ ì½œì—ì„œëŠ” ì¼ë°˜íšŒê³„ì›ì¹™(GAAP)ì— ë”°ë¼ ì‘ì„±ë˜ì§€ ì•Šì€ íŠ¹ì • ì¬ë¬´ì§€í‘œë“¤ì„ ì–¸ê¸‰í•  ì˜ˆì •ì…ë‹ˆë‹¤. ì´ëŸ¬í•œ ë¹„GAAP ì¬ë¬´ì§€í‘œì™€ ê°€ì¥ ì§ì ‘ì ìœ¼ë¡œ ë¹„êµ ê°€ëŠ¥í•œ GAAP ì§€í‘œ ê°„ì˜ ì¡°ì •í‘œëŠ” 2025ë…„ 3ë¶„ê¸° ì‹¤ì  ë³´ë„ìë£Œì™€ ë‹¹ì‚¬ ì›¹ì‚¬ì´íŠ¸ íˆ¬ìì ì„¹ì…˜ì˜ 'ì¬ë¬´ì •ë³´' í•­ëª©ì—ì„œ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ê·¸ëŸ¼ ì´ì œ Marcì—ê²Œ ë§ˆì´í¬ë¥¼ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.<br><br>Marc Casper<br>íšŒì¥, ì‚¬ì¥ ê²¸ CEO<br><br>Raf, ê°ì‚¬í•©ë‹ˆë‹¤. ì•ˆë…•í•˜ì„¸ìš”, ì—¬ëŸ¬ë¶„. ì˜¤ëŠ˜ 3ë¶„ê¸° ì»¨í¼ëŸ°ìŠ¤ ì½œì— ì°¸ì—¬í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
<tr><td>As you saw in our press release, we delivered an outstanding quarter that included excellent operational performance, reflecting our active management of the company. Strong execution from our team with ongoing focus meaningfully advanced a number of our customer relationships. And we made significant progress advancing our proven growth strategy, which continues to strengthen our foundation and build an even brighter future for our company. So first, let me recap the financials. Our revenue grew 5% in the quarter to $11.12 billion. Our adjusted operating income grew 9% to $2.59 billion.</td><td>ë³´ë„ìë£Œì—ì„œ ë³´ì…¨ë“¯ì´, ì €í¬ëŠ” íšŒì‚¬ì˜ ì ê·¹ì ì¸ ê²½ì˜ì„ ë°˜ì˜í•œ ìš°ìˆ˜í•œ ìš´ì˜ ì„±ê³¼ë¥¼ í¬í•¨í•˜ì—¬ íƒì›”í•œ ë¶„ê¸° ì‹¤ì ì„ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ì§€ì†ì ì¸ ì§‘ì¤‘ì„ í†µí•œ íŒ€ì˜ ê°•ë ¥í•œ ì‹¤í–‰ë ¥ìœ¼ë¡œ ë‹¤ìˆ˜ì˜ ê³ ê° ê´€ê³„ë¥¼ ì˜ë¯¸ ìˆê²Œ ë°œì „ì‹œì¼°ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì €í¬ì˜ ê²€ì¦ëœ ì„±ì¥ ì „ëµì„ ì¶”ì§„í•˜ëŠ” ë° ìƒë‹¹í•œ ì§„ì „ì„ ì´ë£¨ì—ˆìœ¼ë©°, ì´ëŠ” ì €í¬ ê¸°ë°˜ì„ ì§€ì†ì ìœ¼ë¡œ ê°•í™”í•˜ê³  íšŒì‚¬ì˜ ë”ìš± ë°ì€ ë¯¸ë˜ë¥¼ êµ¬ì¶•í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë¨¼ì € ì¬ë¬´ ì‹¤ì ì„ ìš”ì•½í•´ ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë¶„ê¸° ë§¤ì¶œì€ 5% ì¦ê°€í•œ 111ì–µ 2ì²œë§Œ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ì¡°ì • ì˜ì—…ì´ìµì€ 9% ì¦ê°€í•œ 25ì–µ 9ì²œë§Œ ë‹¬ëŸ¬ë¥¼ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Adjusted operating margin expanded by 100 basis points to 23.3% and we grew adjusted EPS by 10% to $5.79 per share. Our performance in the third quarter enables us to raise our full year guidance. Now turning to our end markets. In Pharma and Biotech, we delivered another order of mid-single-digit growth. Performance in the quarter was led by our Bioproduction and Analytical Instruments businesses as well as our research and safety market channel. Turning to academic and government. Revenue declined in the low single digits, representing a modest improvement versus last quarter. To provide some additional context, conditions in the U.S. in this end market were similar to Q2.</td><td>ì¡°ì • ì˜ì—…ì´ìµë¥ ì€ 100bp í™•ëŒ€ë˜ì–´ 23.3%ë¥¼ ê¸°ë¡í–ˆìœ¼ë©°, ì¡°ì • ì£¼ë‹¹ìˆœì´ìµì€ 10% ì¦ê°€í•œ 5.79ë‹¬ëŸ¬ë¥¼ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. 3ë¶„ê¸° ì‹¤ì ì„ ë°”íƒ•ìœ¼ë¡œ ì—°ê°„ ê°€ì´ë˜ìŠ¤ë¥¼ ìƒí–¥ ì¡°ì •í•˜ê²Œ ë˜ì—ˆìŠµë‹ˆë‹¤. ì´ì œ ìµœì¢… ì‹œì¥ë³„ í˜„í™©ì„ ì‚´í´ë³´ê² ìŠµë‹ˆë‹¤. ì œì•½ ë° ë°”ì´ì˜¤í…Œí¬ ë¶€ë¬¸ì—ì„œëŠ” ì¤‘ê°„ í•œ ìë¦¿ìˆ˜ ì„±ì¥ë¥ ì„ ë˜ë‹¤ì‹œ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ì´ë²ˆ ë¶„ê¸° ì‹¤ì ì€ ë°”ì´ì˜¤ìƒì‚° ë° ë¶„ì„ê¸°ê¸° ì‚¬ì—…ë¶€ì™€ ì—°êµ¬ ë° ì•ˆì „ ì‹œì¥ ì±„ë„ì´ ì£¼ë„í–ˆìŠµë‹ˆë‹¤. í•™ìˆ  ë° ì •ë¶€ ë¶€ë¬¸ìœ¼ë¡œ ë„˜ì–´ê°€ë©´, ë§¤ì¶œì´ ë‚®ì€ í•œ ìë¦¿ìˆ˜ ê°ì†Œí–ˆìœ¼ë‚˜ ì´ëŠ” ì§€ë‚œ ë¶„ê¸° ëŒ€ë¹„ ì†Œí­ ê°œì„ ëœ ìˆ˜ì¹˜ì…ë‹ˆë‹¤. ì¶”ê°€ì ì¸ ë°°ê²½ì„ ë§ì”€ë“œë¦¬ë©´, ì´ ìµœì¢… ì‹œì¥ì—ì„œ ë¯¸êµ­ ë‚´ ìƒí™©ì€ 2ë¶„ê¸°ì™€ ìœ ì‚¬í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>In Industrial and Applied, revenue grew in the mid-single-digit store in the quarter, representing a nice sequential step up. Performance in the quarter was led by our Electron Microscopy business as well as our research and safety market channel. Finally, in Diagnostics and Healthcare, revenue growth improved over Q2, though it remained down low single digits for the quarter, largely due to conditions in China. Highlights in this quarter included strong growth in our Transplant Diagnostics and Immunodiagnostics businesses. Wrapping up my comments on end markets, our team executed very well to capture the opportunities during the quarter.</td><td>ì‚°ì—… ë° ì‘ìš© ë¶€ë¬¸ì—ì„œëŠ” ë¶„ê¸° ë§¤ì¶œì´ ì¤‘ê°„ í•œ ìë¦¿ìˆ˜ ì„±ì¥ë¥ ì„ ê¸°ë¡í•˜ë©° ìˆœì°¨ì ìœ¼ë¡œ ì–‘í˜¸í•œ ê°œì„ ì„ ë³´ì˜€ìŠµë‹ˆë‹¤. ì´ë²ˆ ë¶„ê¸° ì‹¤ì ì€ ì „ìí˜„ë¯¸ê²½ ì‚¬ì—…ê³¼ ì—°êµ¬ ë° ì•ˆì „ ì‹œì¥ ì±„ë„ì´ ì£¼ë„í–ˆìŠµë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ ì§„ë‹¨ ë° í—¬ìŠ¤ì¼€ì–´ ë¶€ë¬¸ì—ì„œëŠ” 2ë¶„ê¸° ëŒ€ë¹„ ë§¤ì¶œ ì„±ì¥ë¥ ì´ ê°œì„ ë˜ì—ˆìœ¼ë‚˜, ì£¼ë¡œ ì¤‘êµ­ ì‹œì¥ ìƒí™©ìœ¼ë¡œ ì¸í•´ ë¶„ê¸° ê¸°ì¤€ìœ¼ë¡œëŠ” ì—¬ì „íˆ ë‚®ì€ í•œ ìë¦¿ìˆ˜ ê°ì†Œë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ì´ë²ˆ ë¶„ê¸° ì£¼ìš” ì„±ê³¼ë¡œëŠ” ì¥ê¸°ì´ì‹ ì§„ë‹¨ ë° ë©´ì—­ì§„ë‹¨ ì‚¬ì—…ì—ì„œì˜ ê°•ë ¥í•œ ì„±ì¥ì„ ë“¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ìµœì¢… ì‹œì¥ì— ëŒ€í•œ ì œ ì½”ë©˜íŠ¸ë¥¼ ë§ˆë¬´ë¦¬í•˜ë©´ì„œ, ì €í¬ íŒ€ì€ ë¶„ê¸° ë™ì•ˆ ê¸°íšŒë¥¼ í¬ì°©í•˜ê¸° ìœ„í•´ ë§¤ìš° í›Œë¥­í•˜ê²Œ ì‹¤í–‰í–ˆë‹¤ê³  ë§ì”€ë“œë¦½ë‹ˆë‹¤.</td></tr>
<tr><td>Let me turn to our growth strategy, which consists of 3 pillars: high impact innovation, our trusted partner status with customers and our unparalleled commercial engine. Starting with innovation. It was another excellent quarter for our company. Our new offerings demonstrate our continued leadership and further enable our customers to unlock scientific breakthroughs, advanced precision medicine and enhance productivity in their labs. In clinical next-gen sequencing, we continue to expand our offerings strengthening our ability to help clinicians and researchers advance targeted care for patients.</td><td>ì´ì œ 3ê°œì˜ í•µì‹¬ ì¶•ìœ¼ë¡œ êµ¬ì„±ëœ ì €í¬ì˜ ì„±ì¥ ì „ëµì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤: ê³ ì„íŒ©íŠ¸ í˜ì‹ , ê³ ê°ê³¼ì˜ ì‹ ë¢°ë°›ëŠ” íŒŒíŠ¸ë„ˆ ì§€ìœ„, ê·¸ë¦¬ê³  ì €í¬ì˜ ë…ë³´ì ì¸ ìƒì—…ì  ì—”ì§„ì…ë‹ˆë‹¤. ë¨¼ì € í˜ì‹ ë¶€í„° ì‹œì‘í•˜ê² ìŠµë‹ˆë‹¤. ì €í¬ íšŒì‚¬ì—ê²Œ ë˜ ë‹¤ë¥¸ ìš°ìˆ˜í•œ ë¶„ê¸°ì˜€ìŠµë‹ˆë‹¤. ì €í¬ì˜ ìƒˆë¡œìš´ ì œí’ˆë“¤ì€ ì§€ì†ì ì¸ ë¦¬ë”ì‹­ì„ ë³´ì—¬ì£¼ë©°, ê³ ê°ë“¤ì´ ê³¼í•™ì  í˜ì‹ ì„ ì‹¤í˜„í•˜ê³  ì •ë°€ì˜í•™ì„ ë°œì „ì‹œí‚¤ë©° ì—°êµ¬ì‹¤ì—ì„œì˜ ìƒì‚°ì„±ì„ í–¥ìƒì‹œí‚¬ ìˆ˜ ìˆë„ë¡ ë”ìš± ì§€ì›í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì„ìƒ ì°¨ì„¸ëŒ€ ì‹œí€€ì‹± ë¶„ì•¼ì—ì„œ ì €í¬ëŠ” ì§€ì†ì ìœ¼ë¡œ ì œí’ˆ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ í™•ì¥í•˜ì—¬ ì„ìƒì˜ì™€ ì—°êµ¬ìë“¤ì´ í™˜ìë¥¼ ìœ„í•œ í‘œì  ì¹˜ë£Œë¥¼ ë°œì „ì‹œí‚¬ ìˆ˜ ìˆë„ë¡ ë•ëŠ” ì €í¬ì˜ ì—­ëŸ‰ì„ ê°•í™”í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>The Oncomine Dx Express Test on our Ion Torrent Genexus Dx Integrated Sequencer received FDA approval as a companion diagnostic for a targeted therapy used to treat non-small cell lung cancer and for broader tumor profiling applications. We also introduced the Oncomine Comprehensive Assay+ on the Genexus System providing clinical research labs with an all-in-one comprehensive genomic profiling solution that delivers next-day results. This capability provides clinical researchers with faster, more actionable insights to advance precision medicine.</td><td>ë‹¹ì‚¬ì˜ Ion Torrent Genexus Dx í†µí•© ì‹œí€€ì„œì—ì„œ ì‚¬ìš©ë˜ëŠ” Oncomine Dx Express Testê°€ ë¹„ì†Œì„¸í¬íì•” ì¹˜ë£Œì— ì‚¬ìš©ë˜ëŠ” í‘œì ì¹˜ë£Œì œì˜ ë™ë°˜ì§„ë‹¨ ë° ë³´ë‹¤ ê´‘ë²”ìœ„í•œ ì¢…ì–‘ í”„ë¡œíŒŒì¼ë§ ì ìš© ë¶„ì•¼ì—ì„œ FDA ìŠ¹ì¸ì„ ë°›ì•˜ìŠµë‹ˆë‹¤. ë˜í•œ Genexus ì‹œìŠ¤í…œì—ì„œ Oncomine Comprehensive Assay+ë¥¼ ì¶œì‹œí•˜ì—¬ ì„ìƒì—°êµ¬ ì‹¤í—˜ì‹¤ì— ìµì¼ ê²°ê³¼ë¥¼ ì œê³µí•˜ëŠ” ì˜¬ì¸ì› í¬ê´„ì  ìœ ì „ì²´ í”„ë¡œíŒŒì¼ë§ ì†”ë£¨ì…˜ì„ ì œê³µí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì—­ëŸ‰ì€ ì„ìƒì—°êµ¬ìë“¤ì—ê²Œ ì •ë°€ì˜í•™ ë°œì „ì„ ìœ„í•œ ë” ë¹ ë¥´ê³  ì‹¤í–‰ ê°€ëŠ¥í•œ í†µì°°ë ¥ì„ ì œê³µí•©ë‹ˆë‹¤.</td></tr>
<tr><td>For proteomics, we launched the Olink Target 48 Neurodegeneration panel to advance research into conditions such as Alzheimer's, Parkinson's and Multiple Sclerosis. The new panel helps address the need for reliable detection and measurement of biomarkers that can unlock insights into these and other complex neurological diseases, while also enabling researchers to monitor disease progression and therapeutic responses. In Analytical Instruments, we unveiled 2 new electron microscopes at the recent Microscopy and Microanalysis Conference. These include the Thermo Scientific Talos 12 transmission electron microscope.</td><td>í”„ë¡œí…Œì˜¤ë¯¹ìŠ¤ ë¶„ì•¼ì—ì„œëŠ” ì•Œì¸ í•˜ì´ë¨¸, íŒŒí‚¨ìŠ¨ë³‘, ë‹¤ë°œì„± ê²½í™”ì¦ê³¼ ê°™ì€ ì§ˆí™˜ ì—°êµ¬ë¥¼ ë°œì „ì‹œí‚¤ê¸° ìœ„í•´ Olink Target 48 ì‹ ê²½í‡´í–‰ì„± íŒ¨ë„ì„ ì¶œì‹œí–ˆìŠµë‹ˆë‹¤. ì´ ìƒˆë¡œìš´ íŒ¨ë„ì€ ì´ëŸ¬í•œ ë³µì¡í•œ ì‹ ê²½í•™ì  ì§ˆí™˜ë“¤ê³¼ ê¸°íƒ€ ì§ˆí™˜ì— ëŒ€í•œ í†µì°°ë ¥ì„ ì–»ì„ ìˆ˜ ìˆëŠ” ë°”ì´ì˜¤ë§ˆì»¤ì˜ ì‹ ë¢°í•  ìˆ˜ ìˆëŠ” ê²€ì¶œ ë° ì¸¡ì •ì— ëŒ€í•œ í•„ìš”ë¥¼ í•´ê²°í•˜ëŠ” ë° ë„ì›€ì´ ë˜ë©°, ë™ì‹œì— ì—°êµ¬ìë“¤ì´ ì§ˆë³‘ ì§„í–‰ê³¼ ì¹˜ë£Œ ë°˜ì‘ì„ ëª¨ë‹ˆí„°ë§í•  ìˆ˜ ìˆë„ë¡ ì§€ì›í•©ë‹ˆë‹¤. ë¶„ì„ê¸°ê¸° ë¶€ë¬¸ì—ì„œëŠ” ìµœê·¼ í˜„ë¯¸ê²½ ë° ë¯¸ì„¸ë¶„ì„ ì»¨í¼ëŸ°ìŠ¤ì—ì„œ 2ê°œì˜ ìƒˆë¡œìš´ ì „ìí˜„ë¯¸ê²½ì„ ê³µê°œí–ˆìŠµë‹ˆë‹¤. ì—¬ê¸°ì—ëŠ” Thermo Scientific Talos 12 íˆ¬ê³¼ì „ìí˜„ë¯¸ê²½ì´ í¬í•¨ë©ë‹ˆë‹¤.</td></tr>
<tr><td>This powerful new platform built on our popular Talos line and delivers exceptional image quality and ease of use for structural and cellular analysis and biological research, pathology and drug development. We also introduced the Thermo Scientific Scios 3, focused ion beam scanning electron microscope, engineered with advanced automation, precision and ease of use, this instrument accelerates material science research and supports the development of new materials used across clean energy, aerospace, and digital devices.</td><td>ì´ ê°•ë ¥í•œ ìƒˆë¡œìš´ í”Œë«í¼ì€ ë‹¹ì‚¬ì˜ ì¸ê¸° ìˆëŠ” Talos ë¼ì¸ì„ ê¸°ë°˜ìœ¼ë¡œ êµ¬ì¶•ë˜ì—ˆìœ¼ë©°, êµ¬ì¡° ë° ì„¸í¬ ë¶„ì„ê³¼ ìƒë¬¼í•™ ì—°êµ¬, ë³‘ë¦¬í•™ ë° ì‹ ì•½ ê°œë°œ ë¶„ì•¼ì—ì„œ íƒì›”í•œ ì´ë¯¸ì§€ í’ˆì§ˆê³¼ ì‚¬ìš© í¸ì˜ì„±ì„ ì œê³µí•©ë‹ˆë‹¤. ë˜í•œ ë‹¹ì‚¬ëŠ” Thermo Scientific Scios 3 ì§‘ì† ì´ì˜¨ë¹” ì£¼ì‚¬ì „ìí˜„ë¯¸ê²½ì„ ì¶œì‹œí–ˆìŠµë‹ˆë‹¤. ì´ ì¥ë¹„ëŠ” ì²¨ë‹¨ ìë™í™”, ì •ë°€ë„ ë° ì‚¬ìš© í¸ì˜ì„±ìœ¼ë¡œ ì„¤ê³„ë˜ì–´ ì¬ë£Œê³¼í•™ ì—°êµ¬ë¥¼ ê°€ì†í™”í•˜ê³  ì²­ì •ì—ë„ˆì§€, í•­ê³µìš°ì£¼ ë° ë””ì§€í„¸ ê¸°ê¸° ì „ë°˜ì— ì‚¬ìš©ë˜ëŠ” ì‹ ì†Œì¬ ê°œë°œì„ ì§€ì›í•©ë‹ˆë‹¤.</td></tr>
<tr><td>In Chromatography and Mass Spectrometry, we launched Chromeleon 7.4, the first enterprise-ready compliance-focused software platform that unifies chromatography and mass spectrometry workflows. This system offers centralized secure data management and remote access across labs empowering regulated biopharma, clinical and environmental labs to streamline workflows, improve their productivity and accelerate scientific decision-making. This launch is a great enabler for both our mass spec and chromatography instruments. Let me give you a quick update on our trusted partner status and our unparalleled commercial engine. We have a unique relationship with our customers.</td><td>í¬ë¡œë§ˆí† ê·¸ë˜í”¼ ë° ì§ˆëŸ‰ë¶„ì„ ë¶„ì•¼ì—ì„œëŠ” í¬ë¡œë§ˆí† ê·¸ë˜í”¼ì™€ ì§ˆëŸ‰ë¶„ì„ ì›Œí¬í”Œë¡œìš°ë¥¼ í†µí•©í•˜ëŠ” ìµœì´ˆì˜ ì—”í„°í”„ë¼ì´ì¦ˆê¸‰ ì»´í”Œë¼ì´ì–¸ìŠ¤ ì¤‘ì‹¬ ì†Œí”„íŠ¸ì›¨ì–´ í”Œë«í¼ì¸ Chromeleon 7.4ë¥¼ ì¶œì‹œí–ˆìŠµë‹ˆë‹¤. ì´ ì‹œìŠ¤í…œì€ ì¤‘ì•™ì§‘ì¤‘ì‹ ë³´ì•ˆ ë°ì´í„° ê´€ë¦¬ì™€ ì—°êµ¬ì‹¤ ê°„ ì›ê²© ì ‘ê·¼ì„ ì œê³µí•˜ì—¬ ê·œì œ ëŒ€ìƒ ë°”ì´ì˜¤íŒŒë§ˆ, ì„ìƒ ë° í™˜ê²½ ì—°êµ¬ì‹¤ì´ ì›Œí¬í”Œë¡œìš°ë¥¼ ê°„ì†Œí™”í•˜ê³  ìƒì‚°ì„±ì„ í–¥ìƒì‹œí‚¤ë©° ê³¼í•™ì  ì˜ì‚¬ê²°ì •ì„ ê°€ì†í™”í•  ìˆ˜ ìˆë„ë¡ ì§€ì›í•©ë‹ˆë‹¤. ì´ë²ˆ ì¶œì‹œëŠ” ë‹¹ì‚¬ì˜ ì§ˆëŸ‰ë¶„ì„ê¸°ì™€ í¬ë¡œë§ˆí† ê·¸ë˜í”¼ ì¥ë¹„ ëª¨ë‘ì— í›Œë¥­í•œ ì´‰ì§„ì œ ì—­í• ì„ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ì œ ë‹¹ì‚¬ì˜ ì‹ ë¢°ë°›ëŠ” íŒŒíŠ¸ë„ˆ ì§€ìœ„ì™€ ë¹„êµí•  ìˆ˜ ì—†ëŠ” ìƒì—…ì  ì—”ì§„ì— ëŒ€í•´ ê°„ëµíˆ ì—…ë°ì´íŠ¸í•´ ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì €í¬ëŠ” ê³ ê°ë“¤ê³¼ ë…íŠ¹í•œ ê´€ê³„ë¥¼ ë§ºê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>One that has been earned over many years through a relentless focus on anticipating, understanding and meeting their needs. Our trusted partner status provides us with unique insights to guide our strategy and continually strengthen our capabilities. At the same time, our entry leading commercial engine enables us to deliver those capabilities at scale. I'll share a few highlights of the actions we've taken recently to deliver even greater value to our customers and position our company for the future. One example is our strategic collaboration with OpenAI. The collaboration is focused on 2 broad areas.</td><td>ìˆ˜ë…„ì— ê±¸ì³ ê³ ê°ì˜ ë‹ˆì¦ˆë¥¼ ì˜ˆì¸¡í•˜ê³ , ì´í•´í•˜ë©°, ì¶©ì¡±ì‹œí‚¤ëŠ” ë° ëŠì„ì—†ì´ ì§‘ì¤‘í•¨ìœ¼ë¡œì¨ ìŒ“ì•„ì˜¨ ê²ƒì…ë‹ˆë‹¤. ì‹ ë¢°ë°›ëŠ” íŒŒíŠ¸ë„ˆë¡œì„œì˜ ì§€ìœ„ëŠ” ìš°ë¦¬ì˜ ì „ëµì„ ì´ëŒê³  ì—­ëŸ‰ì„ ì§€ì†ì ìœ¼ë¡œ ê°•í™”í•  ìˆ˜ ìˆëŠ” ë…íŠ¹í•œ í†µì°°ë ¥ì„ ì œê³µí•©ë‹ˆë‹¤. ë™ì‹œì—, ìš°ë¦¬ì˜ ì—…ê³„ ì„ ë„ì ì¸ ìƒì—…ì  ì—”ì§„ì€ ì´ëŸ¬í•œ ì—­ëŸ‰ì„ ëŒ€ê·œëª¨ë¡œ ì œê³µí•  ìˆ˜ ìˆê²Œ í•´ì¤ë‹ˆë‹¤. ê³ ê°ì—ê²Œ ë”ìš± í° ê°€ì¹˜ë¥¼ ì „ë‹¬í•˜ê³  ìš°ë¦¬ íšŒì‚¬ì˜ ë¯¸ë˜ë¥¼ ìœ„í•œ í¬ì§€ì…”ë‹ì„ ìœ„í•´ ìµœê·¼ ì·¨í•œ ì¡°ì¹˜ë“¤ì˜ ëª‡ ê°€ì§€ í•˜ì´ë¼ì´íŠ¸ë¥¼ ê³µìœ í•˜ê² ìŠµë‹ˆë‹¤. í•œ ê°€ì§€ ì˜ˆëŠ” OpenAIì™€ì˜ ì „ëµì  í˜‘ì—…ì…ë‹ˆë‹¤. ì´ í˜‘ì—…ì€ 2ê°œì˜ ê´‘ë²”ìœ„í•œ ì˜ì—­ì— ì´ˆì ì„ ë§ì¶”ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>The first opportunity is to embed these capabilities into our products and services to make an even bigger impact for our customers. And the second opportunity is to make Thermo Fisher even more productive. As part of this collaboration, we are embedding OpenAI advanced technology into critical areas of our business, including product development, service delivery, customer engagement and operations. Our initial focus is on clinical research to help improve the speed and success of drug development, ultimately enabling customers to get medicines to patients faster and more cost effectively. We are deploying these capabilities to improve the cycle time of clinical trials.</td><td>ì²« ë²ˆì§¸ ê¸°íšŒëŠ” ì´ëŸ¬í•œ ì—­ëŸ‰ì„ ë‹¹ì‚¬ì˜ ì œí’ˆê³¼ ì„œë¹„ìŠ¤ì— ë‚´ì¬í™”í•˜ì—¬ ê³ ê°ë“¤ì—ê²Œ ë”ìš± í° ì„íŒ©íŠ¸ë¥¼ ì œê³µí•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë‘ ë²ˆì§¸ ê¸°íšŒëŠ” Thermo Fisherë¥¼ ë”ìš± ìƒì‚°ì ìœ¼ë¡œ ë§Œë“œëŠ” ê²ƒì…ë‹ˆë‹¤. ì´ë²ˆ í˜‘ë ¥ì˜ ì¼í™˜ìœ¼ë¡œ, ìš°ë¦¬ëŠ” ì œí’ˆ ê°œë°œ, ì„œë¹„ìŠ¤ ì œê³µ, ê³ ê° ì°¸ì—¬ ë° ìš´ì˜ì„ í¬í•¨í•œ ì‚¬ì—…ì˜ í•µì‹¬ ì˜ì—­ì— OpenAIì˜ ì²¨ë‹¨ ê¸°ìˆ ì„ ë‚´ì¬í™”í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ì˜ ì´ˆê¸° ì§‘ì¤‘ ë¶„ì•¼ëŠ” ì„ìƒ ì—°êµ¬ë¡œ, ì˜ì•½í’ˆ ê°œë°œì˜ ì†ë„ì™€ ì„±ê³µë¥ ì„ ê°œì„ í•˜ì—¬ ê¶ê·¹ì ìœ¼ë¡œ ê³ ê°ë“¤ì´ í™˜ìë“¤ì—ê²Œ ì˜ì•½í’ˆì„ ë” ë¹ ë¥´ê³  ë¹„ìš© íš¨ìœ¨ì ìœ¼ë¡œ ì „ë‹¬í•  ìˆ˜ ìˆë„ë¡ ì§€ì›í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì„ìƒì‹œí—˜ì˜ ì‚¬ì´í´ íƒ€ì„ì„ ê°œì„ í•˜ê¸° ìœ„í•´ ì´ëŸ¬í•œ ì—­ëŸ‰ë“¤ì„ ë°°ì¹˜í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We'll also look to leverage OpenAI's capabilities to unlock value in our deep repository of data and experience to enable customers to focus on the most promising opportunities in their drug development pipelines. To enable the second focus area, we've launched ChatGPT Enterprise internally across the company to drive productivity, innovation and ultimately, smarter customer engagement. I'm really excited about the ways Thermo Fisher and OpenAI, 2 innovation leaders will work together to make a real difference in advancing science and bringing new medicines to patients.</td><td>ë˜í•œ OpenAIì˜ ì—­ëŸ‰ì„ í™œìš©í•˜ì—¬ ë‹¹ì‚¬ì˜ ë°©ëŒ€í•œ ë°ì´í„° ì €ì¥ì†Œì™€ ê²½í—˜ì—ì„œ ê°€ì¹˜ë¥¼ ì°½ì¶œí•˜ê³ , ê³ ê°ë“¤ì´ ì‹ ì•½ ê°œë°œ íŒŒì´í”„ë¼ì¸ì—ì„œ ê°€ì¥ ìœ ë§í•œ ê¸°íšŒì— ì§‘ì¤‘í•  ìˆ˜ ìˆë„ë¡ ì§€ì›í•  ê³„íšì…ë‹ˆë‹¤. ë‘ ë²ˆì§¸ ì¤‘ì  ì˜ì—­ì„ ì‹¤í˜„í•˜ê¸° ìœ„í•´, ìƒì‚°ì„±ê³¼ í˜ì‹ ì„ ì´‰ì§„í•˜ê³  ê¶ê·¹ì ìœ¼ë¡œ ë”ìš± ìŠ¤ë§ˆíŠ¸í•œ ê³ ê° ì°¸ì—¬ë¥¼ ì´ëŒì–´ë‚´ê¸° ìœ„í•´ ChatGPT Enterpriseë¥¼ íšŒì‚¬ ì „ì²´ì— ë‚´ë¶€ì ìœ¼ë¡œ ë„ì…í–ˆìŠµë‹ˆë‹¤. ë‘ í˜ì‹  ë¦¬ë”ì¸ Thermo Fisherì™€ OpenAIê°€ í˜‘ë ¥í•˜ì—¬ ê³¼í•™ ë°œì „ì„ ì´‰ì§„í•˜ê³  í™˜ìë“¤ì—ê²Œ ìƒˆë¡œìš´ ì˜ì•½í’ˆì„ ì œê³µí•˜ëŠ” ë° ì‹¤ì§ˆì ì¸ ë³€í™”ë¥¼ ë§Œë“¤ì–´ë‚¼ ë°©ë²•ë“¤ì— ëŒ€í•´ ì •ë§ ê¸°ëŒ€ê°€ í½ë‹ˆë‹¤.</td></tr>
<tr><td>Another good example of our trusted partner status this quarter was the recently announced strategic partnership with AstraZeneca Bioventure hub in Gothenburg, Sweden. This partnership will leverage the combined expertise of Thermo Fisher in AstraZeneca to drive innovation and strengthen the life sciences ecosystem. A dedicated team from Thermo Fisher will co-locate with AstraZeneca scientists to work on collaborative R&D projects with an initial focus on chromatography, molecular genomics and proteomics. And it was also great to celebrate the grand opening of our Manufacturing Center of Excellence in Mebane, North Carolina this quarter.</td><td>ì´ë²ˆ ë¶„ê¸°ì— ì €í¬ì˜ ì‹ ë¢°ë°›ëŠ” íŒŒíŠ¸ë„ˆ ì§€ìœ„ë¥¼ ë³´ì—¬ì£¼ëŠ” ë˜ ë‹¤ë¥¸ ì¢‹ì€ ì‚¬ë¡€ëŠ” ìµœê·¼ ë°œí‘œëœ ìŠ¤ì›¨ë´ ì˜ˆí…Œë³´ë¦¬ì— ìˆëŠ” ì•„ìŠ¤íŠ¸ë¼ì œë„¤ì¹´ ë°”ì´ì˜¤ë²¤ì²˜ í—ˆë¸Œì™€ì˜ ì „ëµì  íŒŒíŠ¸ë„ˆì‹­ì…ë‹ˆë‹¤. ì´ íŒŒíŠ¸ë„ˆì‹­ì€ ì¨ëª¨ í”¼ì…”ì™€ ì•„ìŠ¤íŠ¸ë¼ì œë„¤ì¹´ì˜ ê²°í•©ëœ ì „ë¬¸ì„±ì„ í™œìš©í•˜ì—¬ í˜ì‹ ì„ ì¶”ì§„í•˜ê³  ìƒëª…ê³¼í•™ ìƒíƒœê³„ë¥¼ ê°•í™”í•  ê²ƒì…ë‹ˆë‹¤. ì¨ëª¨ í”¼ì…”ì˜ ì „ë‹´ íŒ€ì´ ì•„ìŠ¤íŠ¸ë¼ì œë„¤ì¹´ ê³¼í•™ìë“¤ê³¼ í•¨ê»˜ ê³µë™ ì…ì£¼í•˜ì—¬ í¬ë¡œë§ˆí† ê·¸ë˜í”¼, ë¶„ì ìœ ì „ì²´í•™ ë° ë‹¨ë°±ì§ˆì²´í•™ì— ì´ˆì ì„ ë§ì¶˜ í˜‘ë ¥ R&D í”„ë¡œì íŠ¸ë¥¼ ì§„í–‰í•  ì˜ˆì •ì…ë‹ˆë‹¤. ë˜í•œ ì´ë²ˆ ë¶„ê¸°ì— ë…¸ìŠ¤ìºë¡¤ë¼ì´ë‚˜ì£¼ ë©”ë² ì¸ì— ìˆëŠ” ì €í¬ ì œì¡° ìš°ìˆ˜ì„¼í„°ì˜ ì„±ëŒ€í•œ ê°œì†Œì‹ì„ ì¶•í•˜í•  ìˆ˜ ìˆì–´ì„œ ë§¤ìš° ê¸°ë»¤ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>A high-volume, low-cost facility, this site was developed with support from the U.S. government and is capable of producing at least 40 million laboratory pipette tips per week to support Life Science Research and Diagnostic Laboratories and adds to the U.S. national supply chain resilience. So wrapping up our growth strategy. This was an excellent quarter, where our actions strengthened our industry leadership today and positions our company for an even brighter future. Moving on now to capital deployment.</td><td>ëŒ€ëŸ‰ ìƒì‚°, ì €ë¹„ìš© ì‹œì„¤ì¸ ì´ ì‚¬ì´íŠ¸ëŠ” ë¯¸êµ­ ì •ë¶€ì˜ ì§€ì›ì„ ë°›ì•„ ê°œë°œë˜ì—ˆìœ¼ë©°, ìƒëª…ê³¼í•™ ì—°êµ¬ ë° ì§„ë‹¨ ì‹¤í—˜ì‹¤ì„ ì§€ì›í•˜ê¸° ìœ„í•´ ì£¼ë‹¹ ìµœì†Œ 4ì²œë§Œ ê°œì˜ ì‹¤í—˜ì‹¤ìš© í”¼í« íŒì„ ìƒì‚°í•  ìˆ˜ ìˆëŠ” ëŠ¥ë ¥ì„ ê°–ì¶”ê³  ìˆì–´ ë¯¸êµ­ êµ­ê°€ ê³µê¸‰ë§ íšŒë³µë ¥ ê°•í™”ì— ê¸°ì—¬í•˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ì„±ì¥ ì „ëµì„ ë§ˆë¬´ë¦¬í•˜ìë©´, ì´ë²ˆ ë¶„ê¸°ëŠ” ìš°ë¦¬ì˜ í–‰ë™ì´ í˜„ì¬ ì—…ê³„ ë¦¬ë”ì‹­ì„ ê°•í™”í•˜ê³  íšŒì‚¬ë¥¼ ë”ìš± ë°ì€ ë¯¸ë˜ë¡œ ì´ëŒì–´ ë‚˜ê°ˆ ìˆ˜ ìˆëŠ” ìœ„ì¹˜ì— ì˜¬ë ¤ë†“ì€ í›Œë¥­í•œ ë¶„ê¸°ì˜€ìŠµë‹ˆë‹¤. ì´ì œ ìë³¸ ë°°ì¹˜ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We also had a very active quarter successfully executing our proven capital deployment strategy, which, as you know, is a combination of strategic M&A and returning capital to our shareholders. In September, we completed our acquisition of our Filtration and Separation business from Solventum, which is now part of our Life Sciences Solutions segment. As you know, this business expands our bioprocessing offering for Pharma and Biotech as well as industrial filtration capabilities. The integration is progressing smoothly and the early feedback from our customers has been incredibly positive.</td><td>ë˜í•œ ì´ë²ˆ ë¶„ê¸°ì—ëŠ” ê²€ì¦ëœ ìë³¸ ë°°ì¹˜ ì „ëµì„ ì„±ê³µì ìœ¼ë¡œ ì‹¤í–‰í•˜ë©° ë§¤ìš° í™œë°œí•œ í•œ ë¶„ê¸°ë¥¼ ë³´ëƒˆìŠµë‹ˆë‹¤. ì•„ì‹œë‹¤ì‹œí”¼ ì´ ì „ëµì€ ì „ëµì  M&Aì™€ ì£¼ì£¼ í™˜ì›ì˜ ì¡°í•©ì…ë‹ˆë‹¤. 9ì›”ì—ëŠ” Solventumìœ¼ë¡œë¶€í„° ì—¬ê³¼ ë° ë¶„ë¦¬ ì‚¬ì—…ë¶€ ì¸ìˆ˜ë¥¼ ì™„ë£Œí–ˆìœ¼ë©°, ì´ëŠ” í˜„ì¬ ë‹¹ì‚¬ì˜ ìƒëª…ê³¼í•™ ì†”ë£¨ì…˜ ë¶€ë¬¸ì˜ ì¼ë¶€ê°€ ë˜ì—ˆìŠµë‹ˆë‹¤. ì•„ì‹œë‹¤ì‹œí”¼ ì´ ì‚¬ì—…ì€ ì œì•½ ë° ë°”ì´ì˜¤í…Œí¬ ë¶„ì•¼ì˜ ë°”ì´ì˜¤í”„ë¡œì„¸ì‹± ì œí’ˆêµ°ì„ í™•ì¥í•˜ê³  ì‚°ì—…ìš© ì—¬ê³¼ ì—­ëŸ‰ì„ ê°•í™”í•´ì¤ë‹ˆë‹¤. í†µí•© ê³¼ì •ì´ ìˆœì¡°ë¡­ê²Œ ì§„í–‰ë˜ê³  ìˆìœ¼ë©°, ê³ ê°ë“¤ë¡œë¶€í„° ë°›ì€ ì´ˆê¸° í”¼ë“œë°±ì´ ë§¤ìš° ê¸ì •ì ì…ë‹ˆë‹¤.</td></tr>
<tr><td>We also closed our acquisition of the Ridgefield, New Jersey sterile fill-finish site from Sanofi, expanding our U.S. drug product manufacturing. This is an excellent addition to our industry-leading sterile fill-finish network within our Pharma Services business. At this site, we'll continue to manufacture a portfolio of Sanofi's therapies, and we'll invest in additional production lines to meet the growing demand for U.S. manufacturing from our Pharma and Biotech customers as they re-shore more activity to the U.S. Also in the quarter, we repurchased $1 billion of our shares. This brings our total repurchases to $3 billion for the year.</td><td>ë˜í•œ ë‹¹ì‚¬ëŠ” ì‚¬ë…¸í”¼ë¡œë¶€í„° ë‰´ì €ì§€ì£¼ ë¦¬ì§€í•„ë“œ ë¬´ê·  ì¶©ì „-ì™„ì œ ì‚¬ì´íŠ¸ ì¸ìˆ˜ë¥¼ ì™„ë£Œí•˜ì—¬ ë¯¸êµ­ ë‚´ ì˜ì•½í’ˆ ì œì¡° ì—­ëŸ‰ì„ í™•ì¥í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ë‹¹ì‚¬ íŒŒë§ˆ ì„œë¹„ìŠ¤ ì‚¬ì—…ë¶€ ë‚´ ì—…ê³„ ì„ ë„ì ì¸ ë¬´ê·  ì¶©ì „-ì™„ì œ ë„¤íŠ¸ì›Œí¬ì— í›Œë¥­í•œ ì¶”ê°€ ìì‚°ì´ ë  ê²ƒì…ë‹ˆë‹¤. ì´ ì‚¬ì´íŠ¸ì—ì„œëŠ” ì‚¬ë…¸í”¼ì˜ ì¹˜ë£Œì œ í¬íŠ¸í´ë¦¬ì˜¤ ì œì¡°ë¥¼ ì§€ì†í•  ì˜ˆì •ì´ë©°, ì œì•½ ë° ë°”ì´ì˜¤í… ê³ ê°ë“¤ì´ ë” ë§ì€ í™œë™ì„ ë¯¸êµ­ìœ¼ë¡œ ë¦¬ì‡¼ì–´ë§í•¨ì— ë”°ë¼ ì¦ê°€í•˜ëŠ” ë¯¸êµ­ ë‚´ ì œì¡° ìˆ˜ìš”ë¥¼ ì¶©ì¡±í•˜ê¸° ìœ„í•´ ì¶”ê°€ ìƒì‚°ë¼ì¸ì— íˆ¬ìí•  ê³„íšì…ë‹ˆë‹¤. ë˜í•œ ì´ë²ˆ ë¶„ê¸°ì— 10ì–µ ë‹¬ëŸ¬ ê·œëª¨ì˜ ìì‚¬ì£¼ ë§¤ì…ì„ ì‹¤ì‹œí–ˆìŠµë‹ˆë‹¤. ì´ë¡œì¨ ì˜¬í•´ ì´ ìì‚¬ì£¼ ë§¤ì… ê·œëª¨ëŠ” 30ì–µ ë‹¬ëŸ¬ì— ë‹¬í•©ë‹ˆë‹¤.</td></tr>
<tr><td>So overall, a very active quarter for capital deployment. We have a company culture based on continuous improvement through our PPI business system, which once again was a key enabler of outstanding execution. We made great progress in the quarter, leveraging PPI to manage our cost base and deliver very strong earnings growth. The PPI Business System continues to drive great impact, and with the OpenAI collaboration, it will have even more impact going forward. The practical application of AI will enhance our colleagues' ability to find a better way, increasing our productivity and improving the customer experience.</td><td>ì „ë°˜ì ìœ¼ë¡œ ìë³¸ ë°°ì¹˜ì— ìˆì–´ ë§¤ìš° í™œë°œí•œ ë¶„ê¸°ì˜€ìŠµë‹ˆë‹¤. ì €í¬ëŠ” PPI ë¹„ì¦ˆë‹ˆìŠ¤ ì‹œìŠ¤í…œì„ í†µí•œ ì§€ì†ì  ê°œì„ ì— ê¸°ë°˜í•œ ê¸°ì—… ë¬¸í™”ë¥¼ ê°€ì§€ê³  ìˆìœ¼ë©°, ì´ëŠ” ë‹¤ì‹œ í•œë²ˆ ë›°ì–´ë‚œ ì‹¤í–‰ë ¥ì˜ í•µì‹¬ ë™ë ¥ì´ ë˜ì—ˆìŠµë‹ˆë‹¤. ì´ë²ˆ ë¶„ê¸°ì— PPIë¥¼ í™œìš©í•˜ì—¬ ë¹„ìš© ê¸°ë°˜ì„ ê´€ë¦¬í•˜ê³  ë§¤ìš° ê°•ë ¥í•œ ìˆ˜ìµ ì„±ì¥ì„ ë‹¬ì„±í•˜ëŠ” ë° í° ì§„ì „ì„ ì´ë£¨ì—ˆìŠµë‹ˆë‹¤. PPI ë¹„ì¦ˆë‹ˆìŠ¤ ì‹œìŠ¤í…œì€ ê³„ì†í•´ì„œ í° ì„íŒ©íŠ¸ë¥¼ ì°½ì¶œí•˜ê³  ìˆìœ¼ë©°, OpenAIì™€ì˜ í˜‘ë ¥ì„ í†µí•´ ì•ìœ¼ë¡œ ë”ìš± í° ì„íŒ©íŠ¸ë¥¼ ê°€ì ¸ì˜¬ ê²ƒì…ë‹ˆë‹¤. AIì˜ ì‹¤ìš©ì  ì ìš©ì€ ë™ë£Œë“¤ì´ ë” ë‚˜ì€ ë°©ë²•ì„ ì°¾ëŠ” ëŠ¥ë ¥ì„ í–¥ìƒì‹œì¼œ ìƒì‚°ì„±ì„ ë†’ì´ê³  ê³ ê° ê²½í—˜ì„ ê°œì„ í•  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>As I reflect on the quarter, I'm proud of what our team has accomplished and grateful for their contributions to our success. Let me now turn to our guidance. Given our strong performance in the quarter, we're raising both our revenue and earnings guidance for 2025. Stephen will take you through the details in his remarks and I'll cover the highlights. We're raising our revenue guidance to a new range of $44.1 billion to $44.5 billion and raising our adjusted EPS guidance to a range of $22.60 to $22.86 per share. So to summarize our key takeaways from Q3. This was a terrific quarter.</td><td>ì´ë²ˆ ë¶„ê¸°ë¥¼ ëŒì´ì¼œë³´ë©´ì„œ, ì €ëŠ” ìš°ë¦¬ íŒ€ì´ ì´ë£¬ ì„±ê³¼ë¥¼ ìë‘ìŠ¤ëŸ½ê²Œ ìƒê°í•˜ë©° ìš°ë¦¬ì˜ ì„±ê³µì— ê¸°ì—¬í•œ ê·¸ë“¤ì˜ ë…¸ë ¥ì— ê°ì‚¬ë“œë¦½ë‹ˆë‹¤. ì´ì œ ìš°ë¦¬ì˜ ê°€ì´ë˜ìŠ¤ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì´ë²ˆ ë¶„ê¸°ì˜ ê°•ë ¥í•œ ì‹¤ì ì„ ë°”íƒ•ìœ¼ë¡œ, ì €í¬ëŠ” 2025ë…„ ë§¤ì¶œê³¼ ìˆ˜ìµ ê°€ì´ë˜ìŠ¤ë¥¼ ëª¨ë‘ ìƒí–¥ ì¡°ì •í•©ë‹ˆë‹¤. ìŠ¤í‹°ë¸ì´ ê·¸ì˜ ë°œì–¸ì—ì„œ ì„¸ë¶€ì‚¬í•­ì„ ì„¤ëª…í•  ê²ƒì´ë©°, ì €ëŠ” ì£¼ìš” ë‚´ìš©ì„ ë‹¤ë£¨ê² ìŠµë‹ˆë‹¤. ì €í¬ëŠ” ë§¤ì¶œ ê°€ì´ë˜ìŠ¤ë¥¼ 441ì–µ ë‹¬ëŸ¬ì—ì„œ 445ì–µ ë‹¬ëŸ¬ì˜ ìƒˆë¡œìš´ ë²”ìœ„ë¡œ ìƒí–¥ ì¡°ì •í•˜ê³ , ì¡°ì • ì£¼ë‹¹ìˆœì´ìµ(EPS) ê°€ì´ë˜ìŠ¤ë¥¼ ì£¼ë‹¹ 22.60ë‹¬ëŸ¬ì—ì„œ 22.86ë‹¬ëŸ¬ ë²”ìœ„ë¡œ ìƒí–¥ ì¡°ì •í•©ë‹ˆë‹¤. 3ë¶„ê¸°ì˜ ì£¼ìš” ì‹œì‚¬ì ì„ ìš”ì•½í•˜ë©´, ì´ë²ˆ ë¶„ê¸°ëŠ” ì •ë§ í›Œë¥­í•œ ë¶„ê¸°ì˜€ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We delivered excellent operational execution, reflecting consistent and active management of the company and the power of the PPI business system, which resulted in outstanding earnings growth. We continue to advance our growth and capital deployment strategies. And we're raising our full year guidance and remain confident in our midterm and long-term outlook and the proven strength of our strategy to create meaningful value for our shareholders and continued success for our company. With that, I'll now hand the call over to our CFO, Stephen Williamson. Stephen? Stephen Williamson<br>Senior VP & CFO<br><br>Thanks, Marc, and good morning, everyone.</td><td>ìš°ë¦¬ëŠ” ë›°ì–´ë‚œ ìš´ì˜ ì‹¤í–‰ë ¥ì„ ë³´ì—¬ì£¼ì—ˆìœ¼ë©°, ì´ëŠ” íšŒì‚¬ì— ëŒ€í•œ ì¼ê´€ë˜ê³  ì ê·¹ì ì¸ ê²½ì˜ê³¼ PPI ë¹„ì¦ˆë‹ˆìŠ¤ ì‹œìŠ¤í…œì˜ í˜ì„ ë°˜ì˜í•œ ê²ƒìœ¼ë¡œ, íƒì›”í•œ ìˆ˜ìµ ì„±ì¥ì„ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì„±ì¥ ë° ìë³¸ ë°°ì¹˜ ì „ëµì„ ì§€ì†ì ìœ¼ë¡œ ë°œì „ì‹œí‚¤ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì—°ê°„ ê°€ì´ë˜ìŠ¤ë¥¼ ìƒí–¥ ì¡°ì •í•˜ë©°, ì¤‘ê¸° ë° ì¥ê¸° ì „ë§ê³¼ ì£¼ì£¼ë“¤ì„ ìœ„í•œ ì˜ë¯¸ ìˆëŠ” ê°€ì¹˜ ì°½ì¶œ ë° íšŒì‚¬ì˜ ì§€ì†ì ì¸ ì„±ê³µì„ ìœ„í•œ ìš°ë¦¬ ì „ëµì˜ ì…ì¦ëœ ê°•ì ì— ëŒ€í•´ í™•ì‹ ì„ ìœ ì§€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ì œ CFOì¸ ìŠ¤í‹°ë¸ ìœŒë¦¬ì—„ìŠ¨ì—ê²Œ ë°œì–¸ê¶Œì„ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤. ìŠ¤í‹°ë¸?<br><br>ìŠ¤í‹°ë¸ ìœŒë¦¬ì—„ìŠ¨<br>ìˆ˜ì„ ë¶€ì‚¬ì¥ ê²¸ CFO<br><br>ê°ì‚¬í•©ë‹ˆë‹¤, ë§ˆí¬. ê·¸ë¦¬ê³  ì—¬ëŸ¬ë¶„, ì•ˆë…•í•˜ì„¸ìš”.</td></tr>
<tr><td>I'll take you through an overview of our third quarter results for the total company then provide color on our 4 business segments and I'll conclude by providing our updated 2025 guidance. Before I get into the details of our financial performance, let me provide you with a high-level view of how the third quarter played-out versus our expectations at the time of our last earnings call. In Q3, our team executed really well and delivered results significantly ahead of what we'd assumed at the midpoint of our prior guidance on both the top and bottom line.</td><td>ì „ì²´ íšŒì‚¬ì˜ 3ë¶„ê¸° ì‹¤ì  ê°œìš”ë¥¼ ë§ì”€ë“œë¦° í›„, 4ê°œ ì‚¬ì—…ë¶€ë¬¸ì— ëŒ€í•œ ì„¸ë¶€ ë‚´ìš©ì„ ì œê³µí•˜ê³ , ë§ˆì§€ë§‰ìœ¼ë¡œ ì—…ë°ì´íŠ¸ëœ 2025ë…„ ê°€ì´ë˜ìŠ¤ë¥¼ ì œì‹œí•˜ê² ìŠµë‹ˆë‹¤. ì¬ë¬´ ì„±ê³¼ì˜ ì„¸ë¶€ ì‚¬í•­ì— ë“¤ì–´ê°€ê¸° ì „ì—, ì§€ë‚œ ì‹¤ì  ë°œí‘œ ë‹¹ì‹œ ì €í¬ ì˜ˆìƒ ëŒ€ë¹„ 3ë¶„ê¸°ê°€ ì–´ë–»ê²Œ ì „ê°œë˜ì—ˆëŠ”ì§€ ì „ë°˜ì ì¸ ê´€ì ì—ì„œ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. 3ë¶„ê¸°ì— ì €í¬ íŒ€ì€ ì •ë§ í›Œë¥­í•˜ê²Œ ì‹¤í–‰í–ˆìœ¼ë©°, ê¸°ì¡´ ê°€ì´ë˜ìŠ¤ ì¤‘ê°„ê°’ì—ì„œ ê°€ì •í–ˆë˜ ê²ƒë³´ë‹¤ ë§¤ì¶œê³¼ ìˆ˜ìµ ëª¨ë‘ì—ì„œ ìƒë‹¹íˆ ì•ì„œëŠ” ê²°ê³¼ë¥¼ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Q3 reported revenue was approximately $300 million ahead of what we'd included in the midpoint of the prior guide, driven by stronger FX tailwinds, a benefit from our recent acquisitions and a slight beat on organic revenue. The beat on the bottom line was even more significant. We delivered $0.30 of adjusted EPS ahead of what was included in the midpoint of our prior guide for Q3. $0.11 of that beat was from a lower impact of tariffs and related FX than had been assumed in the prior guide. $0.20 of the beat was from very strong operational performance, and this was partially offset by a $0.01 of dilution from the recent acquisitions.</td><td>3ë¶„ê¸° ë³´ê³  ë§¤ì¶œì€ ì´ì „ ê°€ì´ë˜ìŠ¤ ì¤‘ê°„ê°’ì— í¬í•¨ë˜ì—ˆë˜ ê¸ˆì•¡ë³´ë‹¤ ì•½ 3ì–µ ë‹¬ëŸ¬ ì•ì„œë©°, ì´ëŠ” ë” ê°•í•œ ì™¸í™˜ ìˆœí’, ìµœê·¼ ì¸ìˆ˜ì˜ í˜œíƒ, ê·¸ë¦¬ê³  ìœ ê¸°ì  ë§¤ì¶œì˜ ì†Œí­ ìƒíšŒì— ê¸°ì¸í•©ë‹ˆë‹¤. ìˆœì´ìµ ì¸¡ë©´ì—ì„œì˜ ìƒíšŒí­ì€ í›¨ì”¬ ë” ìœ ì˜ë¯¸í–ˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” 3ë¶„ê¸° ì´ì „ ê°€ì´ë˜ìŠ¤ ì¤‘ê°„ê°’ì— í¬í•¨ë˜ì—ˆë˜ ê²ƒë³´ë‹¤ 0.30ë‹¬ëŸ¬ì˜ ì¡°ì • ì£¼ë‹¹ìˆœì´ìµì„ ì•ì„œ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ì´ ìƒíšŒë¶„ ì¤‘ 0.11ë‹¬ëŸ¬ëŠ” ì´ì „ ê°€ì´ë˜ìŠ¤ì—ì„œ ê°€ì •í–ˆë˜ ê²ƒë³´ë‹¤ ê´€ì„¸ ë° ê´€ë ¨ ì™¸í™˜ì˜ ì˜í–¥ì´ ë‚®ì•˜ë˜ ê²ƒì—ì„œ ë¹„ë¡¯ë˜ì—ˆìŠµë‹ˆë‹¤. 0.20ë‹¬ëŸ¬ì˜ ìƒíšŒë¶„ì€ ë§¤ìš° ê°•ë ¥í•œ ìš´ì˜ ì„±ê³¼ì—ì„œ ë‚˜ì™”ìœ¼ë©°, ì´ëŠ” ìµœê·¼ ì¸ìˆ˜ë¡œ ì¸í•œ 0.01ë‹¬ëŸ¬ì˜ í¬ì„íš¨ê³¼ë¡œ ë¶€ë¶„ì ìœ¼ë¡œ ìƒì‡„ë˜ì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>So to summarize, in Q3, we once again delivered excellent operational performance. Let me now provide you with some additional details on Q3. Starting with earnings per share. In the quarter, adjusted EPS grew 10% to $5.79. GAAP EPS in the quarter was $4.27, in line with the prior year quarter. On the top line, Q3 reported revenue grew 5% year-over-year, that included 3% organic revenue growth, a 1% contribution from acquisitions and a 1% tailwind from foreign exchange. Turning to our organic revenue performance by geography. In Q3, North America grew low single digits. Europe and Asia Pacific both grew mid-single digits with China declining mid-single digits.</td><td>ìš”ì•½í•˜ìë©´, 3ë¶„ê¸°ì— ìš°ë¦¬ëŠ” ë‹¤ì‹œ í•œë²ˆ ë›°ì–´ë‚œ ìš´ì˜ ì„±ê³¼ë¥¼ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ì´ì œ 3ë¶„ê¸°ì— ëŒ€í•œ ì¶”ê°€ì ì¸ ì„¸ë¶€ì‚¬í•­ì„ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì£¼ë‹¹ìˆœì´ìµë¶€í„° ì‹œì‘í•˜ê² ìŠµë‹ˆë‹¤. ì´ë²ˆ ë¶„ê¸° ì¡°ì • ì£¼ë‹¹ìˆœì´ìµì€ 10% ì¦ê°€í•œ 5.79ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ë¶„ê¸° ì¤‘ GAAP ì£¼ë‹¹ìˆœì´ìµì€ 4.27ë‹¬ëŸ¬ë¡œ ì „ë…„ ë™ê¸°ì™€ ë™ì¼í•œ ìˆ˜ì¤€ì´ì—ˆìŠµë‹ˆë‹¤. ë§¤ì¶œ ì¸¡ë©´ì—ì„œ, 3ë¶„ê¸° ë³´ê³  ë§¤ì¶œì€ ì „ë…„ ëŒ€ë¹„ 5% ì¦ê°€í–ˆìœ¼ë©°, ì´ëŠ” ìœ ê¸°ì  ë§¤ì¶œ ì„±ì¥ 3%, ì¸ìˆ˜í•©ë³‘ ê¸°ì—¬ë¶„ 1%, ê·¸ë¦¬ê³  ì™¸í™˜ ìˆœí’íš¨ê³¼ 1%ë¥¼ í¬í•¨í•œ ê²ƒì…ë‹ˆë‹¤. ì§€ì—­ë³„ ìœ ê¸°ì  ë§¤ì¶œ ì„±ê³¼ë¥¼ ì‚´í´ë³´ë©´, 3ë¶„ê¸° ë¶ë¯¸ëŠ” ë‚®ì€ í•œ ìë¦¿ìˆ˜ ì„±ì¥ì„ ë³´ì˜€ìŠµë‹ˆë‹¤. ìœ ëŸ½ê³¼ ì•„ì‹œì•„íƒœí‰ì–‘ì€ ëª¨ë‘ ì¤‘ê°„ í•œ ìë¦¿ìˆ˜ ì„±ì¥ì„ ê¸°ë¡í•œ ë°˜ë©´, ì¤‘êµ­ì€ ì¤‘ê°„ í•œ ìë¦¿ìˆ˜ ê°ì†Œë¥¼ ë³´ì˜€ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>With respect to our operational performance, we delivered $2.59 billion of adjusted operating income in the quarter, an increase of 9% year-over-year, and adjusted operating margin was 23.3%, 100 basis points higher than Q3 last year. The very strong earnings results reflect our active management of the business and the power of our PPI Business System. Total company adjusted gross margin in the quarter was 41.9%, 10 basis points higher than Q3 last year. We delivered very strong productivity, which enabled us to fund strategic investments to further advance our industry leadership and offset the impact of tariffs and related FX and unfavorable mix. Moving on to the details of the P&L.</td><td>ìš´ì˜ ì„±ê³¼ì™€ ê´€ë ¨í•˜ì—¬, ë‹¹ë¶„ê¸° ì¡°ì • ì˜ì—…ì´ìµì€ 25ì–µ 9ì²œë§Œ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í•˜ì—¬ ì „ë…„ ë™ê¸° ëŒ€ë¹„ 9% ì¦ê°€í–ˆìœ¼ë©°, ì¡°ì • ì˜ì—…ì´ìµë¥ ì€ 23.3%ë¡œ ì‘ë…„ 3ë¶„ê¸° ëŒ€ë¹„ 100bp ìƒìŠ¹í–ˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ë§¤ìš° ê°•ë ¥í•œ ì‹¤ì ì€ ë‹¹ì‚¬ì˜ ì ê·¹ì ì¸ ì‚¬ì—… ê´€ë¦¬ì™€ PPI ë¹„ì¦ˆë‹ˆìŠ¤ ì‹œìŠ¤í…œì˜ í˜ì„ ë°˜ì˜í•œ ê²ƒì…ë‹ˆë‹¤. ë‹¹ë¶„ê¸° ì „ì‚¬ ì¡°ì • ì´ì´ìµë¥ ì€ 41.9%ë¡œ ì‘ë…„ 3ë¶„ê¸° ëŒ€ë¹„ 10bp ìƒìŠ¹í–ˆìŠµë‹ˆë‹¤. ë‹¹ì‚¬ëŠ” ë§¤ìš° ê°•ë ¥í•œ ìƒì‚°ì„±ì„ ë‹¬ì„±í–ˆìœ¼ë©°, ì´ë¥¼ í†µí•´ ì—…ê³„ ì„ ë„ì  ì§€ìœ„ë¥¼ ë”ìš± ê°•í™”í•˜ê¸° ìœ„í•œ ì „ëµì  íˆ¬ìì— ìê¸ˆì„ ì¡°ë‹¬í•˜ê³  ê´€ì„¸ ë° ê´€ë ¨ í™˜ìœ¨, ë¶ˆë¦¬í•œ ì œí’ˆ ë¯¹ìŠ¤ì˜ ì˜í–¥ì„ ìƒì‡„í•  ìˆ˜ ìˆì—ˆìŠµë‹ˆë‹¤. ì´ì œ ì†ìµê³„ì‚°ì„œì˜ ì„¸ë¶€ ë‚´ìš©ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Adjusted SG&A in the quarter was 15.5% of revenue. R&D expense was $346 million in Q3, reflect our ongoing investments in high-impact innovation. R&D as a percent of our manufacturing revenue was 6.9% in the quarter. Looking at our results below line. Our Q3 net interest expense was $113 million, as expected, the adjusted tax rate in Q3 was 11% and average diluted shares were $378 million, approximately $5 million lower year-over-year, driven by share repurchases, net of option dilution. Turning to free cash flow and the balance sheet. Year-to-date cash flow from operations was $4.4 billion and free cash flow was $3.3 billion after investing $1 billion of net capital expenditure.</td><td>ë¶„ê¸° ì¡°ì • íŒê´€ë¹„ëŠ” ë§¤ì¶œì˜ 15.5%ì˜€ìŠµë‹ˆë‹¤. 3ë¶„ê¸° R&D ë¹„ìš©ì€ 3ì–µ 4,600ë§Œ ë‹¬ëŸ¬ë¡œ, ì´ëŠ” ê³ íš¨ê³¼ í˜ì‹ ì— ëŒ€í•œ ì§€ì†ì ì¸ íˆ¬ìë¥¼ ë°˜ì˜í•œ ê²ƒì…ë‹ˆë‹¤. ì œì¡° ë§¤ì¶œ ëŒ€ë¹„ R&D ë¹„ì¤‘ì€ ë¶„ê¸° ì¤‘ 6.9%ì˜€ìŠµë‹ˆë‹¤. <br><br>ì˜ì—…ì™¸ ì†ìµì„ ì‚´í´ë³´ë©´, 3ë¶„ê¸° ìˆœì´ìë¹„ìš©ì€ ì˜ˆìƒëŒ€ë¡œ 1ì–µ 1,300ë§Œ ë‹¬ëŸ¬ì˜€ê³ , ì¡°ì • ì„¸ìœ¨ì€ 3ë¶„ê¸° 11%ì˜€ìœ¼ë©°, í‰ê·  í¬ì„ì£¼ì‹ìˆ˜ëŠ” 3ì–µ 7,800ë§Œ ì£¼ë¡œ ìì‚¬ì£¼ ë§¤ì…ì—ì„œ ì˜µì…˜ í¬ì„íš¨ê³¼ë¥¼ ì°¨ê°í•œ ì˜í–¥ìœ¼ë¡œ ì „ë…„ ë™ê¸° ëŒ€ë¹„ ì•½ 500ë§Œ ì£¼ ê°ì†Œí–ˆìŠµë‹ˆë‹¤.<br><br>ì‰ì—¬í˜„ê¸ˆíë¦„ê³¼ ëŒ€ì°¨ëŒ€ì¡°í‘œë¥¼ ë³´ë©´, ì—°ì´ˆ ëŒ€ë¹„ ì˜ì—…í˜„ê¸ˆíë¦„ì€ 44ì–µ ë‹¬ëŸ¬ì˜€ê³ , ìˆœìë³¸ì§€ì¶œ 10ì–µ ë‹¬ëŸ¬ë¥¼ íˆ¬ìí•œ í›„ ì‰ì—¬í˜„ê¸ˆíë¦„ì€ 33ì–µ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Q3 was a very active quarter of capital deployment. We deployed approximately $4 billion of capital through the acquisition from our Filtration and Separation business from Solventum and the sterile fill-finish site from Sanofi. In addition, we repurchased $1 billion of shares during the quarter and returned $160 million of capital through dividends. We ended the quarter with $3.5 billion in cash and short-term investments and $35.7 billion of total debt. Our leverage ratio at the end of the quarter was 3.2x gross debt to adjusted EBITDA and 2.9x on a net debt basis. Concluding my comments in our total company performance.</td><td>3ë¶„ê¸°ëŠ” ìë³¸ ë°°ì¹˜ê°€ ë§¤ìš° í™œë°œí–ˆë˜ ë¶„ê¸°ì˜€ìŠµë‹ˆë‹¤. ì†”ë²¤í…€(Solventum)ìœ¼ë¡œë¶€í„° ì—¬ê³¼ ë° ë¶„ë¦¬ ì‚¬ì—…ë¶€ë¥¼ ì¸ìˆ˜í•˜ê³  ì‚¬ë…¸í”¼(Sanofi)ë¡œë¶€í„° ë¬´ê·  ì¶©ì „-ì™„ì„± ì‚¬ì´íŠ¸ë¥¼ ì¸ìˆ˜í•˜ì—¬ ì•½ 40ì–µ ë‹¬ëŸ¬ì˜ ìë³¸ì„ ë°°ì¹˜í–ˆìŠµë‹ˆë‹¤. ë˜í•œ ë¶„ê¸° ì¤‘ 10ì–µ ë‹¬ëŸ¬ì˜ ìì‚¬ì£¼ë¥¼ ë§¤ì…í–ˆìœ¼ë©° ë°°ë‹¹ì„ í†µí•´ 1ì–µ 6ì²œë§Œ ë‹¬ëŸ¬ì˜ ìë³¸ì„ ì£¼ì£¼ì—ê²Œ í™˜ì›í–ˆìŠµë‹ˆë‹¤. ë¶„ê¸°ë§ í˜„ì¬ í˜„ê¸ˆ ë° ë‹¨ê¸°íˆ¬ìëŠ” 35ì–µ ë‹¬ëŸ¬, ì´ ë¶€ì±„ëŠ” 357ì–µ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ë¶„ê¸°ë§ ë ˆë²„ë¦¬ì§€ ë¹„ìœ¨ì€ ì´ë¶€ì±„ ëŒ€ ì¡°ì • EBITDA ê¸°ì¤€ 3.2ë°°, ìˆœë¶€ì±„ ê¸°ì¤€ìœ¼ë¡œëŠ” 2.9ë°°ì˜€ìŠµë‹ˆë‹¤. ì „ì‚¬ ì‹¤ì ì— ëŒ€í•œ ì œ ì½”ë©˜íŠ¸ë¥¼ ë§ˆë¬´ë¦¬í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Adjusted ROIC was 11.3% reflecting the strong returns on investment that we're generating across the company. I'll provide some color on our performance of our 4 business segments. In Life Sciences solutions, Q3 reported revenue in this segment increased 8% versus the prior year quarter and organic revenue growth was 5%. Growth in this segment was led by our Bioproduction business, which had another quarter of excellent growth. Q3 adjusted operating income for Life Sciences Solutions increased 15% and adjusted operating margin was 37.4%, up 200 basis points versus the prior year quarter.</td><td>ì¡°ì • ROICëŠ” 11.3%ë¡œ, íšŒì‚¬ ì „ë°˜ì— ê±¸ì³ ì°½ì¶œí•˜ê³  ìˆëŠ” ê°•ë ¥í•œ íˆ¬ììˆ˜ìµë¥ ì„ ë°˜ì˜í•©ë‹ˆë‹¤. 4ê°œ ì‚¬ì—…ë¶€ë¬¸ì˜ ì‹¤ì ì— ëŒ€í•´ ì¢€ ë” ìì„¸íˆ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ìƒëª…ê³¼í•™ ì†”ë£¨ì…˜ ë¶€ë¬¸ì—ì„œ 3ë¶„ê¸° ë³´ê³  ë§¤ì¶œì€ ì „ë…„ ë™ê¸° ëŒ€ë¹„ 8% ì¦ê°€í–ˆìœ¼ë©°, ìœ ê¸°ì  ë§¤ì¶œ ì„±ì¥ë¥ ì€ 5%ì˜€ìŠµë‹ˆë‹¤. ì´ ë¶€ë¬¸ì˜ ì„±ì¥ì€ ë˜ í•œ ë¶„ê¸° ìš°ìˆ˜í•œ ì„±ì¥ì„ ë³´ì¸ ë°”ì´ì˜¤ìƒì‚° ì‚¬ì—…ì´ ì£¼ë„í–ˆìŠµë‹ˆë‹¤. ìƒëª…ê³¼í•™ ì†”ë£¨ì…˜ ë¶€ë¬¸ì˜ 3ë¶„ê¸° ì¡°ì • ì˜ì—…ì´ìµì€ 15% ì¦ê°€í–ˆê³ , ì¡°ì • ì˜ì—…ì´ìµë¥ ì€ 37.4%ë¡œ ì „ë…„ ë™ê¸° ëŒ€ë¹„ 200bp ìƒìŠ¹í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>During Q3, we delivered very strong productivity and volume leverage, which was partially offset by unfavorable mix, strategic investments and the impact of the acquisition of our Filtration and Separation business, which is included within this segment. In the Analytical Instruments segment, reported revenue increased 5% and organic revenue growth was 4%. Growth in the quarter was led by electron microscopy and chromatography and mass spectrometry businesses. In this segment, Q3 adjusted operating income decreased 5% and adjusted operating margin was 22.6%, down 230 basis points versus the year ago quarter, but this was a sequential improvement from Q2 2025.</td><td>3ë¶„ê¸° ë™ì•ˆ ìš°ë¦¬ëŠ” ë§¤ìš° ê°•ë ¥í•œ ìƒì‚°ì„±ê³¼ ë¬¼ëŸ‰ ë ˆë²„ë¦¬ì§€ë¥¼ ë‹¬ì„±í–ˆìœ¼ë‚˜, ì´ëŠ” ë¶ˆë¦¬í•œ ì œí’ˆ ë¯¹ìŠ¤, ì „ëµì  íˆ¬ì, ê·¸ë¦¬ê³  ì´ ë¶€ë¬¸ì— í¬í•¨ëœ ì—¬ê³¼ ë° ë¶„ë¦¬ ì‚¬ì—… ì¸ìˆ˜ì˜ ì˜í–¥ìœ¼ë¡œ ë¶€ë¶„ì ìœ¼ë¡œ ìƒì‡„ë˜ì—ˆìŠµë‹ˆë‹¤. ë¶„ì„ê¸°ê¸° ë¶€ë¬¸ì—ì„œëŠ” ë³´ê³  ë§¤ì¶œì´ 5% ì¦ê°€í–ˆìœ¼ë©° ìœ ê¸°ì  ë§¤ì¶œ ì„±ì¥ë¥ ì€ 4%ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ì´ë²ˆ ë¶„ê¸° ì„±ì¥ì€ ì „ìí˜„ë¯¸ê²½ê³¼ í¬ë¡œë§ˆí† ê·¸ë˜í”¼ ë° ì§ˆëŸ‰ë¶„ì„ ì‚¬ì—…ì´ ì£¼ë„í–ˆìŠµë‹ˆë‹¤. ì´ ë¶€ë¬¸ì—ì„œ 3ë¶„ê¸° ì¡°ì • ì˜ì—…ì´ìµì€ 5% ê°ì†Œí–ˆìœ¼ë©°, ì¡°ì • ì˜ì—…ì´ìµë¥ ì€ 22.6%ë¡œ ì „ë…„ ë™ê¸° ëŒ€ë¹„ 230bp í•˜ë½í–ˆì§€ë§Œ, ì´ëŠ” 2025ë…„ 2ë¶„ê¸° ëŒ€ë¹„ ìˆœì°¨ì  ê°œì„ ì„ ë³´ì¸ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>The majority of the year-over-year margin change was driven by the impact of tariffs and related FX. Outside of that impact, strong productivity was partially offset by strategic investments and unfavorable mix. Turning to Specialty Diagnostics in Q3 reported revenue grew 4% year-over-year and organic revenue growth was 2%. In Q3, growth in this segment was led by Transplant Diagnostics and Immunodiagnostics businesses. Q3 adjusted operating income for Specialty Diagnostics increased 10% and adjusted operating margin was 27.4%, 150 basis points higher than Q3 2024. During the quarter, we delivered strong productivity and volume leverage.</td><td>ì „ë…„ ë™ê¸° ëŒ€ë¹„ ë§ˆì§„ ë³€í™”ì˜ ëŒ€ë¶€ë¶„ì€ ê´€ì„¸ ë° ê´€ë ¨ ì™¸í™˜ì˜ ì˜í–¥ìœ¼ë¡œ ì¸í•œ ê²ƒì´ì—ˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì˜í–¥ì„ ì œì™¸í•˜ë©´, ê°•ë ¥í•œ ìƒì‚°ì„± í–¥ìƒì´ ì „ëµì  íˆ¬ìì™€ ë¶ˆë¦¬í•œ ì œí’ˆ ë¯¹ìŠ¤ì— ì˜í•´ ë¶€ë¶„ì ìœ¼ë¡œ ìƒì‡„ë˜ì—ˆìŠµë‹ˆë‹¤. <br><br>íŠ¹ìˆ˜ì§„ë‹¨ ë¶€ë¬¸ìœ¼ë¡œ ë„˜ì–´ê°€ì„œ, 3ë¶„ê¸° ë³´ê³  ë§¤ì¶œì€ ì „ë…„ ë™ê¸° ëŒ€ë¹„ 4% ì„±ì¥í–ˆìœ¼ë©° ìœ ê¸°ì  ë§¤ì¶œ ì„±ì¥ë¥ ì€ 2%ì˜€ìŠµë‹ˆë‹¤. 3ë¶„ê¸°ì— ì´ ë¶€ë¬¸ì˜ ì„±ì¥ì€ ì´ì‹ì§„ë‹¨ ë° ë©´ì—­ì§„ë‹¨ ì‚¬ì—…ì´ ì£¼ë„í–ˆìŠµë‹ˆë‹¤. íŠ¹ìˆ˜ì§„ë‹¨ ë¶€ë¬¸ì˜ 3ë¶„ê¸° ì¡°ì • ì˜ì—…ì´ìµì€ 10% ì¦ê°€í–ˆìœ¼ë©°, ì¡°ì • ì˜ì—…ë§ˆì§„ì€ 27.4%ë¡œ 2024ë…„ 3ë¶„ê¸° ëŒ€ë¹„ 150ë² ì´ì‹œìŠ¤í¬ì¸íŠ¸ ìƒìŠ¹í–ˆìŠµë‹ˆë‹¤. ë¶„ê¸° ë™ì•ˆ ìš°ë¦¬ëŠ” ê°•ë ¥í•œ ìƒì‚°ì„±ê³¼ ë¬¼ëŸ‰ ë ˆë²„ë¦¬ì§€ë¥¼ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Finally, in the Laboratory Products and Biopharma Services segment reported revenue increased 4% and organic revenue growth was 3%. Growth in the segment was led by our Research and Safety market channel. The runoff of pandemic-related revenue had a 1% impact on the revenue growth in segment in the quarter. Q3 adjusted operating income in the segment increased 12% and adjusted operating margin was 14.5%, 100 basis points higher than Q3 2024. In the quarter, we delivered very strong productivity which is partially offset by unfavorable mix and strategic investments.</td><td>ë§ˆì§€ë§‰ìœ¼ë¡œ, ì‹¤í—˜ì‹¤ ì œí’ˆ ë° ë°”ì´ì˜¤íŒŒë§ˆ ì„œë¹„ìŠ¤ ë¶€ë¬¸ì˜ ë³´ê³  ë§¤ì¶œì€ 4% ì¦ê°€í–ˆìœ¼ë©° ìœ ê¸°ì  ë§¤ì¶œ ì„±ì¥ë¥ ì€ 3%ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ì´ ë¶€ë¬¸ì˜ ì„±ì¥ì€ ì—°êµ¬ ë° ì•ˆì „ ì‹œì¥ ì±„ë„ì´ ì£¼ë„í–ˆìŠµë‹ˆë‹¤. íŒ¬ë°ë¯¹ ê´€ë ¨ ë§¤ì¶œì˜ ê°ì†ŒëŠ” ì´ë²ˆ ë¶„ê¸° ë¶€ë¬¸ ë§¤ì¶œ ì„±ì¥ë¥ ì— 1%ì˜ ì˜í–¥ì„ ë¯¸ì³¤ìŠµë‹ˆë‹¤. 3ë¶„ê¸° ì¡°ì • ì˜ì—…ì´ìµì€ 12% ì¦ê°€í–ˆìœ¼ë©°, ì¡°ì • ì˜ì—…ì´ìµë¥ ì€ 14.5%ë¡œ 2024ë…„ 3ë¶„ê¸° ëŒ€ë¹„ 100bp ìƒìŠ¹í–ˆìŠµë‹ˆë‹¤. ì´ë²ˆ ë¶„ê¸°ì—ëŠ” ë§¤ìš° ê°•ë ¥í•œ ìƒì‚°ì„±ì„ ë‹¬ì„±í–ˆìœ¼ë‚˜, ì´ëŠ” ë¶ˆë¦¬í•œ ì œí’ˆ ë¯¹ìŠ¤ì™€ ì „ëµì  íˆ¬ìë¡œ ë¶€ë¶„ì ìœ¼ë¡œ ìƒì‡„ë˜ì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>To change to guidance, as Marc outlined, we're raising our 2025 full year guide on both the top and bottom line, reflecting our continued active management of the company. Let me provide you with the details. We're raising our revenue guidance to an expected range of $44.1 billion to $44.5 billion. Organic revenue growth at the midpoint of the guide continues to be 2% for the full year, and as a reminder, that includes a 1 point of headwind from the run-up of pandemic-related revenue. We're increasing our outlook for adjusted operating margin in 2025 to a new range of 22.7% to 22.8%. And we're raising our adjusted EPS guidance to a new range of $22.60 to $22.86.</td><td>ê°€ì´ë˜ìŠ¤ ë³€ê²½ ì‚¬í•­ìœ¼ë¡œ ë„˜ì–´ê°€ì„œ, ë§ˆí¬ê°€ ì„¤ëª…í•œ ë°”ì™€ ê°™ì´ ì €í¬ëŠ” 2025ë…„ ì—°ê°„ ê°€ì´ë˜ìŠ¤ë¥¼ ë§¤ì¶œê³¼ ìˆœì´ìµ ëª¨ë‘ì—ì„œ ìƒí–¥ ì¡°ì •í•˜ê³  ìˆìœ¼ë©°, ì´ëŠ” íšŒì‚¬ì— ëŒ€í•œ ì €í¬ì˜ ì§€ì†ì ì´ê³  ì ê·¹ì ì¸ ê²½ì˜ì„ ë°˜ì˜í•œ ê²ƒì…ë‹ˆë‹¤. ì„¸ë¶€ ì‚¬í•­ì„ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë§¤ì¶œ ê°€ì´ë˜ìŠ¤ë¥¼ 441ì–µ ë‹¬ëŸ¬ì—ì„œ 445ì–µ ë‹¬ëŸ¬ì˜ ì˜ˆìƒ ë²”ìœ„ë¡œ ìƒí–¥ ì¡°ì •í•©ë‹ˆë‹¤. ê°€ì´ë˜ìŠ¤ ì¤‘ê°„ê°’ ê¸°ì¤€ ìœ ê¸°ì  ë§¤ì¶œ ì„±ì¥ë¥ ì€ ì—°ê°„ 2%ë¥¼ ì§€ì†í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë˜ë©°, ì°¸ê³ ë¡œ ì—¬ê¸°ì—ëŠ” íŒ¬ë°ë¯¹ ê´€ë ¨ ë§¤ì¶œ ì¦ê°€ë¡œ ì¸í•œ 1í¬ì¸íŠ¸ì˜ ì—­í’ì´ í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤. 2025ë…„ ì¡°ì • ì˜ì—…ì´ìµë¥  ì „ë§ì„ 22.7%ì—ì„œ 22.8%ì˜ ìƒˆë¡œìš´ ë²”ìœ„ë¡œ ìƒí–¥ ì¡°ì •í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì¡°ì • ì£¼ë‹¹ìˆœì´ìµ ê°€ì´ë˜ìŠ¤ë¥¼ 22.60ë‹¬ëŸ¬ì—ì„œ 22.86ë‹¬ëŸ¬ì˜ ìƒˆë¡œìš´ ë²”ìœ„ë¡œ ìƒí–¥ ì¡°ì •í•©ë‹ˆë‹¤.</td></tr>
<tr><td>The increase at the midpoint of the guidance range reflects $420 million higher revenue than the prior guide, driven by the benefit of our recent acquisitions and an increase in the tailwind from FX. From an earnings standpoint, the increase in the midpoint of the guide reflects 20 basis points of improved adjusted operating margin expansion and $0.20 of higher adjusted EPS. This change includes $0.05 of dilution from the recent acquisitions. We'll continue to actively manage the company and drive excellent operational performance, once again, enabling us to increase our guidance for the year. I'll now move on to an update of some of the modeling elements for the full year.</td><td>ê°€ì´ë˜ìŠ¤ ë²”ìœ„ì˜ ì¤‘ê°„ê°’ ìƒí–¥ ì¡°ì •ì€ ì´ì „ ê°€ì´ë˜ìŠ¤ ëŒ€ë¹„ 4ì–µ 2ì²œë§Œ ë‹¬ëŸ¬ì˜ ë§¤ì¶œ ì¦ê°€ë¥¼ ë°˜ì˜í•˜ëŠ” ê²ƒìœ¼ë¡œ, ì´ëŠ” ìµœê·¼ ì¸ìˆ˜í•©ë³‘ì˜ íš¨ê³¼ì™€ í™˜ìœ¨ ìˆœí’ì˜ ì¦ê°€ì— ê¸°ì¸í•©ë‹ˆë‹¤. ìˆ˜ìµì„± ì¸¡ë©´ì—ì„œëŠ”, ê°€ì´ë˜ìŠ¤ ì¤‘ê°„ê°’ì˜ ìƒí–¥ ì¡°ì •ì´ ì¡°ì • ì˜ì—…ì´ìµë¥  í™•ëŒ€ 20bp ê°œì„ ê³¼ ì¡°ì • ì£¼ë‹¹ìˆœì´ìµ 0.20ë‹¬ëŸ¬ ì¦ê°€ë¥¼ ë°˜ì˜í•©ë‹ˆë‹¤. ì´ëŸ¬í•œ ë³€í™”ì—ëŠ” ìµœê·¼ ì¸ìˆ˜í•©ë³‘ìœ¼ë¡œ ì¸í•œ 0.05ë‹¬ëŸ¬ì˜ í¬ì„ íš¨ê³¼ê°€ í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” ê³„ì†í•´ì„œ íšŒì‚¬ë¥¼ ì ê·¹ì ìœ¼ë¡œ ê´€ë¦¬í•˜ê³  ìš°ìˆ˜í•œ ìš´ì˜ ì„±ê³¼ë¥¼ ì¶”ì§„í•˜ì—¬, ë‹¤ì‹œ í•œë²ˆ ì—°ê°„ ê°€ì´ë˜ìŠ¤ë¥¼ ìƒí–¥ ì¡°ì •í•  ìˆ˜ ìˆê²Œ ë˜ì—ˆìŠµë‹ˆë‹¤. ì´ì œ ì—°ê°„ ì „ë§ì˜ ì¼ë¶€ ëª¨ë¸ë§ ìš”ì†Œë“¤ì— ëŒ€í•œ ì—…ë°ì´íŠ¸ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Our guidance now includes the impact of the recently closed acquisitions. These deals added $260 million to revenue to our prior full year guide, $20 million adjusted operating income, and as I mentioned earlier, $0.05 of adjusted EPS dilution. In terms of tariffs, our guidance reflects the tariffs that are currently in place as of today. This includes the increase in tariff rates between the U.S. and Europe that occurred since the time of our last guidance. The changes in tariffs and trade policy once again caused intra-quarter volatility in FX rates in Q3. As a result, FX in Q3 was $220 million revenue tailwind to our prior guide and a $0.10 adjusted EPS headwind.</td><td>ì €í¬ ê°€ì´ë˜ìŠ¤ì—ëŠ” ìµœê·¼ ì™„ë£Œëœ ì¸ìˆ˜ì˜ ì˜í–¥ì´ í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ê±°ë˜ë“¤ì€ ê¸°ì¡´ ì—°ê°„ ê°€ì´ë˜ìŠ¤ ëŒ€ë¹„ ë§¤ì¶œì— 2ì–µ 6ì²œë§Œ ë‹¬ëŸ¬ë¥¼ ì¶”ê°€í–ˆìœ¼ë©°, ì¡°ì • ì˜ì—…ì´ìµì— 2ì²œë§Œ ë‹¬ëŸ¬, ê·¸ë¦¬ê³  ì•ì„œ ì–¸ê¸‰í•œ ë°”ì™€ ê°™ì´ ì¡°ì • ì£¼ë‹¹ìˆœì´ìµì— 0.05ë‹¬ëŸ¬ì˜ í¬ì„ íš¨ê³¼ë¥¼ ê°€ì ¸ì™”ìŠµë‹ˆë‹¤. ê´€ì„¸ì™€ ê´€ë ¨í•´ì„œëŠ”, ì €í¬ ê°€ì´ë˜ìŠ¤ëŠ” í˜„ì¬ ì‹œì ì—ì„œ ì‹œí–‰ ì¤‘ì¸ ê´€ì„¸ë¥¼ ë°˜ì˜í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì—¬ê¸°ì—ëŠ” ì§€ë‚œ ê°€ì´ë˜ìŠ¤ ë°œí‘œ ì´í›„ ë°œìƒí•œ ë¯¸êµ­ê³¼ ìœ ëŸ½ ê°„ ê´€ì„¸ìœ¨ ì¸ìƒì´ í¬í•¨ë©ë‹ˆë‹¤. ê´€ì„¸ ë° ë¬´ì—­ì •ì±…ì˜ ë³€í™”ë¡œ ì¸í•´ 3ë¶„ê¸°ì— ë‹¤ì‹œ í•œë²ˆ ë¶„ê¸° ë‚´ í™˜ìœ¨ ë³€ë™ì„±ì´ ë°œìƒí–ˆìŠµë‹ˆë‹¤. ê·¸ ê²°ê³¼, 3ë¶„ê¸° í™˜ìœ¨ ì˜í–¥ì€ ê¸°ì¡´ ê°€ì´ë˜ìŠ¤ ëŒ€ë¹„ ë§¤ì¶œì— 2ì–µ 2ì²œë§Œ ë‹¬ëŸ¬ì˜ ìˆœí’ íš¨ê³¼ë¥¼, ì¡°ì • ì£¼ë‹¹ìˆœì´ìµì—ëŠ” 0.10ë‹¬ëŸ¬ì˜ ì—­í’ íš¨ê³¼ë¥¼ ê°€ì ¸ì™”ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>So for the full year, we now expect FX to be a year-over-year tailwind to revenue of $230 million and a headwind to adjusted operating income and adjusted EPS of $110 million and $0.37, respectively. Below the line, we now expect net interest expense to be approximately $440 million in 2025, and we continue to expect an adjusted tax rate of 10.5% for the full year. We expect between $1.4 billion and $1.7 billion of net capital expenditures and around $7 billion of free cash flow for the year.</td><td>ì—°ê°„ ì „ì²´ ê¸°ì¤€ìœ¼ë¡œ, í˜„ì¬ ì™¸í™˜ì´ ë§¤ì¶œì— ì „ë…„ ëŒ€ë¹„ 2ì–µ 3ì²œë§Œ ë‹¬ëŸ¬ì˜ ìˆœí’ ìš”ì¸ì´ ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ë©°, ì¡°ì • ì˜ì—…ì´ìµê³¼ ì¡°ì • ì£¼ë‹¹ìˆœì´ìµì—ëŠ” ê°ê° 1ì–µ 1ì²œë§Œ ë‹¬ëŸ¬ì™€ 0.37ë‹¬ëŸ¬ì˜ ì—­í’ ìš”ì¸ì´ ë  ê²ƒìœ¼ë¡œ ì „ë§í•©ë‹ˆë‹¤. ì˜ì—…ì™¸ í•­ëª©ì—ì„œëŠ” 2025ë…„ ìˆœì´ìë¹„ìš©ì´ ì•½ 4ì–µ 4ì²œë§Œ ë‹¬ëŸ¬ê°€ ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ë©°, ì—°ê°„ ì¡°ì • ì„¸ìœ¨ì€ 10.5%ë¥¼ ì§€ì†ì ìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ìˆœìë³¸ì§€ì¶œì€ 14ì–µ ë‹¬ëŸ¬ì—ì„œ 17ì–µ ë‹¬ëŸ¬ ì‚¬ì´, ì—°ê°„ ì‰ì—¬í˜„ê¸ˆíë¦„ì€ ì•½ 70ì–µ ë‹¬ëŸ¬ë¥¼ ì˜ˆìƒí•©ë‹ˆë‹¤.</td></tr>
<tr><td>Then in terms of capital deployment, our guidance now assumes that we deploy $7.6 billion of capital in 2025, $4 billion on the recently closed acquisitions, $3 billion on already completed share buybacks and $600 million of capital returned to shareholders through dividends. And finally, we estimate the full year average diluted share count will be approximately 378 million shares. So to conclude, we delivered an excellent Q3 and we're in a great position to deliver on our 2025 objectives. With that, I'll turn the call back over to Raf. Rafael Tejada<br>Vice President of Investor Relations<br><br>Thank you, Stephen. So with that, let's get started for the Q&A portion of the call.</td><td>ìë³¸ ë°°ì¹˜ ì¸¡ë©´ì—ì„œëŠ”, ì €í¬ ê°€ì´ë˜ìŠ¤ê°€ 2025ë…„ì— 76ì–µ ë‹¬ëŸ¬ì˜ ìë³¸ì„ ë°°ì¹˜í•  ê²ƒìœ¼ë¡œ ê°€ì •í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ìµœê·¼ ì™„ë£Œëœ ì¸ìˆ˜ì— 40ì–µ ë‹¬ëŸ¬, ì´ë¯¸ ì™„ë£Œëœ ìì‚¬ì£¼ ë§¤ì…ì— 30ì–µ ë‹¬ëŸ¬, ê·¸ë¦¬ê³  ë°°ë‹¹ì„ í†µí•œ ì£¼ì£¼ í™˜ì›ì— 6ì–µ ë‹¬ëŸ¬ë¡œ êµ¬ì„±ë©ë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ, ì—°ê°„ í‰ê·  í¬ì„ì£¼ì‹ìˆ˜ëŠ” ì•½ 3ì–µ 7,800ë§Œ ì£¼ê°€ ë  ê²ƒìœ¼ë¡œ ì¶”ì •í•©ë‹ˆë‹¤.<br><br>ê²°ë¡ ì ìœ¼ë¡œ, ì €í¬ëŠ” ìš°ìˆ˜í•œ 3ë¶„ê¸° ì‹¤ì ì„ ë‹¬ì„±í–ˆìœ¼ë©° 2025ë…„ ëª©í‘œë¥¼ ë‹¬ì„±í•  ìˆ˜ ìˆëŠ” í›Œë¥­í•œ ìœ„ì¹˜ì— ìˆìŠµë‹ˆë‹¤. ì´ì œ ë¼í”„ì—ê²Œ ë‹¤ì‹œ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.<br><br>ë¼íŒŒì—˜ í…Œí•˜ë‹¤<br>íˆ¬ìì ê´€ê³„ ë‹´ë‹¹ ë¶€ì‚¬ì¥<br><br>ê°ì‚¬í•©ë‹ˆë‹¤, ìŠ¤í‹°ë¸. ê·¸ëŸ¼ ì´ì œ ì§ˆì˜ì‘ë‹µ ì‹œê°„ì„ ì‹œì‘í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;">â€¢ ì‹¤ì  í•˜ì´ë¼ì´íŠ¸:<br>- 3ë¶„ê¸° ë§¤ì¶œ 5% ì¦ê°€í•œ 111.2ì–µ ë‹¬ëŸ¬ ê¸°ë¡<br>- ì¡°ì •ì˜ì—…ì´ìµ 9% ì¦ê°€í•œ 25.9ì–µ ë‹¬ëŸ¬, ì˜ì—…ì´ìµë¥  100bp ê°œì„ ëœ 23.3% ë‹¬ì„±<br>- ì¡°ì • EPS 10% ì¦ê°€í•œ ì£¼ë‹¹ 5.79ë‹¬ëŸ¬ ê¸°ë¡<br><br>â€¢ ì‚¬ì—…ë¶€ë¬¸ë³„ ì‹¤ì :<br>- ì œì•½/ë°”ì´ì˜¤í… ë¶€ë¬¸ ì¤‘ê°„ í•œ ìë¦¿ìˆ˜ ì„±ì¥<br>- í•™ìˆ /ì •ë¶€ ë¶€ë¬¸ ì†Œí­ ê°ì†Œ<br>- ì‚°ì—…/ì‘ìš© ë¶€ë¬¸ ì¤‘ê°„ í•œ ìë¦¿ìˆ˜ ì„±ì¥<br>- ì§„ë‹¨/í—¬ìŠ¤ì¼€ì–´ ë¶€ë¬¸ ì¤‘êµ­ ì˜í–¥ìœ¼ë¡œ ì†Œí­ ê°ì†Œ<br><br>â€¢ ì£¼ìš” ì „ëµì  ì§„ì „:<br>- OpenAIì™€ ì „ëµì  í˜‘ë ¥ ì²´ê²°í•˜ì—¬ ì œí’ˆê°œë°œ ë° ê³ ê° ì„œë¹„ìŠ¤ ê°•í™” <br>- Solventumìœ¼ë¡œë¶€í„° ì—¬ê³¼/ë¶„ë¦¬ ì‚¬ì—…ë¶€ë¬¸ ì¸ìˆ˜ ì™„ë£Œ<br>- 30ì–µ ë‹¬ëŸ¬ ê·œëª¨ì˜ ìì‚¬ì£¼ ë§¤ì… ì‹¤ì‹œ<br><br>â€¢ 2025ë…„ ê°€ì´ë˜ìŠ¤ ìƒí–¥:<br>- ë§¤ì¶œ 441-445ì–µ ë‹¬ëŸ¬ë¡œ ìƒí–¥ ì¡°ì •<br>- ì¡°ì • EPS 22.60-22.86ë‹¬ëŸ¬ë¡œ ìƒí–¥ ì¡°ì •</p>
    <hr style="margin:50px 0;">
    

    <h2>â“ Q&A</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>Operator: [Operator Instructions] Our first question comes from Michael Ryskin from Bank of America.</td><td>**Operator:** [ìš´ì˜ì ì•ˆë‚´] ì²« ë²ˆì§¸ ì§ˆë¬¸ì€ ë±…í¬ ì˜¤ë¸Œ ì•„ë©”ë¦¬ì¹´ì˜ ë§ˆì´í´ ë¦¬ìŠ¤í‚¨ë‹˜ê»˜ì„œ ì£¼ì…¨ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Michael Ryskin: BofA Securities, Research Division Congrats on another strong print, guys. I'll start just on market conditions and what you're hearing and what your customers, Marc? I mean a lot has changed since we last were on the 3Q call, especially on Pharma. There's been a lot of progress and, I would say, de-escalation on some of the MFN and tariff concerns with Pharma. So just wondering if anything has changed in your conversations with your major customers over the last couple of weeks and months? Talk of reshoring longer-term. Could you just talk about how Thermo would benefit from that, both from a facility build-out perspective, but also from Patheon and some of the other Pharma services and your fill-finish capacity in the U.S. just sort of how that come up in conversations.</td><td>**Michael Ryskin:** ë˜ ë‹¤ë¥¸ ê°•ë ¥í•œ ì‹¤ì  ë°œí‘œ ì¶•í•˜ë“œë¦½ë‹ˆë‹¤. ë¨¼ì € ì‹œì¥ ìƒí™©ê³¼ ê³ ê°ë“¤ë¡œë¶€í„° ë“£ê³  ìˆëŠ” ë‚´ìš©ì— ëŒ€í•´ ì§ˆë¬¸ë“œë¦¬ê² ìŠµë‹ˆë‹¤, ë§ˆí¬. ì§€ë‚œ 3ë¶„ê¸° ì»¨í¼ëŸ°ìŠ¤ì½œ ì´í›„ ë§ì€ ë³€í™”ê°€ ìˆì—ˆëŠ”ë°, íŠ¹íˆ ì œì•½ ë¶„ì•¼ì—ì„œ ê·¸ë ‡ìŠµë‹ˆë‹¤. MFN(ìµœí˜œêµ­ëŒ€ìš°)ê³¼ ê´€ì„¸ ìš°ë ¤ì‚¬í•­ë“¤ì— ëŒ€í•´ ìƒë‹¹í•œ ì§„ì „ê³¼ ì™„í™”ê°€ ìˆì—ˆë‹¤ê³  ë´…ë‹ˆë‹¤. ê·¸ë˜ì„œ ì§€ë‚œ ëª‡ ì£¼, ëª‡ ë‹¬ ë™ì•ˆ ì£¼ìš” ê³ ê°ë“¤ê³¼ì˜ ëŒ€í™”ì—ì„œ ë³€í™”ëœ ì ì´ ìˆëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ì¥ê¸°ì ì¸ ë¦¬ì‡¼ì–´ë§(reshoring) ë…¼ì˜ë„ ìˆê³ ìš”. ì¨ëª¨ê°€ ì´ëŸ° ìƒí™©ì—ì„œ ì–´ë–¤ í˜œíƒì„ ë°›ì„ ìˆ˜ ìˆëŠ”ì§€ ë§ì”€í•´ ì£¼ì‹¤ ìˆ˜ ìˆë‚˜ìš”? ì‹œì„¤ í™•ì¥ ê´€ì ì—ì„œë¿ë§Œ ì•„ë‹ˆë¼ Patheonê³¼ ê¸°íƒ€ ì œì•½ ì„œë¹„ìŠ¤, ê·¸ë¦¬ê³  ë¯¸êµ­ ë‚´ ì¶©ì „-ì™„ì„±(fill-finish) ìƒì‚°ëŠ¥ë ¥ ì¸¡ë©´ì—ì„œë„ìš”. ì´ëŸ° ì£¼ì œë“¤ì´ ëŒ€í™”ì—ì„œ ì–´ë–»ê²Œ ë‚˜ì˜¤ê³  ìˆëŠ”ì§€ ë§ì”€í•´ ì£¼ì„¸ìš”.</td></tr>
<tr><td>Marc Casper: Chairman, President & CEO Mike, thanks for the question. Very topical. So in terms of our dialogue with our pharma and biotech customers. As you know, we're very engaged, right, with this customer set, the senior executives. And if I say what are they focused on probably is the first thing, right? There's a lot of excitement around scientific breakthroughs. A lot of confidence actually in their pipelines, and they're partnering with us to help them drive their success. As we talk about the actual environment, right, which is a part of how you think about the world and the decisions they make, there's a quiet confidence actually that they're going to be able to navigate the government policies effectively. And you're seeing that in some of the announcements that have been made on pricing as well as on re-shoring more activity in the U.S. in terms of not being exposed to potential tariffs. On that dynamic, what I would say is we're very engaged in helping those customers think about new sites, how to best equip them and support our customers in that effort. And that will benefit our channel business, it will benefit our Bioproduction business, our Analytical Instruments businesses. It will all benefit from those new construction. And that's really a large '27, '28 by the time ground is broken on new things for expansions within existing facilities, it could be a little bit faster than that. So that is something we're actively engaged in, but it takes some time to gestate. More rapidly than that, and in a way, more cost effectively for our customers is leveraging our Pharma Services network to be able to move more of their volume to the U.S. You know that we are the industry leader in drug products, sterile fill-finish. We have very strong capabilities here. We've had very strong demand for those capabilities and our arrangement with Sanofi where we acquired one of their sites, gives us another production node in the U.S. that is well-trained, great workforce and the ability to expand that facility as well. So we're excited to be able to enable our customers and Pharma Biotech has been a good environment for us. So thanks, Mike.</td><td>**Marc Casper:** ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. ë§¤ìš° ì‹œì˜ì ì ˆí•œ ì§ˆë¬¸ì´ë„¤ìš”. ì €í¬ ì œì•½ ë° ë°”ì´ì˜¤í…Œí¬ ê³ ê°ë“¤ê³¼ì˜ ëŒ€í™”ë¥¼ ë§ì”€ë“œë¦¬ë©´, ì•„ì‹œë‹¤ì‹œí”¼ ì €í¬ëŠ” ì´ ê³ ê°ì¸µ, íŠ¹íˆ ê³ ìœ„ ê²½ì˜ì§„ë“¤ê³¼ ë§¤ìš° ê¸´ë°€í•˜ê²Œ ì†Œí†µí•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë“¤ì´ ë¬´ì—‡ì— ì§‘ì¤‘í•˜ê³  ìˆëŠ”ì§€ ë¨¼ì € ë§ì”€ë“œë¦¬ë©´, ê³¼í•™ì  í˜ì‹ ì— ëŒ€í•œ í° ê¸°ëŒ€ê°ì´ ìˆìŠµë‹ˆë‹¤. ì‹¤ì œë¡œ ìì‹ ë“¤ì˜ íŒŒì´í”„ë¼ì¸ì— ëŒ€í•œ í™•ì‹ ë„ ìƒë‹¹í•˜ê³ , ì €í¬ì™€ íŒŒíŠ¸ë„ˆì‹­ì„ í†µí•´ ì„±ê³µì„ ì´ëŒì–´ë‚´ê³ ì í•©ë‹ˆë‹¤. <br><br>ì‹¤ì œ í™˜ê²½ì— ëŒ€í•´ ì´ì•¼ê¸°í•´ë³´ë©´, ì´ëŠ” ê·¸ë“¤ì´ ì„¸ìƒì„ ë°”ë¼ë³´ëŠ” ê´€ì ê³¼ ì˜ì‚¬ê²°ì •ì— ì˜í–¥ì„ ë¯¸ì¹˜ëŠ” ë¶€ë¶„ì¸ë°, ì •ë¶€ ì •ì±…ë“¤ì„ íš¨ê³¼ì ìœ¼ë¡œ í—¤ì³ë‚˜ê°ˆ ìˆ˜ ìˆì„ ê²ƒì´ë¼ëŠ” ì¡°ìš©í•œ ìì‹ ê°ì„ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. ê°€ê²© ì±…ì •ë¿ë§Œ ì•„ë‹ˆë¼ ì ì¬ì ì¸ ê´€ì„¸ ë…¸ì¶œì„ í”¼í•˜ê¸° ìœ„í•´ ë¯¸êµ­ ë‚´ ë¦¬ì‡¼ì–´ë§ í™œë™ì„ ëŠ˜ë¦¬ê² ë‹¤ëŠ” ë°œí‘œë“¤ì—ì„œë„ ì´ëŸ° ì›€ì§ì„ì„ í™•ì¸í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì—­í•™ ê´€ê³„ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ë©´, ì €í¬ëŠ” ê³ ê°ë“¤ì´ ìƒˆë¡œìš´ ì‚¬ì´íŠ¸ë¥¼ êµ¬ìƒí•˜ê³  ìµœì ì˜ ì¥ë¹„ë¥¼ ê°–ì¶”ëŠ” ë°©ë²•ì„ ê³ ë¯¼í•  ë•Œ ì ê·¹ì ìœ¼ë¡œ ë„ì›€ì„ ë“œë¦¬ê³  ìˆìœ¼ë©°, ì´ëŸ¬í•œ ë…¸ë ¥ì„ ì§€ì›í•˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ì´ëŠ” ì €í¬ ì±„ë„ ì‚¬ì—…, ë°”ì´ì˜¤í”„ë¡œë•ì…˜ ì‚¬ì—…, ë¶„ì„ê¸°ê¸° ì‚¬ì—… ëª¨ë‘ì— ë„ì›€ì´ ë  ê²ƒì…ë‹ˆë‹¤. ì´ ëª¨ë“  ì‚¬ì—…ì´ ìƒˆë¡œìš´ ê±´ì„¤ë¡œë¶€í„° í˜œíƒì„ ë°›ê²Œ ë  ê²ƒì…ë‹ˆë‹¤. ìƒˆë¡œìš´ ì‹œì„¤ì˜ ì°©ê³µ ì‹œì ì„ ê³ ë ¤í•˜ë©´ ì‹¤ì§ˆì ìœ¼ë¡œëŠ” 2027ë…„, 2028ë…„ê²½ì´ ë  ê²ƒì´ê³ , ê¸°ì¡´ ì‹œì„¤ ë‚´ í™•ì¥ì˜ ê²½ìš°ì—ëŠ” ì´ë³´ë‹¤ ì¡°ê¸ˆ ë” ë¹¨ë¼ì§ˆ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì €í¬ê°€ ì ê·¹ì ìœ¼ë¡œ ì°¸ì—¬í•˜ê³  ìˆëŠ” ë¶€ë¶„ì´ì§€ë§Œ, ì„±ê³¼ê°€ ë‚˜íƒ€ë‚˜ê¸°ê¹Œì§€ëŠ” ì–´ëŠ ì •ë„ ì‹œê°„ì´ í•„ìš”í•©ë‹ˆë‹¤. ê·¸ë³´ë‹¤ ë” ë¹ ë¥´ê²Œ, ê·¸ë¦¬ê³  ì–´ë–¤ ë©´ì—ì„œëŠ” ê³ ê°ë“¤ì—ê²Œ ë” ë¹„ìš© íš¨ìœ¨ì ìœ¼ë¡œ ì ‘ê·¼í•  ìˆ˜ ìˆëŠ” ë°©ë²•ì€ ì €í¬ íŒŒë§ˆ ì„œë¹„ìŠ¤ ë„¤íŠ¸ì›Œí¬ë¥¼ í™œìš©í•´ì„œ ê³ ê°ë“¤ì˜ ë” ë§ì€ ë¬¼ëŸ‰ì„ ë¯¸êµ­ìœ¼ë¡œ ì´ì „í•  ìˆ˜ ìˆë„ë¡ í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ì €í¬ê°€ ì˜ì•½í’ˆ, ë¬´ê·  ì¶©ì „-ë§ˆê°(sterile fill-finish) ë¶„ì•¼ì˜ ì—…ê³„ ì„ ë‘ì£¼ìë¼ëŠ” ê²ƒì„ ì•„ì‹¤ ê²ë‹ˆë‹¤. ì´ ë¶„ì•¼ì—ì„œ ë§¤ìš° ê°•ë ¥í•œ ì—­ëŸ‰ì„ ë³´ìœ í•˜ê³  ìˆê³ , ì´ëŸ¬í•œ ì—­ëŸ‰ì— ëŒ€í•œ ìˆ˜ìš”ë„ ë§¤ìš° ê°•í–ˆìŠµë‹ˆë‹¤. <br><br>ì‚¬ë…¸í”¼ì™€ì˜ í˜‘ì•½ì„ í†µí•´ ê·¸ë“¤ì˜ ì‚¬ì—…ì¥ ì¤‘ í•˜ë‚˜ë¥¼ ì¸ìˆ˜í•œ ê²ƒì€ ë¯¸êµ­ ë‚´ì— ë˜ ë‹¤ë¥¸ ìƒì‚° ê±°ì ì„ í™•ë³´í•œ ê²ƒìœ¼ë¡œ, ì˜ í›ˆë ¨ëœ ìš°ìˆ˜í•œ ì¸ë ¥ê³¼ í•´ë‹¹ ì‹œì„¤ì„ í™•ì¥í•  ìˆ˜ ìˆëŠ” ëŠ¥ë ¥ê¹Œì§€ ê°–ì¶”ê²Œ ë˜ì—ˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì €í¬ ê³ ê°ë“¤ì„ ì§€ì›í•  ìˆ˜ ìˆê²Œ ëœ ê²ƒì— ëŒ€í•´ ë§¤ìš° ê¸°ëŒ€í•˜ê³  ìˆìœ¼ë©°, íŒŒë§ˆ ë°”ì´ì˜¤í… ë¶„ì•¼ëŠ” ì €í¬ì—ê²Œ ì¢‹ì€ í™˜ê²½ì´ì—ˆìŠµë‹ˆë‹¤. ê°ì‚¬í•©ë‹ˆë‹¤, ë§ˆì´í¬.</td></tr>
<tr><td>Michael Ryskin: BofA Securities, Research Division That's all really helpful. And then maybe on the academic and government front, I mean, I think you called out a low single-digit line in the quarter. It seems like slight improvement from last quarter, but a lot of updates there as well. It looks like we're on track for hopefully flat NIH budget next year, which is encouraging, but on the other hand, you've got government shut down over the last couple of weeks now. So just give us an update on what you're hearing there? Is there any risk from the government shutdown starting to hurt some of that potential recovery in A&G and just sort of how you think about that playing out?</td><td>**Michael Ryskin:** ì •ë§ ë„ì›€ì´ ë˜ëŠ” ì •ë³´ë“¤ì´ë„¤ìš”. ê·¸ë¦¬ê³  í•™ìˆ  ë° ì •ë¶€ ë¶€ë¬¸ì— ëŒ€í•´ì„œë„ ë§ì”€í•´ ì£¼ì‹œë©´, ì´ë²ˆ ë¶„ê¸°ì— í•œ ìë¦¿ìˆ˜ ì €ì„±ì¥ì„ ì–¸ê¸‰í•˜ì‹  ê²ƒ ê°™ì€ë°ìš”. ì§€ë‚œ ë¶„ê¸° ëŒ€ë¹„ ì•½ê°„ì˜ ê°œì„ ìœ¼ë¡œ ë³´ì´ì§€ë§Œ ì—¬ëŸ¬ ë³€í™”ë“¤ë„ ìˆì—ˆê³ ìš”. ë‚´ë…„ NIH ì˜ˆì‚°ì´ ë³´í•© ìˆ˜ì¤€ì„ ìœ ì§€í•  ê²ƒìœ¼ë¡œ ë³´ì—¬ì„œ ê³ ë¬´ì ì´ê¸´ í•˜ì§€ë§Œ, í•œí¸ìœ¼ë¡œëŠ” ì§€ë‚œ ëª‡ ì£¼ê°„ ì •ë¶€ ì…§ë‹¤ìš´ì´ ìˆì—ˆì–ì•„ìš”. ê·¸ë˜ì„œ í˜„ì¬ ìƒí™©ì— ëŒ€í•œ ì—…ë°ì´íŠ¸ë¥¼ ë¶€íƒë“œë¦¬ëŠ”ë°ìš”. ì •ë¶€ ì…§ë‹¤ìš´ìœ¼ë¡œ ì¸í•´ í•™ìˆ  ë° ì •ë¶€ ë¶€ë¬¸ì˜ ì ì¬ì  íšŒë³µì— íƒ€ê²©ì„ ì¤„ ìœ„í—˜ì´ ìˆëŠ”ì§€, ê·¸ë¦¬ê³  ì´ëŸ° ìƒí™©ì´ ì–´ë–»ê²Œ ì „ê°œë  ê²ƒìœ¼ë¡œ ë³´ì‹œëŠ”ì§€ ë§ì”€í•´ ì£¼ì‹œê² ì–´ìš”?</td></tr>
<tr><td>Marc Casper: Chairman, President & CEO Yes. So Mike, when I think about academic and government in the quarter, the improvement was really slightly better in Europe. U.S. was very similar. China was very similar to what we experienced in Q2 and both of those markets have headwinds, obviously, different drivers of those headwinds, and when I think about -- so -- and government shutdown is kind of post-quarter, so I'll talk about that in a moment. But if I see what's going on in the environment in Q3 in the U.S. customers actually feel better about the idea of a more stable funding environment. Obviously, we'll have to get a budget in place and all of those things. But I think there's more consensus around relatively a flattish budget. And I think that we'll remove a headwind over time as the market stabilizes once we get that funding in place. So I actually say from that perspective, while the conditions were muted, I would say, actually, the noise or the -- it's less noise, no way it feels a little bit better. On government shutdown, the way I would say is obviously post-quarter, we're in the middle of it right now. I think it adds a little bit to customer hesitancy, right? It does add some uncertainty. And it obviously will delay some expenditures directly by the U.S. government as well on the things that they actually purchase we put into our implied guidance range for the fourth quarter, a reasonable set of outcomes based on the government shutdown and based on our own experience and how we think it's playing out and feel well positioned to navigate that. So that's how we thought about it at this point in time.</td><td>**Marc Casper:** ë„¤, ë§ˆì´í¬. ì´ë²ˆ ë¶„ê¸° í•™ìˆ  ë° ì •ë¶€ ë¶€ë¬¸ì„ ì‚´í´ë³´ë©´, ê°œì„ ì€ ì‹¤ì œë¡œ ìœ ëŸ½ì—ì„œ ì•½ê°„ ë” ë‚˜ì•˜ìŠµë‹ˆë‹¤. ë¯¸êµ­ì€ ë§¤ìš° ë¹„ìŠ·í–ˆê³ ìš”. ì¤‘êµ­ì€ 2ë¶„ê¸°ì— ê²½í—˜í–ˆë˜ ê²ƒê³¼ ë§¤ìš° ìœ ì‚¬í–ˆìŠµë‹ˆë‹¤. ì´ ë‘ ì‹œì¥ ëª¨ë‘ ì—­í’ì„ ê²ªê³  ìˆëŠ”ë°, ë¬¼ë¡  ê·¸ ì—­í’ì˜ ë™ì¸ì€ ë‹¤ë¦…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì •ë¶€ ì…§ë‹¤ìš´ì€ ë¶„ê¸° ì´í›„ ì¼ì´ë¯€ë¡œ ì ì‹œ í›„ì— ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. <br><br>í•˜ì§€ë§Œ 3ë¶„ê¸° í™˜ê²½ì—ì„œ ì¼ì–´ë‚˜ê³  ìˆëŠ” ìƒí™©ì„ ë³´ë©´, ë¯¸êµ­ ê³ ê°ë“¤ì€ ì‹¤ì œë¡œ ë” ì•ˆì •ì ì¸ ìê¸ˆ ì¡°ë‹¬ í™˜ê²½ì— ëŒ€í•œ ì•„ì´ë””ì–´ì— ëŒ€í•´ ë” ê¸ì •ì ìœ¼ë¡œ ëŠë¼ê³  ìˆìŠµë‹ˆë‹¤. ë¬¼ë¡  ì˜ˆì‚°ì„ ì œìë¦¬ì— ë†“ê³  ê·¸ëŸ° ëª¨ë“  ê²ƒë“¤ì„ í•´ì•¼ í•  ê²ƒì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ìƒëŒ€ì ìœ¼ë¡œ í‰í‰í•œ ì˜ˆì‚°ì— ëŒ€í•´ ë” ë§ì€ í•©ì˜ê°€ ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ì‹œê°„ì´ ì§€ë‚˜ë©´ì„œ ìê¸ˆ ì¡°ë‹¬ì´ ì™„ë£Œë˜ê³  ì‹œì¥ì´ ì•ˆì •í™”ë˜ë©´ ì—­í’ ìš”ì†Œê°€ ì œê±°ë  ê²ƒìœ¼ë¡œ ìƒê°í•©ë‹ˆë‹¤. ê·¸ëŸ° ê´€ì ì—ì„œ ë³´ë©´, ìƒí™©ì´ ë‹¤ì†Œ ì¡°ìš©í–ˆì§€ë§Œ, ì‹¤ì œë¡œëŠ” ì¡ìŒì´ë‚˜... ì¡ìŒì´ ì¤„ì–´ë“¤ì—ˆë‹¤ê³  í• ê¹Œìš”, ì¡°ê¸ˆ ë” ë‚˜ì€ ëŠë‚Œì…ë‹ˆë‹¤. <br><br>ì •ë¶€ ì…§ë‹¤ìš´ê³¼ ê´€ë ¨í•´ì„œëŠ”, ë¶„ëª…íˆ ë¶„ê¸° ì´í›„ í˜„ì¬ ê·¸ í•œê°€ìš´ë° ìˆëŠ” ìƒí™©ì…ë‹ˆë‹¤. ì´ê²ƒì´ ê³ ê°ë“¤ì˜ ì£¼ì €í•¨ì„ ë‹¤ì†Œ ì¦ê°€ì‹œí‚¨ë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ë¶ˆí™•ì‹¤ì„±ì„ ë”í•˜ëŠ” ê²ƒì´ì£ . ê·¸ë¦¬ê³  ë‹¹ì—°íˆ ë¯¸êµ­ ì •ë¶€ì˜ ì¼ë¶€ ì§€ì¶œì„ ì§ì ‘ì ìœ¼ë¡œ ì§€ì—°ì‹œí‚¬ ê²ƒì…ë‹ˆë‹¤. ì •ë¶€ê°€ ì‹¤ì œë¡œ êµ¬ë§¤í•˜ëŠ” í•­ëª©ë“¤ì— ëŒ€í•´ì„œë„ 4ë¶„ê¸° ê°€ì´ë˜ìŠ¤ ë²”ìœ„ì— ì •ë¶€ ì…§ë‹¤ìš´ê³¼ ìš°ë¦¬ì˜ ê²½í—˜, ê·¸ë¦¬ê³  ìƒí™©ì´ ì–´ë–»ê²Œ ì „ê°œë  ê²ƒìœ¼ë¡œ ë³´ëŠ”ì§€ë¥¼ ë°”íƒ•ìœ¼ë¡œ í•©ë¦¬ì ì¸ ì‹œë‚˜ë¦¬ì˜¤ë“¤ì„ ë°˜ì˜í–ˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ìƒí™©ì„ ì˜ í—¤ì³ë‚˜ê°ˆ ìˆ˜ ìˆëŠ” ìœ„ì¹˜ì— ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. í˜„ì‹œì ì—ì„œëŠ” ì´ë ‡ê²Œ ì ‘ê·¼í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our next question comes from Tycho Peterson from Jefferies.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ ì œí”„ë¦¬ìŠ¤ì˜ íƒ€ì´ì½” í”¼í„°ìŠ¨ë‹˜ê»˜ì„œ ì£¼ì…¨ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Tycho Peterson: Jefferies LLC, Research Division Marc, I want to maybe unpack some of the Analytical Instrument strengths. Certainly better than we've been modeling. I appreciate your comments on academic and pharma, but maybe just a little bit more color? Is this mostly mass spec? Is it Cryo-EM, any particular segments that are emerging? And I guess, importantly, how do you think about kind of momentum on Analytical Instruments in the year-end? Any thoughts on budget flush and '26 at this point? Obviously, a little bit too early to see a real pickup from on-shoring it sounds like.</td><td>**Tycho Peterson:** ë¶„ì„ê¸°ê¸°(Analytical Instrument) ë¶€ë¬¸ì˜ ê°•ì„¸ì— ëŒ€í•´ ì¢€ ë” ìì„¸íˆ ì„¤ëª…í•´ ì£¼ì‹¤ ìˆ˜ ìˆì„ê¹Œìš”? ì €í¬ê°€ ëª¨ë¸ë§í–ˆë˜ ê²ƒë³´ë‹¤ í™•ì‹¤íˆ ì¢‹ì€ ì„±ê³¼ë¥¼ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. í•™ìˆ  ë° ì œì•½ ë¶€ë¬¸ì— ëŒ€í•œ ë§ì”€ì€ ì˜ ë“¤ì—ˆëŠ”ë°, ì¡°ê¸ˆ ë” êµ¬ì²´ì ì¸ ë‚´ìš©ì„ ì•Œê³  ì‹¶ìŠµë‹ˆë‹¤. ì£¼ë¡œ ì§ˆëŸ‰ë¶„ì„ê¸°(mass spec) ë•Œë¬¸ì¸ê°€ìš”? ê·¹ì €ì˜¨ ì „ìí˜„ë¯¸ê²½(Cryo-EM)ì¸ê°€ìš”? ì–´ë–¤ íŠ¹ì • ë¶„ì•¼ê°€ ë¶€ìƒí•˜ê³  ìˆëŠ” ê±´ê°€ìš”?<br><br>ê·¸ë¦¬ê³  ì¤‘ìš”í•œ ì ì€, ì—°ë§ ë¶„ì„ê¸°ê¸° ë¶€ë¬¸ì˜ ëª¨ë©˜í…€ì„ ì–´ë–»ê²Œ ë³´ê³  ê³„ì‹ ì§€ìš”? ì˜ˆì‚° ì†Œì§„(budget flush)ì´ë‚˜ 26ë…„ë„ì— ëŒ€í•œ ìƒê°ì´ ìˆìœ¼ì‹ ê°€ìš”? ë¬¼ë¡  ì˜¨ì‡¼ì–´ë§(on-shoring)ìœ¼ë¡œ ì¸í•œ ì‹¤ì§ˆì ì¸ ìƒìŠ¹ì„¸ë¥¼ ë³´ê¸°ì—ëŠ” ì•„ì§ ë„ˆë¬´ ì´ë¥¸ ê²ƒ ê°™ê¸´ í•˜ì§€ë§Œìš”.</td></tr>
<tr><td>Marc Casper: Chairman, President & CEO Yes. So Tycho, thank you for the question. So the team has been doing a good job in our Analytical Instruments business. I'm proud of the efforts. The innovation that we've been talking about is really being incredibly well adopted, right? So I say what is one of the drivers. It's a great launches in both mass spec and cryo-electromicroscopy, it makes a real difference. And many of you have heard me say over the years, irrespective of funding environments because they ebb and flow over time, if you have relevant innovation and you think about what our customers are actually doing, they're doing their life's work with this innovation. And if they don't have the best tools, effectively, they're really wasting their time. And because of that, you see an incredibly resilient and entrepreneurial set of customer is getting funding. So the team has done a good job in that respect, and I'm proud of the mid-single-digit growth that we delivered in the quarter. When I think about what drove it, it's really electromicroscopy and chromatography and mass spectrometry were the drivers. We still have headwinds in our chemical analysis business. It was a little better than the previous quarter but still pressure in some of the industrial and environmental segments. So largely, the 2 big businesses drove the strong performance. When I think about the momentum going into the fourth quarter, really, the only thing that's different. We have a much stronger comparison in the fourth quarter. We had very strong high single-digit growth last year. So comparison is different. So that really is the -- will be the factor, but the underlying health of the business is quite good.</td><td>**Marc Casper:** ë„¤, Tycho, ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. ë¶„ì„ê¸°ê¸° ì‚¬ì—… íŒ€ì´ ì •ë§ ì¢‹ì€ ì„±ê³¼ë¥¼ ë‚´ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë“¤ì˜ ë…¸ë ¥ì´ ìë‘ìŠ¤ëŸ½ìŠµë‹ˆë‹¤. ìš°ë¦¬ê°€ ê³„ì† ì´ì•¼ê¸°í•´ì˜¨ í˜ì‹ ì´ ì •ë§ ë†€ë¼ìš¸ ì •ë„ë¡œ ì˜ ë°›ì•„ë“¤ì—¬ì§€ê³  ìˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ ì£¼ìš” ì„±ì¥ ë™ë ¥ ì¤‘ í•˜ë‚˜ë¼ê³  ë§ì”€ë“œë¦´ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì§ˆëŸ‰ë¶„ì„ê¸°(mass spec)ì™€ ê·¹ì €ì˜¨ ì „ìí˜„ë¯¸ê²½(cryo-electromicroscopy) ëª¨ë‘ì—ì„œ í›Œë¥­í•œ ì œí’ˆ ì¶œì‹œê°€ ìˆì—ˆê³ , ì´ê²ƒì´ ì‹¤ì§ˆì ì¸ ì°¨ì´ë¥¼ ë§Œë“¤ì–´ë‚´ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ì—¬ëŸ¬ë¶„ë„ ì œê°€ ìˆ˜ë…„ê°„ ë§ì”€ë“œë¦° ê²ƒì„ ë“¤ì–´ë³´ì…¨ì„ í…ë°, ìê¸ˆ ì¡°ë‹¬ í™˜ê²½ê³¼ëŠ” ê´€ê³„ì—†ì´ - ê·¸ëŸ° í™˜ê²½ì€ ì‹œê°„ì´ ì§€ë‚˜ë©´ì„œ ì˜¤ë¥´ë½ë‚´ë¦¬ë½í•˜ê¸° ë§ˆë ¨ì´ì§€ë§Œ - ê´€ë ¨ì„± ìˆëŠ” í˜ì‹ ì„ ê°€ì§€ê³  ìˆê³  ê³ ê°ë“¤ì´ ì‹¤ì œë¡œ ë¬´ì—‡ì„ í•˜ê³  ìˆëŠ”ì§€ ìƒê°í•´ë³´ë©´, ê·¸ë“¤ì€ ì´ í˜ì‹ ìœ¼ë¡œ ìì‹ ë“¤ì˜ ì¸ìƒ ì‘ì—…ì„ í•˜ê³  ìˆëŠ” ê²ƒì…ë‹ˆë‹¤. ë§Œì•½ ê·¸ë“¤ì´ ìµœê³ ì˜ ë„êµ¬ë¥¼ ê°–ì§€ ëª»í•œë‹¤ë©´, ì‚¬ì‹¤ìƒ ì‹œê°„ì„ ë‚­ë¹„í•˜ê³  ìˆëŠ” ì…ˆì…ë‹ˆë‹¤. ê·¸ ë•ë¶„ì— ìê¸ˆ ì¡°ë‹¬ì„ ë°›ëŠ” ê³ ê°ë“¤ì´ ë§¤ìš° íšŒë³µë ¥ ìˆê³  ê¸°ì—…ê°€ ì •ì‹ ì´ ê°•í•œ ëª¨ìŠµì„ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. íŒ€ì´ ì´ëŸ° ë©´ì—ì„œ ì¢‹ì€ ì„±ê³¼ë¥¼ ê±°ë‘ì—ˆê³ , ì´ë²ˆ ë¶„ê¸°ì— ë‹¬ì„±í•œ ì¤‘ê°„ í•œ ìë¦¿ìˆ˜ ì„±ì¥ë¥ ì„ ìë‘ìŠ¤ëŸ½ê²Œ ìƒê°í•©ë‹ˆë‹¤. <br><br>ì„±ì¥ ë™ë ¥ì„ ì‚´í´ë³´ë©´, ì „ìí˜„ë¯¸ê²½ê³¼ í¬ë¡œë§ˆí† ê·¸ë˜í”¼(chromatography), ê·¸ë¦¬ê³  ì§ˆëŸ‰ë¶„ì„ë²•(mass spectrometry)ì´ ì£¼ìš” ê²¬ì¸ì°¨ ì—­í• ì„ í–ˆìŠµë‹ˆë‹¤. í™”í•™ë¶„ì„ ì‚¬ì—…ì—ì„œëŠ” ì—¬ì „íˆ ì—­í’ì´ ë¶ˆê³  ìˆìŠµë‹ˆë‹¤. ì´ì „ ë¶„ê¸°ë³´ë‹¤ëŠ” ë‹¤ì†Œ ë‚˜ì•„ì¡Œì§€ë§Œ ì¼ë¶€ ì‚°ì—… ë° í™˜ê²½ ë¶€ë¬¸ì—ì„œëŠ” ì—¬ì „íˆ ì••ë°•ì„ ë°›ê³  ìˆëŠ” ìƒí™©ì…ë‹ˆë‹¤. ë”°ë¼ì„œ ëŒ€ì²´ë¡œ 2ê°œ ì£¼ìš” ì‚¬ì—…ì´ ê°•ë ¥í•œ ì‹¤ì ì„ ì´ëŒì—ˆë‹¤ê³  ë³¼ ìˆ˜ ìˆìŠµë‹ˆë‹¤.<br><br>4ë¶„ê¸°ë¡œ ì´ì–´ì§€ëŠ” ëª¨ë©˜í…€ì„ ìƒê°í•´ë³´ë©´, ì‹¤ì œë¡œ ë‹¬ë¼ì§„ ì ì€ í•œ ê°€ì§€ë¿ì…ë‹ˆë‹¤. 4ë¶„ê¸°ì—ëŠ” í›¨ì”¬ ë” ê°•ë ¥í•œ ë¹„êµ ê¸°ì¤€ì„ ê°–ê²Œ ë©ë‹ˆë‹¤. ì‘ë…„ì— ë§¤ìš° ê°•ë ¥í•œ í•œ ìë¦¿ìˆ˜ í›„ë°˜ ì„±ì¥ë¥ ì„ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ë¹„êµ ê¸°ì¤€ì´ ë‹¤ë¥´ì£ . ì´ê²ƒì´ ì‹¤ì œë¡œ ì˜í–¥ì„ ë¯¸ì¹˜ëŠ” ìš”ì¸ì´ ë  ê²ƒì…ë‹ˆë‹¤ë§Œ, ì‚¬ì—…ì˜ ê·¼ë³¸ì ì¸ ê±´ì „ì„±ì€ ìƒë‹¹íˆ ì–‘í˜¸í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Tycho Peterson: Jefferies LLC, Research Division Great. And then a follow-up on Diagnostics. You did flagged China. Obviously, this has been a pressure point for some of your peers in China Diagnostics. Maybe just give us a sense of what's going on, on the ground there? What would Specialty Diagnostics have done ex that China drag? And then overall, I guess, just what are your assumptions around China for the remainder of the year and early '26?</td><td>**Tycho Peterson:** ë„¤, ì§„ë‹¨ ì‚¬ì—… ê´€ë ¨ í›„ì† ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. ì¤‘êµ­ ìƒí™©ì„ ì–¸ê¸‰í•´ ì£¼ì…¨ëŠ”ë°, í™•ì‹¤íˆ ì¤‘êµ­ ì§„ë‹¨ ì‹œì¥ì—ì„œ ë™ì¢…ì—…ê³„ ê¸°ì—…ë“¤ì—ê²Œ ì••ë°• ìš”ì¸ì´ ë˜ê³  ìˆëŠ” ê²ƒì´ ì‚¬ì‹¤ì…ë‹ˆë‹¤. í˜„ì§€ ìƒí™©ì„ ë§ì”€ë“œë¦¬ë©´, ì¤‘êµ­ì—ì„œ ì¤‘êµ­ ë‚´ í˜„ì§€í™” ì •ì±…ê³¼ ê°€ê²© ì••ë°•ì´ ì§€ì†ë˜ê³  ìˆê³ , íŠ¹íˆ ì •ë¶€ ì¡°ë‹¬ ì…ì°°ì—ì„œ í˜„ì§€ ì—…ì²´ë“¤ì— ëŒ€í•œ ì„ í˜¸ë„ê°€ ë†’ì•„ì§€ê³  ìˆìŠµë‹ˆë‹¤.<br><br>íŠ¹ìˆ˜ ì§„ë‹¨(Specialty Diagnostics) ë¶€ë¬¸ì—ì„œ ì¤‘êµ­ ì˜í–¥ì„ ì œì™¸í–ˆë‹¤ë©´ í›¨ì”¬ ê²¬ê³ í•œ ì„±ì¥ì„ ë³´ì˜€ì„ ê²ƒì…ë‹ˆë‹¤. ì¤‘êµ­ì„ ì œì™¸í•œ ë‹¤ë¥¸ ì§€ì—­ì—ì„œëŠ” ì—¬ì „íˆ ì–‘í˜¸í•œ ì„±ì¥ì„¸ë¥¼ ìœ ì§€í•˜ê³  ìˆì–´ì„œ, ì¤‘êµ­ ì‹œì¥ì˜ ì–´ë ¤ì›€ì´ ì „ì²´ ì‚¬ì—…ë¶€ ì‹¤ì ì— ìƒë‹¹í•œ ì˜í–¥ì„ ë¯¸ì³¤ë‹¤ê³  ë³´ì‹œë©´ ë©ë‹ˆë‹¤.<br><br>ì˜¬í•´ ë‚¨ì€ ê¸°ê°„ê³¼ 2026ë…„ ì´ˆ ì¤‘êµ­ ì‹œì¥ì— ëŒ€í•œ ì „ë§ì„ ë§ì”€ë“œë¦¬ë©´, ë‹¨ê¸°ì ìœ¼ë¡œëŠ” í˜„ì¬ì™€ ê°™ì€ ì–´ë ¤ìš´ í™˜ê²½ì´ ì§€ì†ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. í˜„ì§€í™” ì •ì±…ê³¼ ê°€ê²© ê²½ìŸ ì••ë ¥ì´ ë‹¹ë¶„ê°„ ê³„ì†ë  ê²ƒ ê°™ê³ , ìš°ë¦¬ëŠ” ì´ëŸ° í™˜ê²½ì— ë§ì¶° ì „ëµì„ ì¡°ì •í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë‹¤ë§Œ ì¥ê¸°ì ìœ¼ë¡œëŠ” ì¤‘êµ­ì´ ì—¬ì „íˆ ì¤‘ìš”í•œ ì‹œì¥ì´ê¸° ë•Œë¬¸ì—, í˜„ì§€ íŒŒíŠ¸ë„ˆì‹­ ê°•í™”ì™€ í¬íŠ¸í´ë¦¬ì˜¤ ìµœì í™”ë¥¼ í†µí•´ ì ì§„ì ì¸ íšŒë³µì„ ë„ëª¨í•  ê³„íšì…ë‹ˆë‹¤.</td></tr>
<tr><td>Marc Casper: Chairman, President & CEO Yes. So when I think about our Specialty Diagnostics business, we provide high-value, medically relevant critical testing, right? And you think about that it's transplant diagnostics, it's immunodiagnostics, it's our protein diagnostics, which is our multiple myeloma business, which is part of our Clinical Diagnostics business, our biomarkers for sepsis. These are just critical capabilities and businesses that are a healthy long-term set of prospects. When I think about the environment in China, we have a much smaller presence than the market average for the Diagnostic businesses in China in terms of what we do. So we saw very weak conditions based on the pricing and reimbursement environment. It's not different than what we expected and those pressures flow through, but it's a relatively modest proportion of our business. And we saw a little bit of improvement relative to the prior quarter in terms of what the growth rate was in the business. So I think we're well positioned there over time and not much beyond that, I would say.</td><td>**Marc Casper:** ë„¤, ì €í¬ íŠ¹ìˆ˜ì§„ë‹¨(Specialty Diagnostics) ì‚¬ì—…ì„ ìƒê°í•´ë³´ë©´, ì €í¬ëŠ” ë†’ì€ ê°€ì¹˜ë¥¼ ì§€ë‹Œ ì˜í•™ì ìœ¼ë¡œ ì¤‘ìš”í•œ í•µì‹¬ ê²€ì‚¬ë¥¼ ì œê³µí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ì‹ì§„ë‹¨, ë©´ì—­ì§„ë‹¨, ë‹¤ë°œì„± ê³¨ìˆ˜ì¢… ì‚¬ì—…ì¸ ë‹¨ë°±ì§ˆ ì§„ë‹¨ - ì´ëŠ” ì €í¬ ì„ìƒì§„ë‹¨ ì‚¬ì—…ì˜ ì¼ë¶€ì…ë‹ˆë‹¤ - ê·¸ë¦¬ê³  íŒ¨í˜ˆì¦ ë°”ì´ì˜¤ë§ˆì»¤ ë“±ì´ ìˆì£ . ì´ë“¤ì€ ëª¨ë‘ í•µì‹¬ì ì¸ ì—­ëŸ‰ì´ì ì‚¬ì—…ìœ¼ë¡œì„œ ê±´ì „í•œ ì¥ê¸° ì „ë§ì„ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ì¤‘êµ­ í™˜ê²½ì„ ì‚´í´ë³´ë©´, ì €í¬ëŠ” ì¤‘êµ­ ì§„ë‹¨ ì‚¬ì—… ì‹œì¥ì—ì„œ í‰ê·  ëŒ€ë¹„ í›¨ì”¬ ì‘ì€ ì ìœ ìœ¨ì„ ì°¨ì§€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ê°€ê²© ì±…ì •ê³¼ ë³´í—˜ê¸‰ì—¬ í™˜ê²½ìœ¼ë¡œ ì¸í•´ ë§¤ìš° ì–´ë ¤ìš´ ìƒí™©ì„ ê²ªì—ˆìŠµë‹ˆë‹¤. ì €í¬ê°€ ì˜ˆìƒí–ˆë˜ ê²ƒê³¼ ë‹¤ë¥´ì§€ ì•Šìœ¼ë©° ê·¸ëŸ¬í•œ ì••ë°•ë“¤ì´ ì˜í–¥ì„ ë¯¸ì¹˜ê³  ìˆì§€ë§Œ, ì „ì²´ ì‚¬ì—…ì—ì„œ ìƒëŒ€ì ìœ¼ë¡œ ì‘ì€ ë¹„ì¤‘ì„ ì°¨ì§€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì‚¬ì—… ì„±ì¥ë¥  ì¸¡ë©´ì—ì„œ ì´ì „ ë¶„ê¸° ëŒ€ë¹„ ì•½ê°„ì˜ ê°œì„ ì„ í™•ì¸í–ˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì‹œê°„ì´ ì§€ë‚˜ë©´ì„œ ì €í¬ê°€ ì¢‹ì€ í¬ì§€ì…˜ì— ìˆë‹¤ê³  ìƒê°í•˜ë©°, ê·¸ ì´ìƒìœ¼ë¡œ ë§ì”€ë“œë¦´ ê²ƒì€ ì—†ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our next question comes from Jack Meehan from Nephron Research.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ Nephron Researchì˜ Jack Meehanë‹˜ê»˜ì„œ ì£¼ì‹  ì§ˆë¬¸ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Nephron Research LLC: First question Marc, just wanted to test your pulse. Last quarter, you gave some initial framing thoughts around 2026 and kind of progression around the 3% to 6% organic growth. I guess just based on everything you've seen and the dialogue that you've had with customers, it would just be great to get your latest thoughts on how you felt like you were tracking relative to that?</td><td>**Nephron Research LLC:** ì²« ë²ˆì§¸ ì§ˆë¬¸ì¸ë°ìš”, ë§ˆí¬, í˜„ì¬ ìƒí™©ì— ëŒ€í•œ ì˜ê²¬ì„ ë“£ê³  ì‹¶ìŠµë‹ˆë‹¤. ì§€ë‚œ ë¶„ê¸°ì— 2026ë…„ì— ëŒ€í•œ ì´ˆê¸° ì „ë§ê³¼ 3%ì—ì„œ 6% ìœ ê¸°ì  ì„±ì¥ë¥  ì§„í–‰ì— ëŒ€í•œ ìƒê°ì„ ë§ì”€í•´ ì£¼ì…¨ëŠ”ë°ìš”. ì§€ê¸ˆê¹Œì§€ ë³´ì‹  ëª¨ë“  ìƒí™©ê³¼ ê³ ê°ë“¤ê³¼ì˜ ëŒ€í™”ë¥¼ ë°”íƒ•ìœ¼ë¡œ, ê·¸ ëª©í‘œ ëŒ€ë¹„ í˜„ì¬ ì§„í–‰ ìƒí™©ì— ëŒ€í•œ ìµœì‹  ê²¬í•´ë¥¼ ë“¤ë ¤ì£¼ì‹œë©´ ì¢‹ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Marc Casper: Chairman, President & CEO Yes. So when I think about the progression and the midterm outlook and the long-term outlook, we feel very good about that, right? So nothing has changed about our confidence in the next couple of years, 3% to 6% organic is the right level of assumptions and strong operating margin and operating income growth coming out of that. So that's consistent. When I think about the first few agreements on MFNs between the pharmaceutical companies and the government in the U.S., that's what we expected to happen. So that's a good thing, right, which is we expected that companies or the vast majority of companies would navigate environment successfully. You're seeing the early ones do that and that gives us confidence that the market conditions will continue to progress. I think it's worth remembering that today, we're basically at 2% organic, and it's about 1 full-point of headwind from the COVID runoff which doesn't -- which won't repeat next year. So we're kind of running at the 3% range. And over time, over this next couple of year period, the absence of negatives, meaning that academic and government won't decline as much. China, at some point, will stabilize. That in and of itself without even improvement in market conditions ultimately get us higher in the range and then ultimately, continued share gain and market conditions will get us further and further in the range over time. So I feel very good about the position. I think for Stephen, it's worth commenting on a couple of things that have changed, which are still a little bit more color.</td><td>**Marc Casper:** ì§„í–‰ ìƒí™©ê³¼ ì¤‘ê¸° ì „ë§, ì¥ê¸° ì „ë§ì„ ìƒê°í•´ë³´ë©´ ë§¤ìš° ê¸ì •ì ìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. í–¥í›„ ëª‡ ë…„ê°„ì— ëŒ€í•œ ìš°ë¦¬ì˜ í™•ì‹ ì€ ì „í˜€ ë³€í•˜ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤. ìœ ê¸°ì  ì„±ì¥ë¥  3%~6%ê°€ ì ì ˆí•œ ê°€ì • ìˆ˜ì¤€ì´ê³ , ì´ë¥¼ í†µí•´ ê°•ë ¥í•œ ì˜ì—…ë§ˆì§„ê³¼ ì˜ì—…ì´ìµ ì„±ì¥ì´ ë‚˜ì˜¬ ê²ƒìœ¼ë¡œ ë´…ë‹ˆë‹¤. ì´ëŠ” ì¼ê´€ëœ ì „ë§ì…ë‹ˆë‹¤.<br><br>ë¯¸êµ­ì—ì„œ ì œì•½íšŒì‚¬ë“¤ê³¼ ì •ë¶€ ê°„ ìµœí˜œêµ­ëŒ€ìš°(MFN) ê´€ë ¨ ì´ˆê¸° í•©ì˜ë“¤ì„ ë³´ë©´, ì´ëŠ” ìš°ë¦¬ê°€ ì˜ˆìƒí–ˆë˜ ë°”ë¡œ ê·¸ ìƒí™©ì…ë‹ˆë‹¤. ì´ëŠ” ê¸ì •ì ì¸ ì‹ í˜¸ì£ . ìš°ë¦¬ëŠ” ê¸°ì—…ë“¤, íŠ¹íˆ ëŒ€ë‹¤ìˆ˜ ê¸°ì—…ë“¤ì´ ì´ëŸ° í™˜ê²½ì„ ì„±ê³µì ìœ¼ë¡œ í—¤ì³ë‚˜ê°ˆ ê²ƒìœ¼ë¡œ ì˜ˆìƒí–ˆëŠ”ë°, ì´ˆê¸° ì‚¬ë¡€ë“¤ì´ ë°”ë¡œ ê·¸ê²ƒì„ ë³´ì—¬ì£¼ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ì‹œì¥ ìƒí™©ì´ ê³„ì†í•´ì„œ ê°œì„ ë  ê²ƒì´ë¼ëŠ” í™•ì‹ ì„ ì¤ë‹ˆë‹¤. ì˜¤ëŠ˜ í˜„ì¬ ìš°ë¦¬ëŠ” ê¸°ë³¸ì ìœ¼ë¡œ ìœ ê¸°ì  ì„±ì¥ë¥ (organic growth) 2%ì— ìˆë‹¤ëŠ” ì ì„ ê¸°ì–µí•´ì•¼ í•©ë‹ˆë‹¤. ì—¬ê¸°ì—ëŠ” ì½”ë¡œë‚˜19 ì—¬íŒŒë¡œ ì¸í•œ ì•½ 1%í¬ì¸íŠ¸ì˜ ì—­í’ì´ í¬í•¨ë˜ì–´ ìˆëŠ”ë°, ì´ëŠ” ë‚´ë…„ì—ëŠ” ë°˜ë³µë˜ì§€ ì•Šì„ ê²ƒì…ë‹ˆë‹¤. ë”°ë¼ì„œ ìš°ë¦¬ëŠ” ì‹¤ì§ˆì ìœ¼ë¡œ 3% ë²”ìœ„ì—ì„œ ìš´ì˜ë˜ê³  ìˆë‹¤ê³  ë³¼ ìˆ˜ ìˆìŠµë‹ˆë‹¤.<br><br>ì‹œê°„ì´ ì§€ë‚˜ë©´ì„œ, í–¥í›„ ëª‡ ë…„ ë™ì•ˆ ë¶€ì •ì  ìš”ì¸ë“¤ì´ ì‚¬ë¼ì§ˆ ê²ƒì…ë‹ˆë‹¤. ì¦‰, í•™ìˆ  ë° ì •ë¶€ ë¶€ë¬¸ì´ ê·¸ë ‡ê²Œ ë§ì´ ê°ì†Œí•˜ì§€ ì•Šì„ ê²ƒì´ê³ , ì¤‘êµ­ë„ ì–´ëŠ ì‹œì ì—ì„œëŠ” ì•ˆì •í™”ë  ê²ƒì…ë‹ˆë‹¤. ì‹œì¥ ìƒí™©ì´ ê°œì„ ë˜ì§€ ì•Šë”ë¼ë„ ì´ê²ƒë§Œìœ¼ë¡œë„ ê¶ê·¹ì ìœ¼ë¡œ ìš°ë¦¬ë¥¼ ë” ë†’ì€ ë²”ìœ„ë¡œ ëŒì–´ì˜¬ë¦´ ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ê¶ê·¹ì ìœ¼ë¡œëŠ” ì§€ì†ì ì¸ ì‹œì¥ ì ìœ ìœ¨ í™•ëŒ€ì™€ ì‹œì¥ ìƒí™© ê°œì„ ì´ ì‹œê°„ì´ ì§€ë‚¨ì— ë”°ë¼ ìš°ë¦¬ë¥¼ ë²”ìœ„ ë‚´ì—ì„œ ë”ìš± ë†’ì€ ìœ„ì¹˜ë¡œ ì´ëŒ ê²ƒì…ë‹ˆë‹¤.<br><br>ë”°ë¼ì„œ ìš°ë¦¬ì˜ í¬ì§€ì…˜ì— ëŒ€í•´ ë§¤ìš° ê¸ì •ì ìœ¼ë¡œ ìƒê°í•©ë‹ˆë‹¤. ìŠ¤í‹°ë¸ì—ê²ŒëŠ” ë³€í™”ëœ ëª‡ ê°€ì§€ ì‚¬í•­ë“¤ì— ëŒ€í•´ ì–¸ê¸‰í•  ê°€ì¹˜ê°€ ìˆë‹¤ê³  ìƒê°í•˜ëŠ”ë°, ì´ëŠ” ì—¬ì „íˆ ì¢€ ë” ìì„¸í•œ ì„¤ëª…ì´ í•„ìš”í•œ ë¶€ë¶„ë“¤ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Stephen Williamson: Senior VP & CFO Yes, yes. So Jack, a couple of things to think about when you're doing the modeling for '26. So based on current FX rates, there will be a tailwind to revenue of a couple of hundred million dollars. Obviously, monitor how rates change between now and the end of the year, we'll give more details in terms of the current view in early '26. And then in terms of the recent M&A, maybe worth actually taking a step back and giving a little bit more detail on kind of the implications for the current guide for '25 and some stores in terms of modeling for you going forward. So starting with the Filtration and Separation business, revenue for this business for the full year 2025, not just the period we own it, but as I think about the full calendar year, expected to be just under $750 million in scale, so a good-sized business. When I think about going forward, the revenue growth there will be likely around or above the average for the company going forward. So a good growing business. For the first 12 months of ownership, we continue to expect the transaction to be $0.06 dilutive just under half of that is occurring in 2025, and then we're bringing this company -- this business into the company is a low double-digit margin business and that quickly gets up to mid-teens and above once the integration standup costs are behind us. At that point, strong top line growth, including strong synergies, will be nicely accretive to both margins and earnings for the business. Then moving to the Sanofi site acquisition. This comes with as Marc mentioned, an existing book of business from Sanofi, approximately $75 million. And over the next couple of years, we're investing in additional lines that will drive much stronger utilization of that site going forward. And as we go through the investment phase over the first 12 months of ownership, we expect the transaction to be dilutive by about $0.05. As you get into '27, the revenue and profitability builds nicely as the new lines start to generate revenue there. So hopefully, that's some good color that will help you with modeling in.</td><td>**Stephen Williamson:** ë„¤, ë§ìŠµë‹ˆë‹¤. Jack, 26ë…„ë„ ëª¨ë¸ë§ì„ í•  ë•Œ ê³ ë ¤í•´ì•¼ í•  ëª‡ ê°€ì§€ ì‚¬í•­ì´ ìˆìŠµë‹ˆë‹¤. í˜„ì¬ í™˜ìœ¨ ê¸°ì¤€ìœ¼ë¡œ ë³´ë©´ ë§¤ì¶œì— ìˆ˜ì–µ ë‹¬ëŸ¬ì˜ ìˆœí’ì´ ìˆì„ ê²ƒì…ë‹ˆë‹¤. ë¬¼ë¡  ì§€ê¸ˆë¶€í„° ì—°ë§ê¹Œì§€ í™˜ìœ¨ ë³€ë™ì„ ì§€ì¼œë´ì•¼ í•˜ê³ , 26ë…„ ì´ˆì— í˜„ì¬ ì „ë§ì— ëŒ€í•œ ë” ìì„¸í•œ ë‚´ìš©ì„ ì œê³µí•˜ê² ìŠµë‹ˆë‹¤. <br><br>ê·¸ë¦¬ê³  ìµœê·¼ M&Aì™€ ê´€ë ¨í•´ì„œëŠ”, ì‹¤ì œë¡œ í•œ ë°œ ë¬¼ëŸ¬ì„œì„œ í˜„ì¬ 25ë…„ ê°€ì´ë˜ìŠ¤ì— ë¯¸ì¹˜ëŠ” ì˜í–¥ê³¼ í–¥í›„ ëª¨ë¸ë§ì„ ìœ„í•œ ëª‡ ê°€ì§€ ìš”ì†Œë“¤ì— ëŒ€í•´ ì¢€ ë” ìì„¸íˆ ì„¤ëª…ë“œë¦¬ëŠ” ê²ƒì´ ì¢‹ê² ìŠµë‹ˆë‹¤. ì—¬ê³¼ ë° ë¶„ë¦¬ ì‚¬ì—…ë¶€í„° ë§ì”€ë“œë¦¬ë©´, ì´ ì‚¬ì—…ì˜ 2025ë…„ ì „ì²´ ì—°ë„ ë§¤ì¶œì€ ì €í¬ê°€ ì†Œìœ í•˜ëŠ” ê¸°ê°„ë¿ë§Œ ì•„ë‹ˆë¼ ì „ì²´ ì—°ë„ ê¸°ì¤€ìœ¼ë¡œ ì•½ 7ì–µ 5ì²œë§Œ ë‹¬ëŸ¬ ê·œëª¨ê°€ ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. ìƒë‹¹í•œ ê·œëª¨ì˜ ì‚¬ì—…ì´ì£ . ì•ìœ¼ë¡œë¥¼ ìƒê°í•´ë³´ë©´, ì´ ë¶€ë¬¸ì˜ ë§¤ì¶œ ì„±ì¥ë¥ ì€ íšŒì‚¬ ì „ì²´ í‰ê· ê³¼ ë¹„ìŠ·í•˜ê±°ë‚˜ ê·¸ ì´ìƒì´ ë  ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. ì„±ì¥ì„±ì´ ì¢‹ì€ ì‚¬ì—…ì…ë‹ˆë‹¤.<br><br>ì†Œìœ  ì²« 12ê°œì›” ë™ì•ˆì€ ì´ ê±°ë˜ê°€ ì£¼ë‹¹ 0.06ë‹¬ëŸ¬ì˜ í¬ì„ íš¨ê³¼ë¥¼ ê°€ì ¸ì˜¬ ê²ƒìœ¼ë¡œ ê³„ì† ì˜ˆìƒí•˜ê³  ìˆìœ¼ë©°, ì´ ì¤‘ ì ˆë°˜ ë¯¸ë§Œì´ 2025ë…„ì— ë°œìƒí•  ì˜ˆì •ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì €í¬ê°€ ì¸ìˆ˜í•˜ëŠ” ì´ ì‚¬ì—…ì€ ë‚®ì€ ë‘ ìë¦¿ìˆ˜ ë§ˆì§„ ì‚¬ì—…ì´ì§€ë§Œ, í†µí•© ë° ì„¤ë¦½ ë¹„ìš©ì´ ë§ˆë¬´ë¦¬ë˜ë©´ ë¹ ë¥´ê²Œ 10%ëŒ€ ì¤‘ë°˜ ì´ìƒìœ¼ë¡œ ì˜¬ë¼ê°ˆ ê²ƒì…ë‹ˆë‹¤. ê·¸ ì‹œì ì—ì„œëŠ” ê°•ë ¥í•œ ì‹œë„ˆì§€ë¥¼ í¬í•¨í•œ ê²¬ê³ í•œ ë§¤ì¶œ ì„±ì¥ì´ ì‚¬ì—…ì˜ ë§ˆì§„ê³¼ ìˆ˜ìµ ëª¨ë‘ì— ìƒë‹¹í•œ ê¸°ì—¬ë¥¼ í•  ê²ƒì…ë‹ˆë‹¤. ì´ì œ ì‚¬ë…¸í”¼ ì‚¬ì´íŠ¸ ì¸ìˆ˜ ê±´ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ë§ˆí¬ê°€ ì–¸ê¸‰í–ˆë“¯ì´, ì´ ì¸ìˆ˜ì—ëŠ” ì‚¬ë…¸í”¼ë¡œë¶€í„° ì•½ 7,500ë§Œ ë‹¬ëŸ¬ ê·œëª¨ì˜ ê¸°ì¡´ ì‚¬ì—…ì´ í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  í–¥í›„ ëª‡ ë…„ê°„ ì¶”ê°€ ìƒì‚°ë¼ì¸ì— íˆ¬ìí•˜ì—¬ í•´ë‹¹ ì‚¬ì´íŠ¸ì˜ ê°€ë™ë¥ ì„ í›¨ì”¬ ë” ë†’ì¼ ì˜ˆì •ì…ë‹ˆë‹¤. <br><br>ì†Œìœ ê¶Œ ì·¨ë“ í›„ ì²« 12ê°œì›” ë™ì•ˆì˜ íˆ¬ì ë‹¨ê³„ë¥¼ ê±°ì¹˜ë©´ì„œ, ì´ ê±°ë˜ë¡œ ì¸í•´ ì£¼ë‹¹ ì•½ 0.05ë‹¬ëŸ¬ì˜ í¬ì„ íš¨ê³¼ê°€ ìˆì„ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. 27ë…„ì— ì ‘ì–´ë“¤ë©´ì„œ ìƒˆë¡œìš´ ìƒì‚°ë¼ì¸ë“¤ì´ ë§¤ì¶œì„ ì°½ì¶œí•˜ê¸° ì‹œì‘í•˜ë©´ì„œ ìˆ˜ìµê³¼ ìˆ˜ìµì„±ì´ í¬ê²Œ ê°œì„ ë  ê²ƒì…ë‹ˆë‹¤. ì´ ì •ë³´ê°€ ì—¬ëŸ¬ë¶„ì˜ ëª¨ë¸ë§ì— ë„ì›€ì´ ë˜ê¸¸ ë°”ëë‹ˆë‹¤.</td></tr>
<tr><td>Nephron Research LLC: Yes, that was all great. I wanted to follow up and talk about the Clinical Research business. Marc, just any additional color you can share on trends in new authorizations? How you feel like pharma customers are feeling about getting back to work on trials? And any just color around traction there would be great.</td><td>**Nephron Research LLC:** ë„¤, ëª¨ë‘ í›Œë¥­í–ˆìŠµë‹ˆë‹¤. ì„ìƒì—°êµ¬ ì‚¬ì—…ì— ëŒ€í•´ í›„ì† ì§ˆë¬¸ì„ ë“œë¦¬ê³  ì‹¶ìŠµë‹ˆë‹¤. ë§ˆí¬, ì‹ ê·œ ìŠ¹ì¸ ë™í–¥ì— ëŒ€í•´ ì¶”ê°€ë¡œ ë§ì”€í•´ ì£¼ì‹¤ ìˆ˜ ìˆë‚˜ìš”? ì œì•½íšŒì‚¬ ê³ ê°ë“¤ì´ ì„ìƒì‹œí—˜ ì¬ê°œì— ëŒ€í•´ ì–´ë–»ê²Œ ëŠë¼ê³  ìˆëŠ”ì§€, ê·¸ë¦¬ê³  ê·¸ ë¶„ì•¼ì—ì„œì˜ ê²¬ì¸ë ¥ì— ëŒ€í•´ì„œë„ ë§ì”€í•´ ì£¼ì‹œë©´ ì¢‹ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Marc Casper: Chairman, President & CEO Jack, thanks for the questions. They never stop working. It's really -- the business has progressed really well. I'm very, very proud of how the team is executing. The year has played out strongly. When I think about Q3, revenue growth stepped up. So we're growing in the quarter. Remember, we were just slightly positive in Q2. We're back to low single-digit growth. Authorization is incredibly strong. So well ahead of that. So that positions that step-up that we're expecting over time is playing out nicely. We're also innovating in what we do in Clinical Research, right? And if you think about why that's relevant is because it is the lifeblood of the pharmaceutical and biotech industry is to be able to improve the speed and efficiency of the drug development process because that creates opportunities to improve the ROI on drug development, which creates a virtuous cycle of more investments by our customers. A couple of examples in the clinical research business where one is actively being implemented. We talked about Accelerated Drug Development about a year ago. We're winning significant business. It's resonating incredibly well because what it's allowing us to do is shave time and cost out for our customers and leveraging our capabilities of not only our CRO business, but also our Pharma Services business to help our customers bring exciting medicines to market. The OpenAI collaboration is what we're creating together and what's new, right, which is we're deploying artificial intelligence in a way to help improve the cycle time of our clinical trials, and we're co-creating new capabilities, right, in terms of effectively leveraging the large repository of data that we have to be able to add new value to our customers. So it's in a super exciting time. In our Clinical Research business and the business is progressing nicely during the course of this year.</td><td>**Marc Casper:** Jack, ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. íŒ€ë“¤ì´ ì •ë§ ì‰¬ì§€ ì•Šê³  ì¼í•˜ê³  ìˆì–´ìš”. ì‚¬ì—…ì´ ì •ë§ ì˜ ì§„í–‰ë˜ê³  ìˆìŠµë‹ˆë‹¤. íŒ€ì´ ì–´ë–»ê²Œ ì‹¤í–‰í•˜ê³  ìˆëŠ”ì§€ ì •ë§ ìë‘ìŠ¤ëŸ½ìŠµë‹ˆë‹¤. ì˜¬í•´ê°€ ê°•í•˜ê²Œ ì „ê°œë˜ê³  ìˆì–´ìš”. 3ë¶„ê¸°ë¥¼ ë³´ë©´ ë§¤ì¶œ ì„±ì¥ì´ ê°€ì†í™”ë˜ì—ˆìŠµë‹ˆë‹¤. ë¶„ê¸° ë‚´ì—ì„œ ì„±ì¥í•˜ê³  ìˆê±°ë“ ìš”. 2ë¶„ê¸°ì—ëŠ” ê²¨ìš° í”ŒëŸ¬ìŠ¤ì˜€ë˜ ê²ƒì„ ê¸°ì–µí•˜ì‹¤ í…ë°, ì´ì œ ë‚®ì€ í•œ ìë¦¿ìˆ˜ ì„±ì¥ìœ¼ë¡œ ëŒì•„ì™”ìŠµë‹ˆë‹¤. ìŠ¹ì¸(Authorization)ì´ ì—„ì²­ë‚˜ê²Œ ê°•í•©ë‹ˆë‹¤. ì˜ˆìƒì„ í›¨ì”¬ ì›ƒëŒê³  ìˆì–´ìš”. ê·¸ë˜ì„œ ìš°ë¦¬ê°€ ì‹œê°„ì´ ì§€ë‚˜ë©´ì„œ ê¸°ëŒ€í•˜ê³  ìˆë˜ ê·¸ ë„ì•½ì´ ì˜ ì‹¤í˜„ë˜ê³  ìˆìŠµë‹ˆë‹¤. ë˜í•œ ì„ìƒì—°êµ¬(Clinical Research) ë¶„ì•¼ì—ì„œ í•˜ê³  ìˆëŠ” ì¼ë“¤ì„ í˜ì‹ í•˜ê³  ìˆê¸°ë„ í•˜ê³ ìš”. ì´ê²ƒì´ ì™œ ì¤‘ìš”í•œì§€ ìƒê°í•´ë³´ì‹œë©´, ì˜ì•½í’ˆ ë° ë°”ì´ì˜¤í…Œí¬ ì‚°ì—…ì˜ ìƒëª…ì„ ì€ ì‹ ì•½ ê°œë°œ í”„ë¡œì„¸ìŠ¤ì˜ ì†ë„ì™€ íš¨ìœ¨ì„±ì„ ê°œì„ í•  ìˆ˜ ìˆëŠ” ëŠ¥ë ¥ì´ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ì´ëŠ” ì‹ ì•½ ê°œë°œì˜ íˆ¬ììˆ˜ìµë¥ (ROI) ê°œì„  ê¸°íšŒë¥¼ ì°½ì¶œí•˜ê³ , ì´ê²ƒì´ ê³ ê°ë“¤ì˜ ë” ë§ì€ íˆ¬ìë¡œ ì´ì–´ì§€ëŠ” ì„ ìˆœí™˜ êµ¬ì¡°ë¥¼ ë§Œë“¤ì–´ëƒ…ë‹ˆë‹¤. <br><br>ì„ìƒì—°êµ¬ ì‚¬ì—…ì—ì„œ í˜„ì¬ ì ê·¹ì ìœ¼ë¡œ êµ¬í˜„ë˜ê³  ìˆëŠ” ëª‡ ê°€ì§€ ì‚¬ë¡€ê°€ ìˆìŠµë‹ˆë‹¤. ì•½ 1ë…„ ì „ì— ê°€ì†í™”ëœ ì‹ ì•½ ê°œë°œ(Accelerated Drug Development)ì— ëŒ€í•´ ë§ì”€ë“œë¦° ë°” ìˆëŠ”ë°, ì €í¬ëŠ” ìƒë‹¹í•œ ê·œëª¨ì˜ ì‚¬ì—…ì„ ìˆ˜ì£¼í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê³ ê°ë“¤ì˜ ì‹œê°„ê³¼ ë¹„ìš©ì„ ì ˆì•½í•´ ë“œë¦´ ìˆ˜ ìˆë‹¤ëŠ” ì ì—ì„œ ì—„ì²­ë‚œ ë°˜í–¥ì„ ì–»ê³  ìˆìŠµë‹ˆë‹¤. ì €í¬ CRO ì‚¬ì—…ë¿ë§Œ ì•„ë‹ˆë¼ íŒŒë§ˆ ì„œë¹„ìŠ¤ ì‚¬ì—…ì˜ ì—­ëŸ‰ì„ í™œìš©í•´ì„œ ê³ ê°ë“¤ì´ í˜ì‹ ì ì¸ ì˜ì•½í’ˆì„ ì‹œì¥ì— ì¶œì‹œí•  ìˆ˜ ìˆë„ë¡ ë•ê³  ìˆê±°ë“ ìš”. OpenAIì™€ì˜ í˜‘ì—…ì„ í†µí•´ ì €í¬ê°€ í•¨ê»˜ ë§Œë“¤ì–´ê°€ê³  ìˆëŠ” ìƒˆë¡œìš´ ê²ƒì€ ì¸ê³µì§€ëŠ¥ì„ í™œìš©í•´ì„œ ì„ìƒì‹œí—˜ì˜ ì‚¬ì´í´ íƒ€ì„ì„ ê°œì„ í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì €í¬ê°€ ë³´ìœ í•œ ë°©ëŒ€í•œ ë°ì´í„° ì €ì¥ì†Œë¥¼ íš¨ê³¼ì ìœ¼ë¡œ í™œìš©í•´ì„œ ê³ ê°ë“¤ì—ê²Œ ìƒˆë¡œìš´ ê°€ì¹˜ë¥¼ ì œê³µí•  ìˆ˜ ìˆëŠ” ìƒˆë¡œìš´ ì—­ëŸ‰ë“¤ì„ í•¨ê»˜ ê°œë°œí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì •ë§ í¥ë¯¸ì§„ì§„í•œ ì‹œê¸°ì…ë‹ˆë‹¤. ì €í¬ ì„ìƒì—°êµ¬ ì‚¬ì—…ì€ ì˜¬í•´ ë‚´ë‚´ ìˆœì¡°ë¡­ê²Œ ì§„í–‰ë˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our next question comes from Dan Arias from Stifel.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ ìŠ¤í‹°í ì˜ ëŒ„ ì•„ë¦¬ì•„ìŠ¤ë‹˜ìœ¼ë¡œë¶€í„° ë°›ì•˜ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Daniel Arias: Stifel, Nicolaus & Company, Incorporated, Research Division Marc, maybe just following up on your Biopharma comments. I'm just curious whether demand from smaller emerging biotech is getting any better from where you sit? I mean, obviously, the BTK index is doing better, but I'm wondering if spending is loosening up at all?</td><td>**Daniel Arias:** Stifel, Nicolaus & Company, Incorporated, Research Divisionì—ì„œ Marcì˜ ë°”ì´ì˜¤íŒŒë§ˆ ê´€ë ¨ ì½”ë©˜íŠ¸ì— ëŒ€í•œ í›„ì† ì§ˆë¬¸ì…ë‹ˆë‹¤. ì €í¬ê°€ ë³´ê¸°ì— ì†Œê·œëª¨ ì‹ ìƒ ë°”ì´ì˜¤í…Œí¬ ê¸°ì—…ë“¤ì˜ ìˆ˜ìš”ê°€ ì¡°ê¸ˆì´ë¼ë„ ê°œì„ ë˜ê³  ìˆëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. BTK ì§€ìˆ˜ê°€ ì¢‹ì•„ì§€ê³  ìˆëŠ” ê²ƒì€ ë¶„ëª…í•˜ì§€ë§Œ, ì§€ì¶œì´ ì¡°ê¸ˆì´ë¼ë„ ëŠ˜ì–´ë‚˜ê³  ìˆëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤.</td></tr>
<tr><td>Marc Casper: Chairman, President & CEO Yes. So Dan, in terms of biotech, I'm sure it was a strong quarter, right? When I look at what was going on sort of in a little more detail. We really saw a very nice momentum in our Clinical Research business. Some of the early activities in Pharma Services, obviously, in Pharma Services can be smaller dollars as you get going. But -- there was a really nice progression there, which I feel good about. So I think that is encouraging. I actually think some of the M&A transactions that were done by large pharma acquiring biotech also helps sort of the ecosystem more broadly. So if I say, not only do the equities perform better, but I think also you're seeing deal activity and that deal activity ultimately will help drive a reinvestment cycle or cycling in of new capital to the market over time. So I think Q3 was a nice progression from that perspective.</td><td>**Marc Casper:** ë„¤, ëŒ„, ë°”ì´ì˜¤í…Œí¬ ê´€ë ¨í•´ì„œ ë§ì”€ë“œë¦¬ë©´ í™•ì‹¤íˆ ê°•í•œ ë¶„ê¸°ì˜€ìŠµë‹ˆë‹¤. ì¢€ ë” ìì„¸íˆ ì‚´í´ë³´ë©´, ì„ìƒì—°êµ¬(Clinical Research) ì‚¬ì—…ì—ì„œ ì •ë§ ì¢‹ì€ ëª¨ë©˜í…€ì„ í™•ì¸í•  ìˆ˜ ìˆì—ˆìŠµë‹ˆë‹¤. íŒŒë§ˆ ì„œë¹„ìŠ¤(Pharma Services)ì˜ ì´ˆê¸° í™œë™ë“¤ë„ ìˆì—ˆëŠ”ë°, ë¬¼ë¡  íŒŒë§ˆ ì„œë¹„ìŠ¤ëŠ” ì‹œì‘ ë‹¨ê³„ì—ì„œëŠ” ê·œëª¨ê°€ ì‘ì„ ìˆ˜ ìˆì§€ë§Œ, ì •ë§ ì¢‹ì€ ì§„ì „ì´ ìˆì—ˆê³  ì´ ë¶€ë¶„ì— ëŒ€í•´ ê¸ì •ì ìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ë§¤ìš° ê³ ë¬´ì ì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. <br><br>ì‹¤ì œë¡œ ëŒ€í˜• ì œì•½íšŒì‚¬ë“¤ì´ ë°”ì´ì˜¤í…Œí¬ë¥¼ ì¸ìˆ˜í•˜ëŠ” M&A ê±°ë˜ë“¤ì´ ì „ì²´ ìƒíƒœê³„ì— ë” ê´‘ë²”ìœ„í•˜ê²Œ ë„ì›€ì´ ë˜ê³  ìˆë‹¤ê³  ë´…ë‹ˆë‹¤. ì£¼ì‹ì´ ë” ë‚˜ì€ ì„±ê³¼ë¥¼ ë³´ì¼ ë¿ë§Œ ì•„ë‹ˆë¼ ê±°ë˜ í™œë™ë„ ì¦ê°€í•˜ê³  ìˆë‹¤ê³  ë§ì”€ë“œë¦´ ìˆ˜ ìˆê² ìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ê±°ë˜ í™œë™ì€ ê¶ê·¹ì ìœ¼ë¡œ ì¬íˆ¬ì ì‚¬ì´í´ì„ ì´‰ì§„í•˜ê±°ë‚˜ ì‹œì¥ì— ìƒˆë¡œìš´ ìë³¸ì´ ìˆœí™˜ë˜ëŠ” ë° ë„ì›€ì´ ë  ê²ƒì…ë‹ˆë‹¤. ë”°ë¼ì„œ 3ë¶„ê¸°ëŠ” ì´ëŸ° ê´€ì ì—ì„œ ì¢‹ì€ ì§„ì „ì„ ë³´ì˜€ë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Daniel Arias: Stifel, Nicolaus & Company, Incorporated, Research Division Yes. Okay. That's great. And then maybe just taking the other side of Tycho's China question as it relates to pricing and just the initiatives that they have going on over there to control price. The diagnostics markets are evolving, obviously, but what are you seeing on the research and industrial side. Is that fluid in a way that you think introduces some additional risk? Or do you kind of have your hands around the pricing dynamic such that you can think about it being stable into year-end or into the beginning of '26?</td><td>**Daniel Arias:** ë„¤, ì¢‹ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  Tychoì˜ ì¤‘êµ­ ì§ˆë¬¸ì˜ ë‹¤ë¥¸ ì¸¡ë©´ìœ¼ë¡œ, ê°€ê²©ê³¼ ê´€ë ¨í•´ì„œ ê·¸ë¦¬ê³  ê·¸ë“¤ì´ ê°€ê²©ì„ í†µì œí•˜ê¸° ìœ„í•´ ì§„í–‰í•˜ê³  ìˆëŠ” ì´ë‹ˆì…”í‹°ë¸Œë“¤ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì§„ë‹¨ ì‹œì¥ì€ ë¶„ëª…íˆ ì§„í™”í•˜ê³  ìˆì§€ë§Œ, ì—°êµ¬ ë° ì‚°ì—… ë¶€ë¬¸ì—ì„œëŠ” ì–´ë–¤ ìƒí™©ì„ ë³´ê³  ê³„ì‹ ì§€ìš”. ì¶”ê°€ì ì¸ ë¦¬ìŠ¤í¬ë¥¼ ì•¼ê¸°í•  ìˆ˜ ìˆì„ ì •ë„ë¡œ ìœ ë™ì ì¸ ìƒí™©ì¸ì§€, ì•„ë‹ˆë©´ ê°€ê²© ì—­í•™ì— ëŒ€í•´ ì¶©ë¶„íˆ íŒŒì•…í•˜ê³  ê³„ì…”ì„œ ì—°ë§ì´ë‚˜ 2026ë…„ ì´ˆê¹Œì§€ëŠ” ì•ˆì •ì ì¼ ê²ƒìœ¼ë¡œ ë³´ê³  ê³„ì‹ ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤.</td></tr>
<tr><td>Marc Casper: Chairman, President & CEO Yes, Dan, thanks for the question. So maybe if I step back on China, right? Because we've been able to deliver strong growth around the world now for some period of time, China has become a smaller percentage of the company's total. It's still an important market but smaller. When I look at what's going on in China, academic and government does benefit from some of the stimulus programs, but relatively pressured as the government has tried to manage its own economic challenges, which are meaningful. But what was encouraging was that Pharma Biotech grew in the quarter modestly, but it was nice to see that happen. When I think about the quarter, we declined in the mid-single digits. That was an improvement versus Q2. Really, the difference over those trends was we had that month of [ cession ] of trade activities back in the April timeframe, that absence really allowed us to have a bit more moderate declines. I would expect China for this year, full year to be down between mid- and high single digits. The pricing dynamics, less government affected in the industrial sector in Pharma and Biotech. They are more private enterprises or state-backed enterprises, but they don't have the same reimbursement dynamics that you could see in the diagnostics and healthcare market. So that's a bit more manageable.</td><td>**Marc Casper:** ë„¤, ëŒ„, ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. ì¤‘êµ­ì— ëŒ€í•´ ì¢€ ë” ë„“ì€ ê´€ì ì—ì„œ ë§ì”€ë“œë¦¬ë©´, ì €í¬ê°€ ì „ ì„¸ê³„ì ìœ¼ë¡œ ìƒë‹¹ ê¸°ê°„ ë™ì•ˆ ê²¬ê³ í•œ ì„±ì¥ì„ ë‹¬ì„±í•  ìˆ˜ ìˆì—ˆê¸° ë•Œë¬¸ì— ì¤‘êµ­ì´ íšŒì‚¬ ì „ì²´ì—ì„œ ì°¨ì§€í•˜ëŠ” ë¹„ì¤‘ì€ ì¤„ì–´ë“¤ì—ˆìŠµë‹ˆë‹¤. ì—¬ì „íˆ ì¤‘ìš”í•œ ì‹œì¥ì´ì§€ë§Œ ë¹„ì¤‘ì€ ì‘ì•„ì¡Œì£ . <br><br>ì¤‘êµ­ ìƒí™©ì„ ë³´ë©´, í•™ìˆ  ë° ì •ë¶€ ë¶€ë¬¸ì€ ì¼ë¶€ ë¶€ì–‘ì±…ì˜ í˜œíƒì„ ë°›ê³  ìˆì§€ë§Œ, ì •ë¶€ê°€ ìì²´ì ì¸ ê²½ì œì  ì–´ë ¤ì›€ì„ ê´€ë¦¬í•˜ë ¤ê³  ë…¸ë ¥í•˜ë©´ì„œ ìƒëŒ€ì ìœ¼ë¡œ ì••ë°•ì„ ë°›ê³  ìˆëŠ” ìƒí™©ì…ë‹ˆë‹¤. ì´ëŸ¬í•œ ê²½ì œì  ì–´ë ¤ì›€ì€ ìƒë‹¹íˆ ì˜ë¯¸ê°€ ìˆëŠ” ìˆ˜ì¤€ì…ë‹ˆë‹¤. <br><br>í•˜ì§€ë§Œ ê³ ë¬´ì ì´ì—ˆë˜ ê²ƒì€ íŒŒë§ˆ ë°”ì´ì˜¤í…(Pharma Biotech) ë¶€ë¬¸ì´ ì´ë²ˆ ë¶„ê¸°ì— ì†Œí­ì´ì§€ë§Œ ì„±ì¥í–ˆë‹¤ëŠ” ì ì…ë‹ˆë‹¤. ì´ëŸ° ëª¨ìŠµì„ ë³´ê²Œ ë˜ì–´ ë°˜ê°€ì› ìŠµë‹ˆë‹¤. ì´ë²ˆ ë¶„ê¸°ë¥¼ ë³´ë©´ ì¤‘ê°„ í•œ ìë¦¿ìˆ˜ ê°ì†Œë¥¼ ê¸°ë¡í–ˆëŠ”ë°, ì´ëŠ” 2ë¶„ê¸° ëŒ€ë¹„ ê°œì„ ëœ ê²°ê³¼ì…ë‹ˆë‹¤. ì‹¤ì œë¡œ ì´ëŸ¬í•œ ì¶”ì„¸ì™€ì˜ ì°¨ì´ì ì€ 4ì›” ì‹œê¸°ì— ë¬´ì—­ í™œë™ì´ í•œ ë‹¬ê°„ ì¤‘ë‹¨ë˜ì—ˆë˜ ê²ƒì¸ë°, ì´ëŸ¬í•œ ê³µë°± ë•ë¶„ì— ìš°ë¦¬ê°€ ì¢€ ë” ì™„ë§Œí•œ í•˜ë½ì„¸ë¥¼ ë³´ì¼ ìˆ˜ ìˆì—ˆìŠµë‹ˆë‹¤. ì¤‘êµ­ì˜ ê²½ìš° ì˜¬í•´ ì „ì²´ì ìœ¼ë¡œëŠ” ì¤‘ê°„ì—ì„œ ë†’ì€ í•œ ìë¦¿ìˆ˜ ê°ì†Œë¥¼ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ê°€ê²© ì—­í•™ ì¸¡ë©´ì—ì„œëŠ” ì œì•½ ë° ë°”ì´ì˜¤í… ë¶„ì•¼ì˜ ì‚°ì—… ë¶€ë¬¸ì´ ì •ë¶€ì˜ ì˜í–¥ì„ ëœ ë°›ìŠµë‹ˆë‹¤. ì´ë“¤ì€ ë¯¼ê°„ ê¸°ì—…ì´ê±°ë‚˜ êµ­ê°€ ì§€ì› ê¸°ì—…ë“¤ì´ì§€ë§Œ, ì§„ë‹¨ ë° í—¬ìŠ¤ì¼€ì–´ ì‹œì¥ì—ì„œ ë³¼ ìˆ˜ ìˆëŠ” ê²ƒê³¼ ê°™ì€ ìƒí™˜ ì—­í•™ì„ ê°–ê³  ìˆì§€ ì•ŠìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì´ ë¶€ë¶„ì€ ì¢€ ë” ê´€ë¦¬í•˜ê¸° ìš©ì´í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our next question comes from Dan Brennan from TD Cowen.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ TD Cowenì˜ Dan Brennanìœ¼ë¡œë¶€í„° ì™”ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Daniel Brennan: TD Cowen, Research Division Marc and Stephen. Maybe, Marc, just going back to the on-shoring announcements since there's been a tremendous focus in the investor community, how to think about that. You gave a lot of color already in response to some questions. But I was hoping you can elaborate a little bit on 2 parts. First is, we ultimately think like kind of CapEx and capacity following drug volumes. So if drug volumes aren't necessarily changing. Just trying to understand how to think about like what will be incremental in the U.S. versus kind of that wasn't there before. So any way to help us think about that at this point? I know you talked about for the greenfield, that would come with time, maybe like '27 and beyond. Just trying to think about that. And then I know you did talk about maybe more near-term, maybe some of the brownfield, there could be some equipment uptake in '26. Any way to kind of frame sizing, magnitude or just any way to kind of contemplate what this could mean for Thermo Fisher?</td><td>**Daniel Brennan:** ê¶ê·¹ì ìœ¼ë¡œ ìš°ë¦¬ëŠ” ì„¤ë¹„íˆ¬ì(CapEx)ì™€ ìƒì‚°ëŠ¥ë ¥ì´ ì˜ì•½í’ˆ ë¬¼ëŸ‰ì„ ë”°ë¼ê°„ë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ë”°ë¼ì„œ ì˜ì•½í’ˆ ë¬¼ëŸ‰ì´ ë°˜ë“œì‹œ ë³€í•˜ëŠ” ê²ƒì´ ì•„ë‹ˆë¼ë©´, ë¯¸êµ­ì—ì„œ ì¦ë¶„ì ìœ¼ë¡œ ì¶”ê°€ë  ë¶€ë¶„ì´ ì´ì „ì— ì—†ë˜ ê²ƒê³¼ ë¹„êµí•´ ì–´ë–»ê²Œ ë ì§€ ì´í•´í•˜ë ¤ê³  í•©ë‹ˆë‹¤. ì´ ì‹œì ì—ì„œ ì´ë¥¼ ì–´ë–»ê²Œ ìƒê°í•´ì•¼ í• ì§€ ë„ì›€ì„ ì£¼ì‹¤ ìˆ˜ ìˆë‚˜ìš”? <br><br>ê·¸ë¦°í•„ë“œ í”„ë¡œì íŠ¸ì˜ ê²½ìš° ì‹œê°„ì´ ê±¸ë¦´ ê²ƒì´ê³ , ì•„ë§ˆ 2027ë…„ ì´í›„ê°€ ë  ê²ƒì´ë¼ê³  ë§ì”€í•˜ì‹  ê²ƒìœ¼ë¡œ ì•Œê³  ìˆìŠµë‹ˆë‹¤. ì´ ë¶€ë¶„ì— ëŒ€í•´ ì–´ë–»ê²Œ ìƒê°í•´ì•¼ í• ì§€ìš”? ê·¸ë¦¬ê³  ë” ë‹¨ê¸°ì ìœ¼ë¡œ, ë¸Œë¼ìš´í•„ë“œ(brownfield) í”„ë¡œì íŠ¸ì—ì„œ 2026ë…„ì— ì¼ë¶€ ì¥ë¹„ ìˆ˜ìš” ì¦ê°€ê°€ ìˆì„ ìˆ˜ ìˆë‹¤ê³  ë§ì”€í•˜ì…¨ëŠ”ë°ìš”. ê·œëª¨ë‚˜ í¬ê¸°ë¥¼ ì–´ë–»ê²Œ ê°€ëŠ í•´ë³¼ ìˆ˜ ìˆì„ì§€, ë˜ëŠ” ì´ê²ƒì´ Thermo Fisherì—ê²Œ ì–´ë–¤ ì˜ë¯¸ê°€ ë  ìˆ˜ ìˆëŠ”ì§€ ìƒê°í•´ë³¼ ìˆ˜ ìˆëŠ” ë°©ë²•ì´ ìˆì„ê¹Œìš”?</td></tr>
<tr><td>Marc Casper: Chairman, President & CEO Yes. So Dan, thanks for the question. So when I think about what is the aggregate dynamic, let's all what the dollars are for us, but just what's going on? It is true incremental onetime demand. right? And what I mean by that is there's going to be new equipment, new initial stocking inventory, new labs, all these things. I mean none of these things are material in itself, but -- but you just go through that process of getting a facility online, you do qualification runs. You just -- there's just a bunch of activity that will generate demand over the next few years. But the volume in the industry hasn't changed, right? So it is really incremental in terms of that start-up. But effectively, it doesn't mean that your ongoing consumables business grows more quickly because you're producing the exact same amount of medicines around the world, you're just producing in different sites. So from that perspective, it's kind of an unexpected positive over the next few years. We have a strong presence there. And interestingly enough, we have a much stronger presence today than when those facilities were built many years ago in Europe, right? Just if you think about how strong our production business is, how strong the capabilities we're bringing in from Solventum and Filtration, the product launches around DynaSpin, which is our bioreactor technology. These are great things that position us to actually have a higher share in the new facilities than the existing installed base. I feel very good about the prospects. Can we do it site by site in terms of what the opportunity is. So I don't have a good number to say how big is it in total, but should be a tailwind a bit in Bioproduction. What I would say is our Bioproduction business is doing incredibly well, right? So when I was able to look at a few of the companies that have reported, very strong growth in Thermo Fisher, clearly faster than what the others have reported, broad-based strength geographically across our different businesses there. Really, the team did an excellent job bookings outpacing the strong teens growth and revenues is really the team is just doing great work. So it's an exciting business for us and one with great momentum in the market.</td><td>**Marc Casper:** ë„¤, Dan, ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. ì „ì²´ì ì¸ ì—­í•™ê´€ê³„ê°€ ë¬´ì—‡ì¸ì§€, ìš°ë¦¬ì—ê²Œ ì–´ë–¤ ì˜ë¯¸ì¸ì§€ ìƒê°í•´ë³´ë©´, ì´ëŠ” ì§„ì •í•œ ì¦ë¶„ ì¼íšŒì„± ìˆ˜ìš”ì…ë‹ˆë‹¤. ì œê°€ ë§ì”€ë“œë¦¬ëŠ” ê²ƒì€ ìƒˆë¡œìš´ ì¥ë¹„, ìƒˆë¡œìš´ ì´ˆê¸° ì¬ê³  ë¹„ì¶•, ìƒˆë¡œìš´ ì‹¤í—˜ì‹¤, ì´ ëª¨ë“  ê²ƒë“¤ì´ ìˆì„ ê²ƒì´ë¼ëŠ” ì ì…ë‹ˆë‹¤. ì´ëŸ° ê²ƒë“¤ ê°ê°ì€ ê·¸ ìì²´ë¡œëŠ” ì¤‘ìš”í•˜ì§€ ì•Šì§€ë§Œ, ì‹œì„¤ì„ ì˜¨ë¼ì¸ìœ¼ë¡œ ê°€ë™í•˜ëŠ” ê³¼ì •ì„ ê±°ì¹˜ë©´ì„œ ìê²© ê²€ì¦ ìš´ì˜ì„ í•˜ê²Œ ë˜ê³ , í–¥í›„ ëª‡ ë…„ê°„ ìˆ˜ìš”ë¥¼ ì°½ì¶œí•  ë‹¤ì–‘í•œ í™œë™ë“¤ì´ ìˆìŠµë‹ˆë‹¤. <br><br>í•˜ì§€ë§Œ ì—…ê³„ì˜ ë¬¼ëŸ‰ ìì²´ëŠ” ë³€í•˜ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì´ëŠ” ì •ë§ë¡œ ê·¸ëŸ° ìŠ¤íƒ€íŠ¸ì—… ì¸¡ë©´ì—ì„œì˜ ì¦ë¶„ì ì¸ ê²ƒì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ì‹¤ì§ˆì ìœ¼ë¡œëŠ” ì§€ì†ì ì¸ ì†Œëª¨í’ˆ ì‚¬ì—…ì´ ë” ë¹ ë¥´ê²Œ ì„±ì¥í•œë‹¤ëŠ” ì˜ë¯¸ëŠ” ì•„ë‹™ë‹ˆë‹¤. ì „ ì„¸ê³„ì ìœ¼ë¡œ ìƒì‚°í•˜ëŠ” ì˜ì•½í’ˆì˜ ì–‘ì€ ë™ì¼í•˜ê³ , ë‹¨ì§€ ë‹¤ë¥¸ ìƒì‚° ì‹œì„¤ì—ì„œ ìƒì‚°í•˜ëŠ” ê²ƒë¿ì´ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ê·¸ëŸ° ê´€ì ì—ì„œ ë³´ë©´, í–¥í›„ ëª‡ ë…„ê°„ ì˜ˆìƒì¹˜ ëª»í•œ ê¸ì •ì ì¸ ìš”ì†Œë¼ê³  í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” ê·¸ ì§€ì—­ì—ì„œ ê°•ë ¥í•œ ì…ì§€ë¥¼ í™•ë³´í•˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>í¥ë¯¸ë¡­ê²Œë„, ìˆ˜ë…„ ì „ ìœ ëŸ½ì— ê·¸ ì‹œì„¤ë“¤ì´ ê±´ì„¤ë˜ì—ˆì„ ë•Œë³´ë‹¤ í˜„ì¬ í›¨ì”¬ ë” ê°•ë ¥í•œ ì…ì§€ë¥¼ ê°–ì¶”ê³  ìˆìŠµë‹ˆë‹¤. ì €í¬ ìƒì‚° ì‚¬ì—…ì´ ì–¼ë§ˆë‚˜ ê°•ë ¥í•œì§€, Solventumê³¼ Filtrationì—ì„œ ê°€ì ¸ì˜¤ëŠ” ì—­ëŸ‰ì´ ì–¼ë§ˆë‚˜ ê°•ë ¥í•œì§€, ê·¸ë¦¬ê³  ì €í¬ ë°”ì´ì˜¤ë¦¬ì•¡í„° ê¸°ìˆ ì¸ DynaSpinì„ ì¤‘ì‹¬ìœ¼ë¡œ í•œ ì œí’ˆ ì¶œì‹œë¥¼ ìƒê°í•´ë³´ì‹œë©´ ì•Œ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ìš”ì†Œë“¤ì€ ì‹¤ì œë¡œ ê¸°ì¡´ ì„¤ì¹˜ ê¸°ë°˜ë³´ë‹¤ ì‹ ê·œ ì‹œì„¤ì—ì„œ ë” ë†’ì€ ì ìœ ìœ¨ì„ í™•ë³´í•  ìˆ˜ ìˆë„ë¡ í•´ì£¼ëŠ” í›Œë¥­í•œ í¬ì§€ì…”ë‹ì…ë‹ˆë‹¤. ì „ë§ì— ëŒ€í•´ ë§¤ìš° ê¸ì •ì ìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ê° ì‚¬ì´íŠ¸ë³„ë¡œ ê¸°íšŒê°€ ì–´ëŠ ì •ë„ì¸ì§€ íŒŒì•…í•  ìˆ˜ ìˆì„ê¹Œìš”? ì „ì²´ ê·œëª¨ê°€ ì–¼ë§ˆë‚˜ ë˜ëŠ”ì§€ì— ëŒ€í•œ ì •í™•í•œ ìˆ˜ì¹˜ëŠ” ì—†ì§€ë§Œ, ë°”ì´ì˜¤í”„ë¡œë•ì…˜(Bioproduction) ë¶€ë¬¸ì—ëŠ” ì–´ëŠ ì •ë„ ìˆœí’ì´ ë  ê²ƒìœ¼ë¡œ ë´…ë‹ˆë‹¤.<br><br>ë§ì”€ë“œë¦¬ê³  ì‹¶ì€ ê²ƒì€ ìš°ë¦¬ ë°”ì´ì˜¤í”„ë¡œë•ì…˜ ì‚¬ì—…ì´ ì •ë§ ë†€ë¼ìš¸ ì •ë„ë¡œ ì˜í•˜ê³  ìˆë‹¤ëŠ” ì ì…ë‹ˆë‹¤. ë³´ê³ ì„œë¥¼ ë°œí‘œí•œ ëª‡ëª‡ íšŒì‚¬ë“¤ì„ ì‚´í´ë³¼ ìˆ˜ ìˆì—ˆëŠ”ë°, ì¨ëª¨ í”¼ì…”(Thermo Fisher)ì˜ ì„±ì¥ì„¸ê°€ ë§¤ìš° ê°•ë ¥í•˜ê³ , ë‹¤ë¥¸ íšŒì‚¬ë“¤ì´ ë³´ê³ í•œ ê²ƒë³´ë‹¤ í™•ì‹¤íˆ ë¹ ë¥¸ ì„±ì¥ì„ ë³´ì´ê³  ìˆìœ¼ë©°, ì§€ì—­ì ìœ¼ë¡œë‚˜ ì—¬ëŸ¬ ì‚¬ì—… ë¶€ë¬¸ì—ì„œ ê´‘ë²”ìœ„í•œ ê°•ì„¸ë¥¼ ë‚˜íƒ€ë‚´ê³  ìˆìŠµë‹ˆë‹¤. ì •ë§ë¡œ íŒ€ì´ íƒì›”í•œ ì„±ê³¼ë¥¼ ê±°ë‘ì—ˆê³ , ìˆ˜ì£¼ê°€ 10%ëŒ€ í›„ë°˜ì˜ ê°•ë ¥í•œ ë§¤ì¶œ ì„±ì¥ì„ ì•ì§€ë¥´ê³  ìˆëŠ” ê²ƒì€ íŒ€ì´ ì •ë§ í›Œë¥­í•œ ì¼ì„ í•´ë‚´ê³  ìˆë‹¤ëŠ” ì¦ê±°ì…ë‹ˆë‹¤. ì €í¬ì—ê²ŒëŠ” ë§¤ìš° í¥ë¯¸ì§„ì§„í•œ ì‚¬ì—…ì´ë©° ì‹œì¥ì—ì„œ í° ëª¨ë©˜í…€ì„ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Daniel Brennan: TD Cowen, Research Division Terrific. And then just a follow-up, maybe to Stephen, just on the EPS impact on tariffs, could you just kind of level set? I know you gave the impact in the quarter and you said you mark-to-market the European tariffs, but you had the $0.50 potential from China. I think you recaptured some of that. Could you just kind of bottom line, like how much ultimately kind of the tariff changes occurred and kind of what's happening in 4Q?</td><td>**Daniel Brennan:** ì •ë§ ì¢‹ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ìŠ¤í‹°ë¸ì—ê²Œ í›„ì† ì§ˆë¬¸ì¸ë°, ê´€ì„¸ê°€ ì£¼ë‹¹ìˆœì´ìµ(EPS)ì— ë¯¸ì¹˜ëŠ” ì˜í–¥ì— ëŒ€í•´ ê¸°ì¤€ì ì„ ì¡ì•„ì£¼ì‹¤ ìˆ˜ ìˆë‚˜ìš”? ë¶„ê¸° ë‚´ ì˜í–¥ì„ ë§ì”€í•´ì£¼ì…¨ê³  ìœ ëŸ½ ê´€ì„¸ë¥¼ ì‹œê°€í‰ê°€(mark-to-market)í–ˆë‹¤ê³  í•˜ì…¨ëŠ”ë°, ì¤‘êµ­ì—ì„œ 0.50ë‹¬ëŸ¬ì˜ ì ì¬ì  ì˜í–¥ì´ ìˆì—ˆì£ . ê·¸ ì¤‘ ì¼ë¶€ë¥¼ íšŒìˆ˜í•˜ì‹  ê²ƒ ê°™ì€ë°ìš”. ê²°ë¡ ì ìœ¼ë¡œ ê´€ì„¸ ë³€í™”ê°€ ê¶ê·¹ì ìœ¼ë¡œ ì–¼ë§ˆë‚˜ ë°œìƒí–ˆëŠ”ì§€, ê·¸ë¦¬ê³  4ë¶„ê¸°ì—ëŠ” ì–´ë–¤ ìƒí™©ì¸ì§€ ì •ë¦¬í•´ì„œ ë§ì”€í•´ì£¼ì‹¤ ìˆ˜ ìˆë‚˜ìš”?</td></tr>
<tr><td>Stephen Williamson: Senior VP & CFO Yes. So thanks, Dan. So when I think about the tariffs and the kind of the actual experience in Q3 came in favorably to what we've had in the prior guide. In my prepared remarks, I called out the $0.11 pickup, and that's a combination of tariffs and the related FX in terms of the changes in those kind of tariff and trade environment. Looking to Q4, given the tariffs increased, i think from the time of last guide, most materially between U.S. and Europe. Our initial view is that kind of the assumptions we had around tariffs pretty much hold for Q4. So I'm not expecting a significant pickup in Q4. That's kind of how we've kind of framed the guidance for -- in terms of this update.</td><td>**Stephen Williamson:** ë„¤, ëŒ„, ê°ì‚¬í•©ë‹ˆë‹¤. ê´€ì„¸ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ë©´, 3ë¶„ê¸° ì‹¤ì œ ê²½í—˜ì€ ì´ì „ ê°€ì´ë˜ìŠ¤ì—ì„œ ì˜ˆìƒí–ˆë˜ ê²ƒë³´ë‹¤ ìš°í˜¸ì ìœ¼ë¡œ ë‚˜íƒ€ë‚¬ìŠµë‹ˆë‹¤. ì œê°€ ì¤€ë¹„ëœ ë°œì–¸ì—ì„œ 0.11ë‹¬ëŸ¬ ìƒìŠ¹ë¶„ì„ ì–¸ê¸‰í–ˆëŠ”ë°, ì´ëŠ” ê´€ì„¸ì™€ ê´€ë ¨ ì™¸í™˜ì˜ ì¡°í•©ìœ¼ë¡œ, ê´€ì„¸ ë° ë¬´ì—­ í™˜ê²½ ë³€í™” ì¸¡ë©´ì—ì„œ ë‚˜íƒ€ë‚œ ê²ƒì…ë‹ˆë‹¤. <br><br>4ë¶„ê¸°ë¥¼ ë³´ë©´, ì§€ë‚œ ê°€ì´ë˜ìŠ¤ ì´í›„ ê´€ì„¸ê°€ ì¸ìƒë˜ì—ˆê³ , íŠ¹íˆ ë¯¸êµ­ê³¼ ìœ ëŸ½ ê°„ì— ê°€ì¥ í° í­ìœ¼ë¡œ ì¦ê°€í–ˆìŠµë‹ˆë‹¤. ì €í¬ì˜ ì´ˆê¸° ê²¬í•´ë¡œëŠ” ê´€ì„¸ì— ëŒ€í•´ ê°€ì§€ê³  ìˆë˜ ê°€ì •ë“¤ì´ 4ë¶„ê¸°ì—ë„ ê±°ì˜ ê·¸ëŒ€ë¡œ ìœ ì§€ë  ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. ë”°ë¼ì„œ 4ë¶„ê¸°ì— ìƒë‹¹í•œ ìƒìŠ¹ì„ ê¸°ëŒ€í•˜ì§€ëŠ” ì•ŠìŠµë‹ˆë‹¤. ì´ê²ƒì´ ì €í¬ê°€ ì´ë²ˆ ì—…ë°ì´íŠ¸ì—ì„œ ê°€ì´ë˜ìŠ¤ë¥¼ êµ¬ì„±í•œ ë°©ì‹ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our next question is from Andrew Cooper from Raymond James.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ Raymond Jamesì˜ Andrew Cooperë¡œë¶€í„° ë°›ì•˜ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Andrew Cooper: Raymond James & Associates, Inc., Research Division Maybe just first, would love a little bit more color on the contract research side of the house. And maybe in particular, how that accelerator bundled program has gained traction and kind of layering that into the context of all the discussion that's already occurred in terms of onshoring, how that changes the applicability of the customers and how they look at that kind of wrap around 360 partnership versus CRO and CDMO kind of separately historically?</td><td>**Andrew Cooper:** ê³„ì•½ ì—°êµ¬(contract research) ë¶€ë¬¸ì— ëŒ€í•´ ì¢€ ë” ìì„¸í•œ ì„¤ëª…ì„ ë¶€íƒë“œë¦½ë‹ˆë‹¤. íŠ¹íˆ ê·¸ ê°€ì†í™” ë²ˆë“¤ í”„ë¡œê·¸ë¨(accelerator bundled program)ì´ ì–´ë–»ê²Œ ê²¬ì¸ë ¥ì„ ì–»ê³  ìˆëŠ”ì§€, ê·¸ë¦¬ê³  ì´ë¯¸ ë…¼ì˜ëœ ì˜¨ì‡¼ì–´ë§(onshoring) ë§¥ë½ì—ì„œ ì´ê²ƒì´ ê³ ê°ë“¤ì˜ ì ìš© ê°€ëŠ¥ì„±ì„ ì–´ë–»ê²Œ ë³€í™”ì‹œí‚¤ëŠ”ì§€ ë§ì…ë‹ˆë‹¤. ê³ ê°ë“¤ì´ ê¸°ì¡´ì— CROì™€ CDMOë¥¼ ë³„ë„ë¡œ ë³´ë˜ ê²ƒê³¼ ë‹¬ë¦¬, ì´ëŸ° í¬ê´„ì ì¸ 360ë„ íŒŒíŠ¸ë„ˆì‹­ì„ ì–´ë–»ê²Œ ë°”ë¼ë³´ê³  ìˆëŠ”ì§€ë„ ê¶ê¸ˆí•©ë‹ˆë‹¤.</td></tr>
<tr><td>Marc Casper: Chairman, President & CEO Yes. So Andrew, thank you for the question. So when I think about accelerator, right, we are one of the largest Clinical Research organizations. We are also one of the largest Pharma Services organization that's developing medicines on the physical side from early development all the way through commercial scale production, both in drug substance and drug product and all of the physical clinical trials activities around there. So we are touching these pipeline, these molecules in many different ways. And a hypothesis that we had at the time of deciding to acquire PPD back in 2021 was that there would be insights and capabilities that could streamline the way the companies develop medicines and how they produce them ultimately. We didn't bake that into our models, but we had a strong hypothesis. We spent a couple of years doing a significant number of co-creation with our customers, to bring that to life. We launched the official capabilities a year ago, and the adoption has been very strong. You see it very aggressively in biotech because effectively, they outsource pretty much all of their work, right? So when they think about it, they are looking for a partner that can help them bring insights, not only in how to design and execute their trials. But also, how do you develop and produce the medicines, and it's been very compelling and it's built us a nice book of authorizations. That turns into revenue over time, right? It takes a while for this to flow through the pipeline. And in large pharma, there's been great interest in our leading clinical trials, the physical capabilities, the logistics packaging, distribution of experimental medicines. And what that has allowed us to do is to continue to drive share gain momentum because, again, there the linkages with clinical research shaves time and cost out of the process as well. So it's been -- it's early days, but they've been very positive.</td><td>**Marc Casper:** ë„¤, Andrew, ì§ˆë¬¸í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. ì•¡ì…€ëŸ¬ë ˆì´í„°ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ë©´, ì €í¬ëŠ” ìµœëŒ€ ê·œëª¨ì˜ ì„ìƒì—°êµ¬ê¸°ê´€(Clinical Research Organization) ì¤‘ í•˜ë‚˜ì…ë‹ˆë‹¤. ë˜í•œ ì´ˆê¸° ê°œë°œë¶€í„° ìƒì—…ì  ê·œëª¨ ìƒì‚°ê¹Œì§€, ì›ë£Œì˜ì•½í’ˆ(drug substance)ê³¼ ì™„ì œì˜ì•½í’ˆ(drug product) ëª¨ë‘ì—ì„œ ë¬¼ë¦¬ì  ì¸¡ë©´ì˜ ì˜ì•½í’ˆ ê°œë°œì„ ë‹´ë‹¹í•˜ëŠ” ìµœëŒ€ ê·œëª¨ì˜ ì œì•½ ì„œë¹„ìŠ¤ ê¸°ê´€ ì¤‘ í•˜ë‚˜ì´ê¸°ë„ í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ì™€ ê´€ë ¨ëœ ëª¨ë“  ë¬¼ë¦¬ì  ì„ìƒì‹œí—˜ í™œë™ë“¤ë„ í¬í•¨í•´ì„œ ë§ì´ì£ .<br><br>ë”°ë¼ì„œ ì €í¬ëŠ” ì´ëŸ¬í•œ íŒŒì´í”„ë¼ì¸, ì´ëŸ° ë¶„ìë“¤ì„ ë‹¤ì–‘í•œ ë°©ì‹ìœ¼ë¡œ ë‹¤ë£¨ê³  ìˆìŠµë‹ˆë‹¤. 2021ë…„ PPD ì¸ìˆ˜ë¥¼ ê²°ì •í•  ë‹¹ì‹œ ì €í¬ê°€ ê°€ì¡Œë˜ ê°€ì„¤ì€, ê¸°ì—…ë“¤ì´ ì˜ì•½í’ˆì„ ê°œë°œí•˜ê³  ê¶ê·¹ì ìœ¼ë¡œ ìƒì‚°í•˜ëŠ” ë°©ì‹ì„ ê°„ì†Œí™”í•  ìˆ˜ ìˆëŠ” í†µì°°ë ¥ê³¼ ì—­ëŸ‰ì´ ìˆì„ ê²ƒì´ë¼ëŠ” ì ì´ì—ˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” ê·¸ê²ƒì„ ëª¨ë¸ì— ë°˜ì˜í•˜ì§€ëŠ” ì•Šì•˜ì§€ë§Œ, ê°•ë ¥í•œ ê°€ì„¤ì„ ê°€ì§€ê³  ìˆì—ˆìŠµë‹ˆë‹¤. ëª‡ ë…„ì— ê±¸ì³ ê³ ê°ë“¤ê³¼ ìƒë‹¹í•œ ìˆ˜ì˜ ê³µë™ ì°½ì¡° ì‘ì—…ì„ ì§„í–‰í•˜ì—¬ ì´ë¥¼ ì‹¤í˜„ì‹œì¼°ìŠµë‹ˆë‹¤. 1ë…„ ì „ì— ê³µì‹ ì—­ëŸ‰ì„ ì¶œì‹œí–ˆëŠ”ë°, ë„ì…ë¥ ì´ ë§¤ìš° ë†’ì•˜ìŠµë‹ˆë‹¤. ë°”ì´ì˜¤í…Œí¬ ë¶„ì•¼ì—ì„œ íŠ¹íˆ ì ê·¹ì ìœ¼ë¡œ ë‚˜íƒ€ë‚˜ê³  ìˆëŠ”ë°, ì‚¬ì‹¤ìƒ ê·¸ë“¤ì€ ê±°ì˜ ëª¨ë“  ì—…ë¬´ë¥¼ ì•„ì›ƒì†Œì‹±í•˜ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ê·¸ë“¤ì´ ìƒê°í•  ë•Œ, ì„ìƒì‹œí—˜ì„ ì„¤ê³„í•˜ê³  ì‹¤í–‰í•˜ëŠ” ë°©ë²•ë¿ë§Œ ì•„ë‹ˆë¼ ì˜ì•½í’ˆì„ ê°œë°œí•˜ê³  ìƒì‚°í•˜ëŠ” ë°©ë²•ì— ëŒ€í•œ ì¸ì‚¬ì´íŠ¸ë¥¼ ì œê³µí•  ìˆ˜ ìˆëŠ” íŒŒíŠ¸ë„ˆë¥¼ ì°¾ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ë§¤ìš° ë§¤ë ¥ì ì´ì—ˆê³  ìƒë‹¹í•œ ìˆ˜ì£¼ ì”ê³ ë¥¼ êµ¬ì¶•í•´ì£¼ì—ˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ ì‹œê°„ì´ ì§€ë‚˜ë©´ì„œ ë§¤ì¶œë¡œ ì „í™˜ë˜ëŠ” ê²ƒì´ì£ . íŒŒì´í”„ë¼ì¸ì„ í†µí•´ í˜ëŸ¬ê°€ëŠ” ë°ëŠ” ì‹œê°„ì´ ê±¸ë¦½ë‹ˆë‹¤. ëŒ€í˜• ì œì•½íšŒì‚¬ë“¤ì´ ì €í¬ì˜ ì„ ë„ì ì¸ ì„ìƒì‹œí—˜, ë¬¼ë¦¬ì  ì—­ëŸ‰, ì‹¤í—˜ìš© ì˜ì•½í’ˆì˜ ë¬¼ë¥˜ í¬ì¥ ë° ìœ í†µì— ëŒ€í•´ í° ê´€ì‹¬ì„ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. ì´ë¥¼ í†µí•´ ì €í¬ëŠ” ì§€ì†ì ìœ¼ë¡œ ì‹œì¥ì ìœ ìœ¨ í™•ëŒ€ ëª¨ë©˜í…€ì„ ì´ì–´ê°ˆ ìˆ˜ ìˆì—ˆëŠ”ë°, ì„ìƒì—°êµ¬ì™€ì˜ ì—°ê³„ê°€ í”„ë¡œì„¸ìŠ¤ì—ì„œ ì‹œê°„ê³¼ ë¹„ìš©ì„ ì ˆì•½í•´ì£¼ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ì•„ì§ ì´ˆê¸° ë‹¨ê³„ì´ì§€ë§Œ ë§¤ìš° ê¸ì •ì ì¸ ê²°ê³¼ë¥¼ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Andrew Cooper: Raymond James & Associates, Inc., Research Division That's helpful. And then maybe just 1 kind of financial question. $0.20 operational beat in 3Q, you had the FX and tariff tailwinds as well. But you're raising the range about $0.20 in the midpoint as well. Maybe what's going on to offset some of that operational traction as we think about 4Q? Is it reinvestment? Is it a little bit of mix? Is there something different to think about now and we have that $0.05 of dilution in the acquisitions you called out as well? Just would love a little bit of color on kind of 3Q to 4Q.</td><td>**Andrew Cooper:** ë„ì›€ì´ ë˜ì—ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì¬ë¬´ì ì¸ ì§ˆë¬¸ì„ í•˜ë‚˜ ë” ë“œë¦¬ê² ìŠµë‹ˆë‹¤. 3ë¶„ê¸°ì— ìš´ì˜ìƒ 0.20ë‹¬ëŸ¬ì˜ ì‹¤ì  ê°œì„ ì´ ìˆì—ˆê³ , í™˜ìœ¨ê³¼ ê´€ì„¸ ìˆœí’ë„ ìˆì—ˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ê°€ì´ë˜ìŠ¤ ì¤‘ê°„ê°’ì„ ì•½ 0.20ë‹¬ëŸ¬ ìƒí–¥ ì¡°ì •í•˜ì…¨ëŠ”ë°ìš”. 4ë¶„ê¸°ë¥¼ ìƒê°í•´ë³¼ ë•Œ ì´ëŸ° ìš´ì˜ìƒ ê²¬ì¸ë ¥ì„ ìƒì‡„í•˜ëŠ” ìš”ì¸ë“¤ì´ ë¬´ì—‡ì¸ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ì¬íˆ¬ìì¸ê°€ìš”? ì œí’ˆ ë¯¹ìŠ¤ì˜ ì˜í–¥ì¸ê°€ìš”? ì•„ë‹ˆë©´ ì§€ê¸ˆ ë‹¤ë¥´ê²Œ ìƒê°í•´ì•¼ í•  ë¶€ë¶„ì´ ìˆë‚˜ìš”? ê·¸ë¦¬ê³  ë§ì”€í•˜ì‹  ì¸ìˆ˜í•©ë³‘ìœ¼ë¡œ ì¸í•œ 0.05ë‹¬ëŸ¬ì˜ í¬ì„ íš¨ê³¼ë„ ìˆê³ ìš”. 3ë¶„ê¸°ì—ì„œ 4ë¶„ê¸°ë¡œ ë„˜ì–´ê°€ëŠ” ë¶€ë¶„ì— ëŒ€í•´ ì¡°ê¸ˆ ë” ìì„¸í•œ ì„¤ëª…ì„ ë¶€íƒë“œë¦½ë‹ˆë‹¤.</td></tr>
<tr><td>Stephen Williamson: Senior VP & CFO Yes. Andrew, so we peaked by $0.30 in Q3. As you mentioned, we have $0.05 of additional dilution from the acquisitions. And overall, $0.20 raise at the midpoint given where we are in the year, how we're performing, what the end markets are like, I think this -- on an even stronger raise on the low end of our guide, I think that's a good position to be in as we think about going into the fourth quarter. We're in a good position for us to finish the year. I don't overread into -- we're raising our guidance by $0.20 in the midpoint. We're significantly raising on the low end. I think that's a strong statement. Thanks, Andrew.</td><td>**Stephen Williamson:** ë„¤, Andrew. 3ë¶„ê¸°ì— 0.30ë‹¬ëŸ¬ë¡œ ì •ì ì„ ì°ì—ˆìŠµë‹ˆë‹¤. ë§ì”€í•˜ì‹  ëŒ€ë¡œ ì¸ìˆ˜í•©ë³‘ìœ¼ë¡œ ì¸í•œ ì¶”ê°€ í¬ì„íš¨ê³¼ê°€ 0.05ë‹¬ëŸ¬ ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì „ì²´ì ìœ¼ë¡œ ì¤‘ê°„ê°’ ê¸°ì¤€ 0.20ë‹¬ëŸ¬ ìƒí–¥ ì¡°ì •ì¸ë°, ì˜¬í•´ ìš°ë¦¬ê°€ ì²˜í•œ ìƒí™©, ì‹¤ì , ê·¸ë¦¬ê³  ìµœì¢… ì‹œì¥ ìƒí™©ì„ ê³ ë ¤í•  ë•Œ, ì´ëŠ” - íŠ¹íˆ ê°€ì´ë˜ìŠ¤ í•˜í•œì„ ì„ ë”ìš± í¬ê²Œ ìƒí–¥ ì¡°ì •í•œ ê²ƒì€ 4ë¶„ê¸°ë¡œ í–¥í•˜ëŠ” ì‹œì ì—ì„œ ì¢‹ì€ í¬ì§€ì…˜ì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ì—°ë§ì„ ë§ˆë¬´ë¦¬í•˜ê¸°ì— ì¢‹ì€ ìœ„ì¹˜ì— ìˆìŠµë‹ˆë‹¤. <br><br>ê³¼ë„í•˜ê²Œ í•´ì„í•˜ì§€ëŠ” ë§ˆì„¸ìš” - ìš°ë¦¬ê°€ ì¤‘ê°„ê°’ì„ 0.20ë‹¬ëŸ¬ ìƒí–¥ ì¡°ì •í•˜ê³  ìˆê³ , í•˜í•œì„ ì€ ìƒë‹¹íˆ í¬ê²Œ ì˜¬ë ¸ìŠµë‹ˆë‹¤. ì´ê²ƒì´ ê°•ë ¥í•œ ë©”ì‹œì§€ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ê°ì‚¬í•©ë‹ˆë‹¤, Andrew.</td></tr>
<tr><td>Operator: Our next question comes from Patrick Donnelly from Citi.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ ì‹œí‹°ì˜ íŒ¨íŠ¸ë¦­ ë„ë„¬ë¦¬ë‹˜ê»˜ì„œ ì£¼ì…¨ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Patrick Donnelly: Citigroup Inc. Exchange Research Marc, maybe one for you on just the capital allocation side. You obviously continue to buy back stock as you talked about. Can you just talk about the M&A appetite, what the discussions look like? Any areas you're focused on? I know you guys always have a good pulse on that front. So just curious what the appetite there looks like in the conversation. And I just have a quick follow-up.</td><td>**Patrick Donnelly:** ë§ˆí¬, ìë³¸ ë°°ë¶„ ì¸¡ë©´ì—ì„œ ì§ˆë¬¸ í•˜ë‚˜ ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë§ì”€í•˜ì‹  ëŒ€ë¡œ ê³„ì†í•´ì„œ ìì‚¬ì£¼ ë§¤ì…ì„ ì§„í–‰í•˜ê³  ê³„ì‹ ë°ìš”. M&Aì— ëŒ€í•œ ê´€ì‹¬ë„ëŠ” ì–´ë–¤ì§€, ì–´ë–¤ ë…¼ì˜ë“¤ì´ ì´ë£¨ì–´ì§€ê³  ìˆëŠ”ì§€ ë§ì”€í•´ ì£¼ì‹¤ ìˆ˜ ìˆë‚˜ìš”? ì§‘ì¤‘í•˜ê³  ê³„ì‹  íŠ¹ì • ë¶„ì•¼ê°€ ìˆëŠ”ì§€ìš”? í•­ìƒ ì´ ë¶€ë¶„ì— ëŒ€í•´ ì¢‹ì€ ê°ê°ì„ ê°€ì§€ê³  ê³„ì‹  ê²ƒìœ¼ë¡œ ì•Œê³  ìˆì–´ì„œ, M&Aì— ëŒ€í•œ ê´€ì‹¬ë„ì™€ ê´€ë ¨ ë…¼ì˜ ìƒí™©ì´ ê¶ê¸ˆí•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ê°„ë‹¨í•œ í›„ì† ì§ˆë¬¸ë„ í•˜ë‚˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Marc Casper: Chairman, President & CEO Yes. So we have been active all year, right? We've deployed about 7.5 -- a little over $7.5 billion, $4 billion on M&A, $3.5 billion on return on capital through buybacks and dividends. We have a very busy pipeline. It's exciting. I like this environment because there are good companies that struggle in environments where it's all about execution. And so we're busy and we're looking at some interesting things. Obviously, those things will always fit well with our strategy. It's going to be whether we can generate really good returns. And for those that we feel good about, you'll see us continue to be active. And there are many parts of the company given how fragmented our industry is, to expand our offerings that would be highly valued for our customers. So we're going to execute well against what we closed and at the same point in time, continue to look for great opportunities to build more value.</td><td>**Marc Casper:** ë„¤, ì €í¬ëŠ” ì˜¬í•´ ë‚´ë‚´ í™œë°œí•˜ê²Œ í™œë™í•´ì™”ìŠµë‹ˆë‹¤. ì•½ 75ì–µ ë‹¬ëŸ¬ë¥¼ ì¡°ê¸ˆ ë„˜ê²Œ ë°°ì¹˜í–ˆëŠ”ë°, M&Aì— 40ì–µ ë‹¬ëŸ¬, ìì‚¬ì£¼ ë§¤ì…ê³¼ ë°°ë‹¹ì„ í†µí•œ ìë³¸ ìˆ˜ìµë¥ ì— 35ì–µ ë‹¬ëŸ¬ë¥¼ íˆ¬ì…í–ˆìŠµë‹ˆë‹¤. ë§¤ìš° ë°”ìœ íŒŒì´í”„ë¼ì¸ì„ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. í¥ë¯¸ì§„ì§„í•©ë‹ˆë‹¤. ì €ëŠ” ì´ëŸ° í™˜ê²½ì„ ì¢‹ì•„í•©ë‹ˆë‹¤. ì‹¤í–‰ë ¥ì´ ì „ë¶€ì¸ í™˜ê²½ì—ì„œ ì–´ë ¤ì›€ì„ ê²ªëŠ” ì¢‹ì€ íšŒì‚¬ë“¤ì´ ìˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ê·¸ë˜ì„œ ì €í¬ëŠ” ë°”ì˜ê²Œ ì›€ì§ì´ê³  ìˆê³  í¥ë¯¸ë¡œìš´ ê²ƒë“¤ì„ ì‚´í´ë³´ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ë‹¹ì—°íˆ ì´ëŸ° ê²ƒë“¤ì€ í•­ìƒ ì €í¬ ì „ëµê³¼ ì˜ ë§ì•„ì•¼ í•©ë‹ˆë‹¤. ì •ë§ ì¢‹ì€ ìˆ˜ìµë¥ ì„ ì°½ì¶œí•  ìˆ˜ ìˆëŠ”ì§€ê°€ ê´€ê±´ì…ë‹ˆë‹¤. ì €í¬ê°€ í™•ì‹ ì„ ê°–ëŠ” ê²ƒë“¤ì— ëŒ€í•´ì„œëŠ” ê³„ì†í•´ì„œ ì ê·¹ì ìœ¼ë¡œ ë‚˜ì„œëŠ” ëª¨ìŠµì„ ë³´ì‹¤ ìˆ˜ ìˆì„ ê²ƒì…ë‹ˆë‹¤. ì €í¬ ì—…ê³„ê°€ ë§¤ìš° ì„¸ë¶„í™”ë˜ì–´ ìˆë‹¤ëŠ” ì ì„ ê³ ë ¤í•  ë•Œ, ê³ ê°ë“¤ì—ê²Œ ë†’ì€ ê°€ì¹˜ë¥¼ ì œê³µí•  ìˆ˜ ìˆëŠ” ì„œë¹„ìŠ¤ í™•ì¥ ê¸°íšŒê°€ íšŒì‚¬ ê³³ê³³ì— ë§ì´ ìˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” ì„±ì‚¬ëœ ê±°ë˜ë“¤ì„ ì˜ ì‹¤í–‰í•´ ë‚˜ê°€ëŠ” ë™ì‹œì—, ë” ë§ì€ ê°€ì¹˜ë¥¼ ì°½ì¶œí•  ìˆ˜ ìˆëŠ” í›Œë¥­í•œ ê¸°íšŒë“¤ì„ ì§€ì†ì ìœ¼ë¡œ ëª¨ìƒ‰í•´ ë‚˜ê°ˆ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Patrick Donnelly: Citigroup Inc. Exchange Research Okay. That's helpful. And then as we look ahead, it seems like the exit rate for 4Q is somewhere at 2% or 3% organic. Obviously, you talked a little bit about 26% last quarter. Is the view that growth just continues to accelerate throughout next year? It sounds like China is turning the corner to a degree, Pharma sounds a little bit better. I guess, what segments are holding you back, if any, in terms of when you look at what's improving right now? And again, as that acceleration happens next year, what are the key drivers? And what are you looking for to still turn the corner?</td><td>**Patrick Donnelly:** ë„ì›€ì´ ë˜ëŠ” ë‹µë³€ì´ì—ˆìŠµë‹ˆë‹¤. ì•ìœ¼ë¡œë¥¼ ë³´ë©´ 4ë¶„ê¸° ì¢…ë£Œ ì‹œì ì˜ ìœ ê¸°ì  ì„±ì¥ë¥ ì´ 2~3% ì •ë„ì¸ ê²ƒ ê°™ìŠµë‹ˆë‹¤. ì§€ë‚œ ë¶„ê¸°ì— 26%ì— ëŒ€í•´ ë§ì”€í•˜ì…¨ëŠ”ë°, ë‚´ë…„ ë‚´ë‚´ ì„±ì¥ì´ ê³„ì† ê°€ì†í™”ë  ê²ƒì´ë¼ëŠ” ì „ë§ì¸ê°€ìš”? ì¤‘êµ­ì´ ì–´ëŠ ì •ë„ ì „í™˜ì ì„ ë§ê³  ìˆê³ , ì œì•½ ë¶€ë¬¸ë„ ì¡°ê¸ˆ ë‚˜ì•„ì§€ê³  ìˆëŠ” ê²ƒ ê°™ìŠµë‹ˆë‹¤. í˜„ì¬ ê°œì„ ë˜ê³  ìˆëŠ” ìƒí™©ì„ ë³¼ ë•Œ, í˜¹ì‹œ ë°œëª©ì„ ì¡ê³  ìˆëŠ” ë¶€ë¬¸ì´ ìˆë‹¤ë©´ ì–´ë–¤ ê²ƒë“¤ì¸ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë‚´ë…„ì— ì´ëŸ° ê°€ì†í™”ê°€ ì¼ì–´ë‚  ë•Œ í•µì‹¬ ë™ë ¥ì€ ë¬´ì—‡ì´ê³ , ì—¬ì „íˆ ì „í™˜ì ì„ ë§ê¸° ìœ„í•´ ì£¼ëª©í•˜ê³  ê³„ì‹  ë¶€ë¶„ì€ ë¬´ì—‡ì¸ê°€ìš”?</td></tr>
<tr><td>Marc Casper: Chairman, President & CEO We are looking forward to our call at the beginning of the year to give you all the details. We'll benefit from, obviously, the perspective on how we exit the year. And our view is, over the next couple of years, growth is going to build over time, and I'm very excited about exiting this year with a couple of percent organic and 3% when you have the non-repeats of the final bits of COVID runoff. So we entered the year at a good part, and we're going to execute really well and turning the revenue growth into excellent, excellent earnings growth and like we did in the quarter and finish up on a great note in '25 and set ourselves up for a great '26 and beyond. So Patrick, thank you for the final question. Let me wrap up. Thanks, everyone, joining us on the call today. We're very pleased to deliver another strong quarter. We're well positioned to deliver differentiated performance in 2025 and continue to create value for all of our stakeholders and build an even brighter future for our company. We look forward to updating you on the fourth quarter and the full year performance early in 2026. And as always, thank you for your support of Thermo Fisher Scientific. Thanks, everyone.</td><td>**Marc Casper:** ì—°ì´ˆ ì½œì—ì„œ ëª¨ë“  ì„¸ë¶€ì‚¬í•­ì„ ë§ì”€ë“œë¦´ ìˆ˜ ìˆê¸°ë¥¼ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì—°ë§ì„ ì–´ë–»ê²Œ ë§ˆë¬´ë¦¬í•˜ëŠ”ì§€ì— ëŒ€í•œ ê´€ì ì—ì„œ ë¶„ëª…íˆ ë„ì›€ì´ ë  ê²ƒì…ë‹ˆë‹¤. ì €í¬ ê²¬í•´ë¡œëŠ” í–¥í›„ ëª‡ ë…„ê°„ ì„±ì¥ì´ ì‹œê°„ì´ ì§€ë‚˜ë©´ì„œ ìŒ“ì—¬ê°ˆ ê²ƒì´ê³ , ì˜¬í•´ë¥¼ ìœ ê¸°ì  ì„±ì¥ë¥  ëª‡ í¼ì„¼íŠ¸ë¡œ ë§ˆë¬´ë¦¬í•˜ê³  ì½”ë¡œë‚˜ ì—¬íŒŒì˜ ë§ˆì§€ë§‰ ë¶€ë¶„ë“¤ì´ ë°˜ë³µë˜ì§€ ì•ŠëŠ” íš¨ê³¼ê¹Œì§€ í¬í•¨í•˜ë©´ 3%ë¡œ ë§ˆë¬´ë¦¬í•˜ê²Œ ë˜ì–´ ë§¤ìš° ê¸°ëŒ€ë©ë‹ˆë‹¤. <br><br>ì¢‹ì€ ìƒí™©ì—ì„œ í•œ í•´ë¥¼ ì‹œì‘í–ˆê³ , ì •ë§ ì˜ ì‹¤í–‰í•´ì„œ ë§¤ì¶œ ì„±ì¥ì„ ì´ë²ˆ ë¶„ê¸°ì— í–ˆë˜ ê²ƒì²˜ëŸ¼ íƒì›”í•˜ê³  ë›°ì–´ë‚œ ìˆ˜ìµ ì„±ì¥ìœ¼ë¡œ ì „í™˜ì‹œì¼œ 25ë…„ì„ ë©‹ì§€ê²Œ ë§ˆë¬´ë¦¬í•˜ê³  26ë…„ê³¼ ê·¸ ì´í›„ë¥¼ ìœ„í•œ í›Œë¥­í•œ ê¸°ë°˜ì„ ë§ˆë ¨í•  ê²ƒì…ë‹ˆë‹¤. <br><br>íŒ¨íŠ¸ë¦­, ë§ˆì§€ë§‰ ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. ì´ì œ ë§ˆë¬´ë¦¬í•˜ê² ìŠµë‹ˆë‹¤. ì˜¤ëŠ˜ ì»¨í¼ëŸ°ìŠ¤ ì½œì— ì°¸ì—¬í•´ ì£¼ì‹  ëª¨ë“  ë¶„ë“¤ê»˜ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤. ë˜ í•œ ë²ˆ ê°•ë ¥í•œ ì‹¤ì ì„ ë°œí‘œí•˜ê²Œ ë˜ì–´ ë§¤ìš° ê¸°ì©ë‹ˆë‹¤. ì €í¬ëŠ” 2025ë…„ì— ì°¨ë³„í™”ëœ ì„±ê³¼ë¥¼ ë‹¬ì„±í•  ìˆ˜ ìˆëŠ” ì¢‹ì€ ìœ„ì¹˜ì— ìˆìœ¼ë©°, ëª¨ë“  ì´í•´ê´€ê³„ìë“¤ì„ ìœ„í•œ ê°€ì¹˜ ì°½ì¶œì„ ì§€ì†í•˜ê³  íšŒì‚¬ì˜ ë”ìš± ë°ì€ ë¯¸ë˜ë¥¼ êµ¬ì¶•í•´ ë‚˜ê°ˆ ê²ƒì…ë‹ˆë‹¤. 2026ë…„ ì´ˆì— 4ë¶„ê¸° ë° ì—°ê°„ ì‹¤ì ì— ëŒ€í•´ ì—…ë°ì´íŠ¸í•´ ë“œë¦´ ìˆ˜ ìˆê¸°ë¥¼ ê¸°ëŒ€í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì–¸ì œë‚˜ ê·¸ë ‡ë“¯ì´, ì¨ëª¨ í”¼ì…” ì‚¬ì´ì–¸í‹°í”½ì— ëŒ€í•œ ì—¬ëŸ¬ë¶„ì˜ ì§€ì›ì— ê°ì‚¬ë“œë¦½ë‹ˆë‹¤. ëª¨ë“  ë¶„ë“¤ê»˜ ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: This concludes today's call. Thank you all for joining. You may now disconnect your lines.</td><td>**Operator:** ì˜¤ëŠ˜ ì»¨í¼ëŸ°ìŠ¤ ì½œì„ ë§ˆì¹˜ê² ìŠµë‹ˆë‹¤. ì°¸ì—¬í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. ì´ì œ ì—°ê²°ì„ ì¢…ë£Œí•˜ì…”ë„ ë©ë‹ˆë‹¤.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;">Here's a summary of the key points from the earnings call in Korean:<br><br>â€¢ ì‹¤ì  ë° ì „ë§:<br>- 3ë¶„ê¸° ìœ ê¸°ì  ì„±ì¥ë¥  2% ë‹¬ì„±, COVID ê´€ë ¨ ë§¤ì¶œ ì œì™¸ì‹œ ì•½ 3% ì„±ì¥<br>- ë¶„ì„ê¸°ê¸° ë¶€ë¬¸ì—ì„œ ì§ˆëŸ‰ë¶„ì„ê¸°ì™€ ì „ìí˜„ë¯¸ê²½ ì‚¬ì—…ì´ ê²¬ì¡°í•œ ì„±ì¥ ê¸°ë¡<br>- 2026ë…„ 3-6% ìœ ê¸°ì  ì„±ì¥ ì „ë§ ìœ ì§€<br><br>â€¢ ì œì•½/ë°”ì´ì˜¤í… ë™í–¥:<br>- ë¯¸êµ­ ë‚´ ìƒì‚°ê¸°ì§€ ì´ì „(ë¦¬ì‡¼ì–´ë§) ì›€ì§ì„ ì¦ê°€ë¡œ ì¥ê¸°ì  ê¸°íšŒ ì˜ˆìƒ<br>- ì„ìƒì‹œí—˜ ì‚¬ì—…ì˜ ìˆ˜ì£¼ ê°•ì„¸ ì§€ì†<br>- ë°”ì´ì˜¤í”„ë¡œë•ì…˜ ì‚¬ì—…ì—ì„œ ê²½ìŸì‚¬ ëŒ€ë¹„ ë†’ì€ ì„±ì¥ë¥  ê¸°ë¡<br><br>â€¢ ì§€ì—­ë³„ í˜„í™©:<br>- ì¤‘êµ­: ì „ë…„ ëŒ€ë¹„ ì¤‘ê°„~ë†’ì€ í•œìë¦¬ ìˆ˜ ê°ì†Œ ì˜ˆìƒ<br>- ë¯¸êµ­/ìœ ëŸ½: í•™ìˆ /ì •ë¶€ ë¶€ë¬¸ ì†Œí­ ê°œì„ ë˜ì—ˆìœ¼ë‚˜ ì—¬ì „íˆ ì•½ì„¸<br>- ì •ë¶€ ì…§ë‹¤ìš´ì˜ ì˜í–¥ì€ 4ë¶„ê¸° ê°€ì´ë˜ìŠ¤ì— ë°˜ì˜<br><br>â€¢ M&A/ìë³¸ë°°ë¶„:<br>- ì—°ê°„ ì•½ 75ì–µ ë‹¬ëŸ¬ íˆ¬ì (M&A 40ì–µ ë‹¬ëŸ¬, ìì‚¬ì£¼/ë°°ë‹¹ 35ì–µ ë‹¬ëŸ¬)<br>- ì ê·¹ì ì¸ M&A íŒŒì´í”„ë¼ì¸ ìœ ì§€ ì¤‘<br><br>ì´ ë‚´ìš©ì€ ì „ë¬¸ íˆ¬ììë“¤ì„ ìœ„í•´ ê°ê´€ì ì´ê³  í•µì‹¬ì ì¸ ì •ë³´ë§Œì„ ìš”ì•½í•œ ê²ƒì…ë‹ˆë‹¤.</p>
    <hr style="margin:50px 0;">
    
</body></html>